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Abstract	
Background	
Gastro	 oesophageal	 reflux	 disease	 (GORD)	 is	 a	 leading	 cause	 of	 morbidity	 and	 economic	
importance	 worldwide.	 It	 is	 currently	 defined	 by	 the	 Montreal	 definition	 as	 a	 condition,	 which	
develops	when	 the	 reflux	 of	 gastric	 content	 causes	 troublesome	 symptoms	or	 complications.	 This	
definition	 based	 on	 symptoms	 is	 all	 encompassing,	 and	 further	 classification	 is	 made	 based	 on	
macroscopic	mucosal	injury	as	seen	on	gastroscopy,	increased	distal	oesophageal	acid	and	non	acid	
exposure,	based	on	24	hour	pH	and	impedance	pH	testing,	and	reflux	symptom	association.	
	
Thus,	 GORD	 may	 be	 sub	 classified	 into	 the	 following	 conditions	 –	 erosive	 reflux	 disease	
(ERD),	non	erosive	reflux	disease	(NERD),	reflux	hypersensitivity	(RH),	functional	heartburn	(FH)	and	
functional	chest	pain	(FCP).	Treatment	of	GORD	is	with	acid	suppression	therapy,	anti	reflux	therapy	
and	pain	modulation.	The	pathophysiology	of	GORD	is	thought	to	occur	in	a	spectrum,	with	varying	
contributions	from	direct	mucosal	injury	to	peripheral	sensitization	and	central	sensitization.	
	
Further	 efforts	 to	 phenotype	 GORD	 populations,	 investigate	 mechanisms	 of	 symptom	
evolution	 and	 treatments	 are	 driven	 by	 a	 significant	 proportion	 of	 patients	who	 are	 refractory	 to	
currently	available	therapies.		
	
Aims	
The	aim	of	this	body	of	work	was	to	phenotype	patients	with	RH,	the	least	studied	subtype	
of	GORD,	to	investigate	the	effect	of	ONO	8539,	a	novel	antagonist	to	the	Prostaglandin	E	1	receptor	
thought	 to	 be	 involved	 in	 pain	 perception	 on	 acid	 induced	 oesophageal	 pain	 hypersensitivity	 in	
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patients	with	NERD,	to	investigate	the	effect	of	transcutaneous	vagal	nerve	stimulation	(tVNS)	on	an	
oesophageal	pain	model	in	healthy	volunteers,	and	to	investigate	the	effect	of	slow	deep	breathing	
on	oesophageal	pain	hypersensitivity	in	patients	with	NERD.		
	
Methods	
I	 investigated	 the	 above	 aims	 in	 a	 retrospective	 cohort	 study	 on	 patients	 referred	 to	 the	
gastro	 intestinal	 physiology	 unit	 of	 the	 Royal	 London	 Hospital	 for	 investigation	 of	 typical	 GORD	
symptoms,	a	double	blind	placebo	controlled	two	period	cross	over	study	in	patients	with	NERD,	a	
single	blind	sham	controlled	two	period	cross	over	study	in	healthy	volunteers	and	single	blind	sham	
controlled	parallel	 study	 in	patients	with	NERD	 respectively.	 The	 first	 study	was	done	as	 a	 service	
evaluation	exercise	and	the	latter	three	studies	had	ethical	approval	from	the	National	Research	and	
Ethics	Service	(NRES),	QMUL	Ethics	and	NRES	respectively.		
	
Results	
I	demonstrated	that	phenotypic	characteristics	in	patients	with	RH	were	distinct	from	NERD	
and	 FH/FCP.	 This	 was	 the	 largest	 cohort	 of	 RH	 patients	 evaluated,	 and	 this	 body	 of	 work	 will	
contribute	to	further	research	on	mechanisms,	pathophysiology	and	treatments	in	RH.	In	my	second	
study,	 I	 was	 not	 able	 to	 demonstrate	 an	 anti	 nociceptive	 effect	 of	 ONO	 8539	 versus	 placebo	 on	
oesophageal	 pain	 hypersensitivity	 in	 patients	 with	 NERD.	 In	 my	 third	 study,	 I	 was	 able	 to	
demonstrate	an	increase	in	anti	nociceptive	parasympathetic	tone,	and	an	increase	in	pain	tolerance	
threshold	with	tVNS	compared	to	sham	stimulation	in	an	oesophageal	pain	hypersensitivity	model	in	
healthy	 volunteers.	 In	 my	 final	 study,	 I	 was	 able	 to	 demonstrate	 an	 increase	 in	 parasympathetic	
tone,	 but	 no	 improvement	 in	 lag	 time	 to	 pain	 perception	 with	 a	 slow	 deep	 breathing	 protocol	
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compared	 to	 a	 sham	breathing	protocol	 in	 a	Modified	Bernstein	 test	model	 of	 distal	 oesophageal	
acid	infusion	in	patients	with	NERD.	
	
Conclusions	
This	body	of	work	 improves	upon	current	knowledge	of	 the	phenotypic	 characteristics	of	RH,	
adding	further	weight	to	the	definition	of	RH	as	a	distinct	condition.	tVNS	and	deep	slow	breathing	
were	 shown	 to	 increase	 parasympathetic	 tone	 in	 healthy	 volunteers	 and	 patients	 with	 NERD	
respectively.	The	anti	nociceptive	effect	of	raising	parasympathetic	tone	was	only	demonstrated	 in	
the	 healthy	 volunteer	 model	 of	 oesophageal	 pain	 hypersensitivity.	 The	 performance	 of	 the	 MBT	
model	used	in	the	two	patient	studies	was	not	as	reliable	as	the	healthy	volunteer	model,	and	a	new	
oesophageal	pain	hypersensitivity	model	for	patients	with	NERD	was	proposed,			
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NERD	 groups	 as	 well	 as	 the	 RH	 and	 FH/FCP	 groups	 (p	 =	 0.0001	 and	 0.0004	
respectively).	
Figure	2.14:		 Percentage	of	PPI	use	in	the	RH	group	(n=211),	NERD	group	(n=33)	and	the	FH/FCP	
group	(n=31)	
Figure	2.15:		 Percentage	of	H2RA	use	in	the	RH	group	(n=211),	NERD	group	(n=33)	and	the	FH/FCP	
group	(n=31).	
Figure	2.16:		 Percentage	of	neuromodulator	use	in	the	RH	group	(n=211),	NERD	group	(n=33)	and	
the	FH/FCP	group	(n=31).	
Figure	3.1:		 Mechanisms	 underlying	 sensitization.	 Luminal	 factors	 and	 mediators	 released	 in	
response	 to	 ischemia,	 injury,	and	 inflammation	act	on	 the	sensory	endings	 to	drive	
sensitization.	These	peripheral	mechanisms	are	reinforced	by	central	mechanisms	in	
the	 spinal	 cord	 and	 CNS.	 ATP,	 adenosine	 triphosphate;	 LIF,	 leukaemia	 inhibitory	
factor;	NGF,	nerve	growth	factor;	PGE,	prostaglandin	E;	TNF,	tumour	necrosis	factor.	
Figure	3.2:	 Schematic	of	study	design.	
Figure	3.3:	 This	plot	 illustrates	the	lack	of	a	consistent	response	in	APSS	within	each	treatment	
group.	 The	 large	 within	 and	 inter	 subject	 variability	 is	 demonstrated	 as	 well.	 The	
data	in	red	indicate	the	mean	(SD)	at	each	visit.		
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Figure	3.4:		 This	plot	illustrates	the	lack	of	a	consistent	response	within	each	treatment	group	in	
sensory	 intensity	 rating.	 A	 large	 within	 and	 inter	 subject	 variability	 is	 also	
demonstrated.	The	data	in	red	indicate	the	mean	(SD)	at	each	visit.	
Figure	3.5:	 This	plot	illustrates	the	lack	of	a	consistent	response	within	each	treatment	group	in	
sensory	 intensity	 rating.	Similar	 to	 the	previous	 two	stimulus	 response	measures,	a	
large	within	 and	 inter	 subject	 variability	 is	 demonstrated.	 The	 data	 in	 red	 indicate	
the	mean	(SD)	at	each	visit;	a	negative	time	 indicates	 that	 the	discomfort	occurred	
during	the	saline	perfusion.	
Figure	4.1:		 Implanted	vagal	nerve	stimulator	
Figure	4.2:		 Surface	anatomy	of	the	ear	
Figure	4.3:			 Distribution	of	the	nerve	supply	of	the	ear.	
Figure	4.4:		 NEMOS	tVNS	device	(www.cerbomed.com).	
Figure	4.5:		 Study	design	flowchart.		
Figure	4.6:		 Distal	oesophageal	acid	infusion	and	electrical	stimulation.		
Figure	4.7:		 Electrode	placement	in	the	active	and	sham	positions	
Figure	4.8:		 Distal	stimulating	electrode	pair	and	infusion	port.		
Figure	4.9:		 Combined	 electrical	 stimulation	 and	 perfusion	 catheter	 (Unisensor,	 Gaeltec,	 Isle	 of	
Skye,	UK).	
Figure	4.10:		 Lab	set	up	for	distal	oesophageal	electrical	stimulation	and	acid	infusion.	
Figure	4.11:		 Oesophageal	 pain	 tolerance	 threshold	 (mA)	 for	 the	 tVNS	 group	 and	 the	 sham	
stimulation	group.	The	magnitude	of	change	in	pain	tolerance	threshold	was	similar	
to	that	seen	by	Botha	et	al	(174).	 	 	 	 	 	 	
Figure	4.12:		 Change	 in	 oesophageal	 pain	 tolerance	 threshold	 (mA)	 for	 the	 tVNS	 group	 and	 the	
sham	stimulation	group.	
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Figure	4.13:	 Mean	CVT	pain	tolerance	threshold	at	T0,	T30,	T60	and	T90	for	the	tVNS		group	and	
the	sham	stimulation	group,	showing	an	increase	in	CVT	with	time	in	the	tVNS	group	
compared	to	the	sham	stimulation	group	
Figure	4.14:		 Absolute	change	in	CVT	(and	thus	parasympathetic	tone)	from	baseline	to	T90,	was	
significantly	positive	in	the	tVNS	group	compared	to	the	sham	stimulation	group.	
Figure	5.1:		 Schematic	diagram	of	study	design.	
Figure	5.2:		 Distribution	of	lag	time	for	the	slow	deep	breathing	group.			
Figure	5.3:	 	Distribution	of	lag	time	for	the	sham	breathing	group.			
Figure	5.4:		 There	was	no	significant	difference	between	the	two	groups	when	comparing	median	
lag	times	(p	=	0.6022).	
Figure	5.5:		 There	 was	 a	 significant	 rise	 from	 mean	 baseline	 CVT	 in	 the	 deep	 slow	 breathing	
group	 with	 deep	 slow	 breathing	 alone	 (p	 =	 0.0052)	 as	 well	 as	 with	 deep	 slow	
breathing	 during	 a	Modified	 Bernstein	 test	 (p	 =	 0052).	 This	was	 not	 shown	 in	 the	
sham	breathing	group	(p	=	0.5245	and	p	=	0.7197)	respectively.	
Figure	5.6:	 There	was	no	significant	difference	between	the	mean	baseline	RESQ7	vs	 follow	up	
scores	for	either	the	DSB	group	(p	=	0.2354)	or	the	sham	group	(p	=	0.8867).	
Figure	5.7:	 Mean	 change	 from	 baseline	 RESQ7	 score	 to	 follow	 up	 score	 was	 not	 significant	
between	the	2	groups	(p	=	0.6150).	
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Chapter	1	
Oesophageal	 hypersensitivity	 in	 patients	 with	 gastro-oesophageal	
reflux	symptoms:	Prevalence	and	novel	treatments	
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General	Introduction	
In	this	thesis,	I	look	at	oesophageal	pain	in	reflux	hypersensitivity	(RH)	and	non-erosive	reflux	
disease	(NERD),	both	of	which	are	recognised	as	increasingly	important	entities	in	the	field	of	gastro	
oesophageal	 reflux	 disease	 (GORD).	 GORD	 is	 characterised	 by	 pathologically	 increased	 distal	
oesophageal	 acid	 exposure.	 On	 endoscopy,	 there	 may	 be	 evidence	 of	 macroscopic	 oesophageal	
injury.	NERD	is	defined	as	a	diagnosis	of	GORD	in	the	absence	of	macroscopic	oesophageal	injury	(1).			
RH	 is	 defined	 as	 an	 increased	 sensitivity	 of	 the	oesophagus	 to	physiological	 acid	 exposure	
and	reflux,	in	the	absence	of	any	macroscopic	injury	(2).	In	this	thesis,	I	have	focussed	primarily	on	
reflux	hypersensitivity	and	NERD,	as	patients	with	these	two	conditions	make	up	a	large	proportion	
of	 patients	 who	 are	 refractory	 to,	 or	 only	 partially	 responsive	 to	 the	 current	 best	 available	
pharmacological	 therapies	 for	 GORD	 (proton	 pump	 inhibitors	 and	 H2	 receptor	 antagonists	 (3).	 In	
some	sections	of	this	thesis,	I	compared	these	two	groups	to	patients	with	functional	heartburn	(FH)	
and	 functional	 chest	pain	 (FCP).	Patients	with	FH	and	FCP	have	 symptoms	of	heartburn	and	chest	
pain,	but	with	no	evidence	of	oesophageal	injury	at	oesophago	gastro	duodenoscopy	(OGD)	as	well	
as	normal	oesophageal	acid	exposure	with	no	significant	reflux-symptom	association	at	24	hour	pH	
or	impedance	pH	studies(4).		
In	patients	with	GORD,	where	macroscopic	injury	of	the	oesophagus	(such	as	oesophagitis)	is	
evident,	oesophageal	 injury	 is	 thought	 to	be	 the	 cause	of	 sensitivity	 to	 stimuli.	 The	mechanism	of	
oesophageal	 sensitivity	 to	stimuli	 in	patients	with	NERD	and	RH	 is	 less	clear.	Microscopic	 injury	or	
other	neurophysiological	mechanisms	may	play	a	role	in	the	development	of	oesophageal	symptoms	
in	all	these	patients,	especially	those	with	RH	and	NERD,	and	certainly	there	is	a	definite	difference	
between	 patients	 with	 NERD	 and	 FH	 (5).	 In	 fact,	 it	 may	 even	 be	 a	 continuum,	 ranging	 from	
macroscopic	 oesophageal	 injury	 to	 microscopic	 oesophageal	 injury	 as	 well	 as	 neurophysiological	
changes,	 which	 account	 for	 hypersensitivity	 to	 mechanical,	 chemical	 and	 electrical	 stimuli.	
Therefore,	understanding	the	patient	with	a	hypersensitive	oesophagus	in	terms	of	prevalence	and	
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characteristics	is	an	important	step	towards	formulating	novel	treatment	strategies	in	this	group	of	
patients	who	are	refractory	(completely	or	partially)	to	conventional	therapies	currently	available.		
In	 this	 thesis,	 in	 the	 first	 chapter,	 I	 briefly	 review	 the	 human	 oesophagus,	 considering	 in	
particular	 current	 advances	 of	 knowledge	 in	 innervation	 of	 the	 human	 oesophagus,	 as	 well	 as	
current	 ideas	of	mechanisms	of	oesophageal	sensation.	 I	 then	review	typical	 reflux	symptoms,	 the	
starting	 point	 of	 a	 patients’	 journey	 as	 they	 present	 to	 the	 gastroenterologist,	 as	 well	 as	 discuss	
GORD,	NERD,	RH,	FH	and	FCP.	Advances	 in	diagnostic	 techniques	and	current	 thinking	 in	 terms	of	
diagnostic	algorithms	and,	the	significant	therapeutic	gap	currently	faced	by	patients	suffering	with	
GORD	as	well	as	RH	are	discussed.	I	finally	introduce	potential	novel	treatment	avenues	–such	as	the	
treatment	 of	 oesophageal	 pain	 by	 modulation	 of	 the	 autonomic	 nervous	 system	 as	 well	 as	
pharmacological	modulation	of	oesophageal	pain.				
In	the	second	chapter,	I	 initially	focus	on	the	prevalence	of	RH	in	our	department.	This	will	
form	the	 largest	cohort	of	patients	 identified	with	RH	studied	thus	 far.	 	My	aim	was	to	phenotype	
this	 population	 and	 then	 compare	 this	 population	 with	 patients	 diagnosed	 with	 NERD	 and	 those	
diagnosed	with	functional	oesophageal	symptoms	(FH	and	FCP).	The	aim	of	this	comparison	was	to	
assess	possible	avenues	of	therapies	for	RH,	some	of	which	have	informed	the	following	chapters.	
In	 the	 third	 chapter	of	 this	 thesis,	 I	 present	a	 clinical	 trial	of	 a	pharmacological	 agent	 that	
causes	blockade	of	prostaglandin	EP1	receptors,	and	the	effect	of	 this	agent	on	oesophageal	pain.	
This	was	a	two	centre,	double	blinded	placebo	controlled	two	period	cross	over	study,	and	the	effect	
of	 the	 treatment	 agent	was	 assessed	 via	 responses	 to	 acid	 stimulation	 in	 the	 form	 of	 a	modified	
Bernstein	test	as	well	as	change	in	psychological	parameters.	
In	 the	 fourth	chapter,	 I	 focus	on	neurophysiological	modulation	of	 the	autonomic	nervous	
system	as	a	possible	means	of	treating	patients	with	NERD	and	RH.	Here,	I	investigated	the	effect	of	
transcutaneous	vagal	nerve	stimulation	on	acid	 induced	oesophageal	hyperalgesia	 in	healthy	adult	
volunteers.		
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In	 the	 fifth	 chapter,	 I	 investigated	 the	 effect	 of	 slow	 deep	 breathing	 (which	 has	 been	
previously	demonstrated	by	our	group	to	increase	parasympathetic	tone)	as	a	means	of	autonomic	
modulation	of	oesophageal	pain	 in	patients	with	NERD	in	a	single	blinded	parallel	 sham	controlled	
study.	The	control	group	of	patients	used	a	type	of	sham	breathing	as	their	treatment	intervention.	
Response	 to	 acid	 stimulation	 in	 the	 form	 of	 a	 modified	 Bernstein	 test,	 as	 well	 as	 change	 in	
psychological	parameters	were	assessed.	
In	 the	 final	chapter,	 I	 summarise	 the	body	of	work	 in	 this	PhD,	discussing	 the	contribution	
that	has	been	made	towards	furthering	our	knowledge	of	RH	and	NERD	as	well	as	the	advancement	
of	treatments	for	oesophageal	pain.	I	discuss	limitations	encountered	as	well	as	further	directions	of	
study.	
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The	adult	human	oesophagus	
By	adulthood,	the	human	oesophagus	is	on	average	18	to	26	cm	measured	from	the	upper	
oesophageal	sphincter	at	the	level	of	C5/6,	to	the	lower	oesophageal	sphincter	at	the	level	of	T10.	It	
is	 able	 to	 distend	 by	 2cm	 in	 the	 antero-posterior	 plane,	 and	 by	 3cm	 in	 the	 lateral	 plane	 in	 the	
presence	 of	 a	 bolus.	 In	 the	 absence	 of	 a	 bolus,	 it	 appears	 as	 a	 compressed	 tubular	 structure,	
extending	from	the	suprasternal	notch	to	the	diaphragmatic	hiatus,	passing	posterior	to	the	trachea,	
the	 tracheal	 bifurcation,	 and	 the	 left	 main	 stem	 bronchus.	 The	 aortic	 arch	 lies	 anterior	 to	 the	
oesophagus	until	the	level	of	T8,	where	the	oesophagus	is	shifted	anterior	to	the	descending	aorta.	
Macroscopically,	three	distinct	segments	are	recognised	–	the	cervical	oesophagus	(from	the	
upper	 oesophageal	 sphincter	 to	 the	 suprasternal	 notch),	 the	 thoracic	 oesophagus	 (from	 the	
suprasternal	 notch	 to	 the	 diaphragmatic	 hiatus)	 and	 the	 abdominal	 oesophagus	 (from	 the	
diaphragmatic	hiatus	to	the	gastric	cardia).	
The	upper	and	 lower	oesophageal	 sphincters	are	delineated	by	high	pressure	zones	at	 the	
upper	and	 lower	ends	of	 the	oesophagus	respectively.	Once	developed	fully,	 the	oesophageal	wall	
consists	of	4	layers	from	a	histological	perspective.	
• Mucosa	 –	 this	 is	 the	 luminal	 layer	 and	 it	 is	 composed	 of	 nonkeratinised	 stratified	
squamous	epithelium.		At	the	gastro-oesophageal	junction,	this	changes	to	columnar	
epithelium.	The	point	of	 change	 is	 the	squamocolumnar	 junction,	also	called	 the	Z	
line.		
• Submucosa	 –	 this	 is	 a	 layer	 of	 connective	 tissue,	 connecting	 the	 mucosa	 to	 the	
muscular	 later	 below	 it.	 It	 contains	 blood	 vessels,	 submucosal	 nerve	 plexi	 and	
oesophageal	glands.	
• Muscularis	mucosa	–	 this	 layer	 is	 formed	of	circular	and	 longitudinal	muscle	fibres.	
The	 inner	 circular	 muscle	 fibre	 layer	 is	 continuous	 with	 muscles	 in	 the	
cricopharyngeal	 part	 of	 the	 inferior	 constrictor	 muscles	 of	 the	 pharynx	 and	 the	
	 31	
oblique	muscle	 fibres	of	 the	 stomach.	The	outer	 longitudinal	muscle	 layer	 forms	a	
continuous	coat	around	the	oesophagus	except	posterosuperiorly,	3-4	cm	below	the	
cricoid	cartilage;	here,	the	muscle	layer	diverges	as	2	fascicles	that	ascend	obliquely	
to	the	anterior	aspect	of	the	oesophagus.	These	muscle	fibres	in	general	are	striated	
fibres	 in	 the	proximal	 third	of	 the	oesophagus	and	 smooth	 fibres	 in	 the	distal	 two	
thirds	of	the	oesophagus.		
• Adventitia	 –	 this	 is	 an	 elastic,	 dense,	 fibrous	 connective	 tissue	 layer	 covering	 the	
oesophagus.	The	oesophagus	does	not	have	a	serosal	layer	in	contrast	to	the	rest	of	
the	gastrointestinal	tract.		
The	lower	oesophageal	sphincter	
The	 lower	 oesophageal	 sphincter	 (LOS)	 and	 the	 diaphragm	 control	 movement	 of	
oesophageal	 contents	 into	 the	 stomach	 as	well	 as	 the	movement	 of	 gastric	 contents	 (reflux)	 and	
vented	gas	(belching)	into	the	oesophagus.		
The	 LOS	 is	 2	 to	 4	 cm	 in	 length.	 The	 circular	 and	 longitudinal	 smooth	muscle	 layers	 of	 the	
oesophagus	continue	into	the	LOS,	where	the	circular	muscles	fibres	become	C	shaped	towards	the	
lower	LOS,	with	those	arising	from	the	left	side	of	the	LOS	clasping	fibres	arising	from	the	right	side.	
The	 left	sided	fibres	also	combine	with	gastric	sling	fibres,	which	 loop	around	the	GOJ,	and	 in	turn	
form	 the	 oblique	muscle	 layer	 of	 the	 stomach.	 The	 C	 shaped	 clasping	 fibres	 are	 able	 to	maintain	
basal	 tone	 more	 effectively	 than	 the	 sling	 fibres	 which	 are	 more	 responsive	 to	 cholinergic	
stimulation	(6).	This	allows	for	an	asymmetric	configuration	of	the	LOS.		
The	diaphragmatic	sphincter	occurs	as	a	result	of	the	action	of	the	crural	diaphragm	on	the	
lower	 oesophagus	 during	 inspiration,	 hence	 the	 characteristic	 pressure	 inversion	point	 recognised	
on	 high-resolution	 manometry.	 During	 inspiration,	 when	 gastric	 pressures	 are	 higher,	 the	
diaphragmatic	sphincter	augments	 the	 integrity	of	 the	osephago-	gastric	 junction	 (OGJ)	 to	prevent	
reflux	 of	 gastric	 contents.	 The	 effect	 of	 the	 diaphragmatic	 sphincter	 can	 be	 disrupted	 by	 gastric	
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causes	 (hiatal	 hernias,	 obesity,	 overeating,	 reduced	 gastric	 fundic	 compliance,	 delayed	 gastric	
emptying)	 and	 respiratory	 causes	 of	 lower	 intrathoracic	 pressure	 (obstructive	 sleep	 apnoea	 and	
asthma),	thus	reducing	the	integrity	of	the	LOS	and	increasing	the	likelihood	of	gastro	oesophageal	
reflux	disease.	
Innervation	 of	 the	 LOS	 is	 via	 the	 vagus	 (parasympathetic)	 nerve	 and	 splanchnic	
(sympathetic)	nerves.	Vagal	afferents	 from	the	LOS	travel	 to	the	nucleus	tractus	solitarius	 (NTS)	of	
the	hindbrain	whilst	vagal	efferents	travel	from	the	preganglionic	fibres	of	the	dorsal	motor	nucleus	
of	 the	 vagus	 to	 the	 LOS.	 Therefore	 this	 circuit	 involving	 the	 NTS	 and	 the	 dorsal	 motor	 nucleus	
controls	LOS	relaxation.	
Neurotransmitters	 and	 hormones	 involved	 in	 lowering	 LOS	 tone	 include	 nitric	 oxide	 (NO)	
and	 nitrates,	 vasoactive	 intestinal	 peptide	 (VIP),	 nicotine,	 β-adrenergic	 agonists	 (1,2,and	 3),	
dopamine	 (D2),	cholecystokinin	 (CCK),	 secretin,	calcitonin	gene-related	peptide	 (CGRP),	adenosine,	
and	 prostaglandin	 E.	 LOS	 tone	 is	 increased	 by	 muscarinic	M2	 and	M3	 receptor	 agonists,	 gastrin,	
substance	P,	a-adrenergic	agonists,	and	prostaglandin	F2	alpha	(7).		
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Innervation	of	the	human	oesophagus	
Sympathetic	afferent	
innervation	
	
Parasympathetic	afferent	
innervation	
Enteric	innervation	
Spinal	afferent	nerve	endings	in	
the	muscle	layer	and	serosa	act	
as	nociceptors	for	perception	of	
discomfort	and	pain	and	are	
also	sensitive	to	mechanical	
distention.	
	
Spinal	afferent	nerve	endings	in	
the	mucosa	are	sensitive	to	
acid-induced	pain	during	topical	
exposure	to	intraluminal	acid.		
	
Many	of	these	spinal	afferents	
contain	CGRP	and	substance	P.	
	
Cell	bodies	of	the	spinal	
afferents	occur	in	the	dorsal	
root	ganglia	and	terminate	in	
the	spinal	column,	and	in	the	
nucleus	gracilis	and	cuneatus	in	
the	brainstem.	From	there,	they	
project,	through	the	thalamus,	
to	primary	sensory	and	insular	
cortical	areas.	
	
Nerve	endings	in	oesophageal	
smooth	muscle	layer	are	
sensitive	to	mechanical	
distention.	
	
Nerve	endings	in	the	
oesophageal	mucosa	are	
sensitive	to	various	osmo-,	
chemo-,	thermo-,	and	
mechanical	intraluminal	stimuli.	
	
Cell	bodies	of	vagal	afferents	
occur	in	the	nodose	ganglia	and	
project	to	the	nucleus	solitarius.	
	
Parasympathetic	afferents	
comprise	of	80%	of	the	vagal	
trunk.		
	
	
	
The	enteric	nerves	in	the		
myenteric	and	submucosal	plexi	
provide	the	intrinsic	innervation	
of	the	oesophagus.		
	
The	myenteric	(also	knowns	as	
the	Auerbach's	plexus)	ganglia	
lie	between	the	longitudinal	
and	the	circular	layers	of	the	
tunica	muscularis.	There	are	
more	myenteric	ganglia	in	the	
smooth	muscle	part	of	the	
oesophagus	than	the	striated	
muscle	part	of	the	oesophagus.	
	
The	myenteric	plexus	regulates	
contraction	of	the	outer	muscle	
layers.	
	
The	submucous	(also	known	as	
the	Meissner's	plexus)	ganglia		
lie	in	the	submucosa.	
	
The	submucous		plexus	
regulates	secretion	and	
peristaltic	contractions	of	the	
muscularis	mucosae.	
Sympathetic	efferent	
innervation	
	
Parasympathetic	efferent	
innervation	
Sympathetic	efferents	come	
from	the	cervical	and	the	
thoracic	sympathetic	chain	
(spinal	segments	T1–T10),	
regulating	vascular	constriction,	
contraction	of	oesophageal	
sphincters,	relaxation	of	the	
muscular	wall,	and	increases	in	
glandular	and	peristaltic	
activity.	
	
Parasympathetic	efferents	
come	from	the	nucleus	
ambiguus	and	dorsal	motor	
nucleus	of	the	vagus	nerve,	
providing	motor	innervation	to	
the	oesophageal	muscular	coat	
and	secretomotor	innervation	
to	oesophageal	glands.	
A	network	of	fibers	
interconnects	these	two	plexi.	
	
	
Table	1.1:	Innervation	of	the	oesophagus	is	via	the	enteric	nervous	system	(ENS)	as	well	as	neurons	
from	the	sympathetic	and	parasympathetic	ganglia.		(8)	
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Development	of	innervation	of	the	human	oesophagus	
Development	of	neural	tissue	in	the	embryo	begins	very	early	starting	with	the	neural	plate	
(a	thickening	 in	the	ectoderm	lining	the	base	of	 the	amniotic	cavity).	 In	the	third	week,	 the	 lateral	
ends	of	the	neural	plate	fold	over	and	join	together	forming	the	neural	tube,	the	lumen	of	which	is	
the	neural	canal.	The	cells	at	the	leading	edge	of	the	neural	fold	migrate	to	either	side	of	the	neural	
tube	to	form	the	neural	crest,	which	then	lies	on	either	side	of	the	neural	tube.	The	cells	lining	the	
neural	 tube	 (neuroepithelium)	 give	 rise	 to	 cells	 of	 the	 central	 nervous	 system	 (CNS)	whilst	 neural	
crest	cells	and	ectodermal	placode	cells	give	rise	to	cells	of	the	peripheral	nervous	system	(PNS).		
Development	of	the	central	nervous	system	
The	neural	tube	epithelium	forms	neurons,	glial	cells	and	ependymal	cells	that	make	up	the	
developing	 brainstem	 and	 spinal	 cord.	 The	 neurons	 migrate	 outwards	 forming	 the	 mantle	 layer	
(future	 grey	matter)	with	 their	 axons	 pointing	 outwards	 forming	 the	marginal	 layer	 (future	white	
matter).	 	The	mantle	 layer	of	the	brainstem	and	spinal	cord	has	a	dorsal	“alar”	plate	and	a	ventral	
“basal”	plate.	Cranial	nerve	motor	nuclei	develop	from	the	brainstem	basal	plates,	and	cranial	nerve	
sensory	 nuclei	 develop	 from	 the	 brainstem	 alar	 plates.	 All	 the	 nuclei	 in	 turn	 are	 grouped	 into	 7	
longitudinal	columns	in	the	brainstem	–	three	basal	columns	and	four	alar	columns.		
Three	basal	columns			
1. Somatic	efferent	(containing	the	nuclei	of	III,	IV,	VI	and	XII)	
2. Special	visceral	efferent	(containing	nuclei	of	V,	VII	located	cranially,	with	the	nuclei	for	X,	X	
and	XI	supplied	by	the	nucleus	ambiguous)	
3. General	visceral	efferent	(containing	the	parasympathetic	component	of	VII	and	IX	as	well	as	
the	dorsal	nucleus	of	X	containing	the	parasympathetic	component	of	the	vagus	nerve	
supplying	the	viscera)	
	
Four	alar	columns		
1. General	visceral	afferent	(contains	a	nucleus	receiving	information	from	IX	and	X)	
2. Special	visceral	afferent	(contains	the	nucleus	tractus	solitarius	receiving	information	from	
VII,	IX	and	X).	
3. General	somatic	afferent	(contains	nuclei	receiving	information	from	V,	VII,	IX	and	X).		
4. Special	somatic	afferent	(contains	the	cochlear	and	vestibular	nuclei	receiving	information	
from	VIII).	
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Meanwhile,	neural	crest	cells	differentiate	in	the	cranio-caudal	direction	into	cranial	neural	
crest	cells,	vagal	neural	crest	cells,	trunk	neural	crest	cells	and	sacral/lumbosacral	neural	crest	cells.	
A	population	of	cranial	neural	crest	cells	gives	rise	to	the	cranial	component	of	the	parasympathetic	
nervous	system	(CN	III,	VII,	IX	and	X).	
Development	of	the	peripheral	nervous	system	
A	population	of	trunk	neural	crest	cells	aggregate	lateral	to	the	neural	tube	forming	clumps	
of	cells,	which	differentiate	into	dorsal	root	ganglia,	which	will	receive	sensory	information	from	the	
viscera	and	extremities.	Here,	 the	beginning	of	 the	basis	 of	 central	 sensitization	 is	 seen	as	 some	
overlap	 in	 the	 corresponding	 levels	 of	 the	 neural	 tube	 and	 the	 dorsal	 root	 ganglia	 becomes	
evident.		
Other	trunk	neural	crest	cells	migrate	to	an	area	ventral	to	the	dorsal	root	ganglia	to	form	
the	 chain	 ganglia,	 which	 eventually	 become	 the	 sympathetic	 chain,	 providing	 autonomic	 motor	
innervation	 to	viscera	as	well	as	controlling	glandular	 secretions,	peristalsis	and	heart	 rate.	 	These	
nerves	develop	 in	 the	 intermediolateral	 columns	of	 T1	 to	 L2/L3	 	 (thoracolumbar	 system),	 growing	
through	the	ventral	root,	branching	off	to	form	the	white	ramus,	which	enters	the	sympathetic	chain	
at	 that	 level.	 Some	 neurons	 synapse	with	 postganglionic	 sympathetic	 neurons	 in	 the	 sympathetic	
chain	 (these	 postganglionic	 neurons	 leave	 the	 sympathetic	 chain	 via	 the	 grey	 ramus	 to	 enter	 the	
spinal	 nerve),	 whilst	 others	 just	 pass	 though,	 to	 synapse	 with	 another	 sympathetic	 chain	 ganglia	
above	or	below	it	(providing	autonomic	innervation	to	other	spinal	levels	other	than	T1	to	L2/3)	or,	
more	 distally	 in	 the	 prevertebral	 ganglia.	 The	 sympathetic	 prevertebral	 ganglia	 are	 formed	 from	
populations	of	thoracic	and	lumbar	neural	crest	cells,	and	they	develop	in	association	with	the	celiac	
artery,	superior	mesenteric	artery,	renal	arteries	and	the	inferior	mesenteric	arteries,	migrating	with	
the	vessel	closer	to	their	target	organ.		
Somatic	motor	axons	grow	out	from	the	basal	columns	of	the	developing	spinal	cord	forming	
a	pair	of	ventral	roots	at	the	level	of	each	somite.	Autonomic	neurons	from	the	intermediolateral	cell	
	 36	
columns	join	the	ventral	roots	at	the	levels	of	T1	to	L2/3.	This	 is	followed	by	neurons	in	the	dorsal	
root	ganglions	growing	both	proximally	towards	the	spinal	cord	and	distally	via	the	spinal	nerves	to	
the	periphery.	Considering	growth	in	the	proximal	direction,	when	the	axons	reach	the	spinal	cord,	
they	synapse	with	association	neurons	that	in	turn	synapse	with	autonomic	motor	neurons,	somatic	
motor	 neurons,	 or,	 they	 ascend	 to	 higher	 levels	 in	 the	 cord	where	 they	 synapse	with	 autonomic	
motor	or	somatic	motor	neurons.		
Preganglioninc	parasympathetic	neurons	form	from	a	population	of	cranial	neural	crest	cells	
and	 sacral	 neural	 crest	 cells	 (craniosacral	 system)	 that	 migrate	 distally	 to	 form	 parasympathetic	
ganglia	 close	 to	 the	 viscera	 they	 supply.	 The	 cranial	 parasympathetic	 fibres	 travel	 to	 the	
parasympathetic	ganglia	via	the	vagus	nerve.	The	sacral	parasympathetic	fibres	travel	to	the	hindgut	
and	 pelvic	 visceral	 ganglia	 via	 the	 pelvic	 splanchnic	 nerves.	 The	 parasympathetic	 ganglia	 that	
become	localised	in	the	gut	become	enteric	ganglia.	
In	addition	to	the	above,	vagal	and	lumbosacral	neural	crest	cells	migrate	into	the	wall	of	the	
gut	tube	to	form	the	enteric	nervous	system	(ENS).	Vagal	neural	crest	cells	invade	the	gut	tube	in	a	
cranio-caudal	 direction	 from	 the	 oesophagus	 to	 the	 rectum	 whilst	 lumbosacral	 neural	 crest	 cells	
invade	 the	 gut	 tube	 form	 the	 rectum	 in	 a	 cranial	 direction,	 resulting	 in	 the	 terminal	 portion	
(colon/rectum)	of	the	gut	tube	having	ENS	fibres	derived	from	both	cranial	and	lumbosacral	neural	
crest	cells	 (lack	of	 this	migration	process	 is	 implicated	 in	Hirshsprung	disease).	The	neurons	of	 the	
ENS	become	grouped	into	ganglia	localised	to	the	submucosal	plexus	(Meissners	plexus),	which	lies	
adjacent	 to	 the	 circular	 muscle	 layer,	 and	 the	 myenteric	 plexus	 (Auerbachs	 plexus),	 which	 lies	
between	 the	 circular	 and	 longitudinal	 muscle	 layers	 (with	 some	 neurons	 located	 in	 the	 lamina	
propria).	 It	 consists	 of	 glia,	 interconnected	 afferent	 and	 efferent	 neurons	 and	 interneurons.	 It	
regulates	 peristalsis,	 blood	 flow,	 secretion,	 absorption,	 and	 endocrine	 processes.	 It	 is	 able	 to	
function	without	 CNS	 input.	 The	 interstitial	 cells	 of	 Cajal	 are	 involved	 in	 the	 integration	of	 signals	
between	the	ENS	and	the	smooth	muscle	cells	of	the	gut.	They	function	as	pacemaker	cells,	driving	
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peristalsis	in	the	gut.	They	are	thought	to	arise	from	mesodermal	precursors	of	smooth	muscle	cells	
(and	not	neural	crest	cells)	(9,	10).		
The	sympathetic	innervation	of	the	(heart	and)	gut	
The	sympathetic	supply	of	the	heart	originates	from	T1	to	T4.	Some	fibres	from	T1	travel	up	
the	 sympathetic	 chain	 to	 synapse	 with	 postganglionic	 nerves	 in	 the	 three	 cervical	 chain	 ganglia.	
Other	 fibres	 from	 T1	 as	 well	 as	 those	 from	 T2	 to	 T4	 synapse	 with	 postganglionic	 nerves	 in	 the	
sympathetic	chain,	and	both	these	sets	of	postganglionic	fibres	form	the	cardiac	nerves.	The	trachea	
and	lungs	are	also	innervated	by	postganglionic	fibres	originating	either	from	the	sympathetic	chain	
or	cervical	chain	ganglia	innervated	by	preganglionic	fibres	originating	from	T1	to	T4.		
The	gut	is	supplied	by	preganglionic	fibres	from	T5	to	L2/3,	which	pass	into	the	sympathetic	
chain	 and	 then	 leave	 as	 splanchnic	 nerves	 (without	 synapsing	 in	 the	 sympathetic	 chain),	 which	
synapse	with	postganglionic	nerves	in	the	prevertebral	ganglia.	These	postsynaptic	nerves	supply	the	
gut	 from	 the	 oesophagus	 to	 the	 anus.	 Therefore,	 fibres	 from	 T5	 to	 T9	 /10	 supply	 the	 greater	
splanchnic	nerves	 serving	 the	coeliac	ganglion	 (distal	 foregut),	 fibres	 from	T10	and	T11	supply	 the	
lesser	 splanchnic	 nerves	 serving	 the	 superior	 mesenteric	 (midgut	 and	 asecending	 colon	 and	 two	
thirds	of	 the	 transverse	 colon)	and	aorticorenal	 ganglia	 (kidney	and	 suprarenal	 gland),	 fibres	 from	
T12	 supply	 the	 least	 splanchnic	 nerves	 serving	 the	 renal	 plexus,	 and	 fibres	 from	 L1/L2	 supply	 the	
lumbar	splanchnic	nerves	serving	the	inferior	mesenteric	ganglion	plexus	(hindgut,	so	distal	third	of	
transverse	colon,	descending	colon,	sigmoid	colon	and	proximal	2/3	of	the	anal	canal).	
The	parasympathetic	innervation	of	the	(heart	and)	gut	
The	 cranial	 parasympathetic	 (efferent)	 ganglia	 (arising	 from	 neural	 crest	 cells)	 and	 the	
cranial	sensory	(afferent)	ganglia	(arising	from	neural	crest	cells	and	placode	cells)	start	to	appear	in	
week	 5.	 The	 cranial	 parasympathetic	 ganglia	 are	 the	 ganglia	 associated	 with	 the	 vagus	 nerve	
(supplying	the	gut,	heart,	lungs	and	pelvic	organs)	and	the	parasympathetic	ganglia	associated	with	
III,	VII	and	IX	(supplying	the	relevant	structures	of	the	head).		
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The	 vagus	 nerve	 in	 particular	 contains	 somatic	 motor	 and	 sensory	 fibres	 as	 well	 as	
preganglionic	 parasympathetic	 fibres.	 Its	 branches	 subsequently	 supply	 structures	 of	 the	 head	 as	
well	 as	 the	 thorax	 and	 abdomen,	 to	 synapse	 with	 postganglionic	 vagal	 fibres	 at	 the	 many	 small	
parasympathetic	ganglia	located	in	the	walls	of	the	organs	supplied.	Parasympathetic	preganglionic	
fibres	that	arise	from	the	sacral	spinal	cord	(S2	–	S4)	travel	through	the	ventral	rami	and	join	to	make	
up	 the	 pelvic	 splanchnic	 nerves,	 which	 supply	 ganglia	 in	 the	 descending	 colon,	 sigmoid	 colon,	
rectum,	 ureter,	 bladder	 and	 genitals.	 The	 postganglionic	 fibres	 from	 all	 these	 ganglia	 innervate	
smooth	muscle	and	glands	(10)	(11).		
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The	vagus	nerve	
The	vagus	nerve	is	longest	and	most	complex	of	the	cranial	nerves.	It	contains	somatic	and	
visceral	afferent	 fibres,	as	well	as	general	and	special	visceral	efferent	 fibres.	The	vagus	nerve	 is	a	
major	 component	 of	 the	parasympathetic	 component	 of	 the	ANS,	 hence	 stimulation	of	 the	 vagus	
nerve	is	a	possible	means	of	increasing	parasympathetic	tone,	harnessing	an	analgesic	effect	(12).		
The	vagus	nerve	exits	from	the	medulla	oblongata	in	the	groove	between	the	olive	and	the	
inferior	 cerebellar	peduncle	of	 the	brain.	 It	 leaves	 the	 skull	 through	 the	 jugular	 foramen,	where	 it	
has	upper	and	lower	ganglionic	swellings,	which	are	the	sensory	ganglia	of	the	nerve	-	the	superior	
jugular	ganglion	and	the	 inferior	nodose	ganglion.	 	The	vagus	nerve	 is	 joined	by	the	cranial	root	of	
the	accessory	nerve,	just	below	the	inferior	ganglion.	
The	meningeal	branch	of	the	vagus	nerve	arises	at	the	superior	ganglion	and	re-enters	the	
cranium	 through	 the	 jugular	 foramen	 to	 supply	 the	 posterior	 fossa	 dura.	 The	 auricular	 branch	
supplies	sensations	to	the	posterior	aspect	of	the	external	ear	(pinna)	and	the	posterior	part	of	the	
external	auditory	canal.	It	arises	also	from	the	superior	ganglion	and	enters	the	mastoid	canaliculus	
in	the	lateral	part	of	the	jugular	foramen.	It	exits	again	through	the	tympanomastoid	suture	of	the	
temporal	bone	 to	 reach	 the	 skin.	 It	 communicates	with	branches	of	 the	 seventh	 (facial)	and	ninth	
(glossopharyngeal)	cranial	nerves.	
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Components	 Function	 Central	
connection	
Cell	bodies	 Peripheral	distribution	
	
Branchial	motor	
(efferent	special	
visceral)	
Swallowing,	
phonation	
Nucleus	
ambiguus	
Nucleus	ambiguus	 Pharyngeal	branches,	
superior	and	inferior	
laryngeal	nerves	
	
Visceral	motor	
(efferent	general	
visceral)	
Involuntary	
muscle	and	
gland	control	
Dorsal	
motor	
nucleus	X	
Dorsal	motor	
nucleus	X	
Cardiac,	pulmonary,	
esophageal,	gastric,	
celiac	plexuses,	and	
muscles,	and	glands	of	
the	digestive	tract	
	
Visceral	sensory	
(afferent	general	
visceral)	
Visceral	
sensibility	
Nucleus	
tractus	
solitarius	
Inferior	ganglion	X	 Cervical,	thoracic,	
abdominal	fibers,	and	
carotid	and	aortic	bodies	
	
Visceral	sensory	
(afferent	special	
visceral)	
Taste	 Nucleus	
tractus	
solitarius	
Inferior	ganglion	X	 Branches	to	epiglottis	and	
taste	buds	
General	sensory	
(afferent	general	
somatic)	
Cutaneous	
sensibility	
Nucleus	
spinal	tract	
V	
Superior	ganglion	X	 Auricular	branch	to	
external	ear,	meatus,	and	
tympanic	membrane	
	
	
Table	1.2:	Summary	of	Central	Connections,	Components,	Function,	and	Peripheral	Distribution	of	the	
Vagus	Nerve.	Adapted	from	https://emedicine.medscape.com/article/1875813-overview#a1	
	
The	 vagus	 nerve	 descends	 within	 the	 carotid	 sheath,	 posterolateral	 to	 the	 internal	 and	
common	carotid	arteries	and	medial	to	the	internal	jugular	vein	at	the	root	of	the	neck.	Branches	of	
the	vagus	nerve	arising	at	the	neck	are	the	pharyngeal	branches,	 the	superior	 laryngeal	nerve,	 the	
recurrent	laryngeal	nerve	and	the	superior	cardiac	nerve.	
The	right	vagus	crosses	in	front	of	the	first	part	of	the	subclavian	artery.	It	then	reaches	the	
thorax	 on	 the	 right	 side	 of	 the	 trachea,	 inclines	 behind	 the	 hilum	 of	 the	 right	 lung	 and	 courses	
medially	toward	the	oesophagus	to	form	the	oesophageal	plexus	with	the	left	vagus	nerve.		
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The	 left	vagus	crosses	 in	front	of	the	 left	subclavian	artery	to	enter	the	thorax.	 It	descends	
on	the	left	side	of	the	aortic	arch,	and	travels	behind	the	phrenic	nerve.	It	courses	behind	the	root	of	
the	 left	 lung	 to	 reach	 the	 oesophagus	 and	 form	 the	 oesophageal	 plexus	 by	 joining	 the	 opposite	
(right)	vagus	nerve.	
The	 inferior	 cardiac	 branch	 on	 the	 right	 side	 arises	 from	 the	 trunk	 of	 the	 vagus	 as	 it	 lies	
beside	 the	 trachea.	 On	 the	 left	 side,	 it	 originates	 from	 the	 recurrent	 laryngeal	 nerve	 only.	 These	
branches	end	in	the	deep	part	of	the	cardiac	plexus.	It	is	important	to	note	that	the	right	vagus	nerve	
is	 involved	 in	 innervation	of	 the	sinoatrial	node	of	 the	heart	whilst	 the	 left	vagus	nerve	 innervates	
the	atrioventricular	node.	Experimental	evidence	 in	 rats	has	demonstrated	 that	 stimulation	of	 the	
left	vagal	nerve	does	not	affect	heart	rate,	whereas	right	vagal	nerve	stimulation	does	affect	heart	
rate	(13).	
The	anterior	and	posterior	bronchial	branches	of	the	vagus	nerve	are	distributed	as	branches	
on	the	anterior	surface	of	the	root	of	the	lung,	forming	the	anterior	pulmonary	plexus	after	joining	
branches	from	the	sympathetic	trunk.	The	posterior	bronchial	branches	are	larger	than	the	anterior	
and	lie	on	the	posterior	surface	of	the	root	of	the	lung	to	form	the	posterior	pulmonary	plexus	(with	
contributory	sympathetic	fibres)	as	well.		
The	hepatic	branches	originate	from	the	 left	vagus,	and	join	the	hepatic	plexus.	From	here	
further	branches	are	distributed	to	the	liver.	The	gastric	branches	supply	the	stomach	with	the	right	
vagus	forming	the	posterior	gastric	plexus	and	the	left	vagus	forming	the	anterior	gastric	plexus.	The	
coeliac	branches	are	derived	mainly	from	the	right	vagus	nerve,	and	they	join	the	coeliac	plexus	and	
supply	the	pancreas,	spleen,	kidneys,	adrenals,	and	intestine.			
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Figure	1.1:	The	vagus	nerve	and	its	distribution.	
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Vagal	nerve	stimulation	
Stimulation	of	the	vagus	nerve	using	implanted	electrical	stimulators	is	well	established	as	a	
therapy	 for	 conditions	 such	 as	 epilepsy	 (14)	 depression	 (15)	 and	 gastroparesis	 (16).	 In	 terms	 of	
nausea,	 vomiting	 and	 sensitivity	 to	 distension,	 gastric	 electrical	 stimulation	 has	 been	 shown	 to	
improve	symptoms	in	patients	with	gastroparesis,	especially	diabetic	gastroparesis	in	the	short	and	
long	term	(16,	17).	The	evidence	for	vagal	nerve	stimulation	in	other	conditions	such	as	sepsis	and	
inflammation	as	described	in	the	previous	paragraph,	is	emerging	(18).	In	the	context	of	pain,	vagal	
nerve	 stimulation	has	been	used	 to	 treat	 fibromyalgia	 (19)	and	migraine	 (20).	 Implanted	electrical	
stimulators,	bring	with	them	complications	associated	with	an	invasive	procedure.	
Non	 invasive	 electrical	 vagal	 nerve	 stimulation	 is	 increasingly	 being	 considered,	 with	 the	
advent	of	several	devices	on	the	market	of	late.	There	is	some	evidence	to	show	possible	utility	and	
effectiveness	in	epilepsy	(21),	migraine	(22),	nausea	and	gastroparesis	(23)	at	present.		
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Oesophageal	nociception	
The	 uncontrolled	 activation	 of	 nociceptors	 is	 a	 problem	 in	 allodynia	 and	 hyperalgesia.	
Allodynia	is	the	sensation	of	pain	in	response	to	a	stimulus	that	does	not	usually	cause	pain.	In	the	
absence	of	a	stimulus,	pain	is	not	felt.	In	hyperalgesia,	there	is	an	exaggerated	response	to	noxious	
stimuli	 with	 persistence,	 despite	 removal	 of	 the	 stimuli.	 This	 persistent	 pain	 can	 be	 either	
nociceptive	 pain	 (activation	 of	 nociceptors	 in	 response	 to	 inflammation	 or	 injury)	 or	 neuropathic	
pain	(direct	injury	to	nerves	in	the	peripheral	nervous	system	(PNS)	or	central	nervous	system	(CNS)	
resulting	in	burning	or	electrifying	pain).	
Nociceptors	 are	 free	 nerve	 endings	 of	 primary	 sensory	 neurons.	 They	 are	 unlike	 more	
specialised	 sensory	 receptors	 for	 touch	 and	 pressure.	 They	 are	 widely	 distributed	 and	 often	
coactivated.	The	initial	pain	perceived	by	a	nociceptor	is	via	Aδ	axons.	More	longer	lasting	duller	pain	
is	perceived	by	C	fibres.	Receptors	on	the	membrane	of	the	nociceptor	axon	convert	stimuli	 into	a	
depolarising	action	potential.		
Nociceptors	can	be	thermal,	mechanical,	polymodal	and	silent.		
• Thermal	 nociceptors	 –	 usually	 activated	 by	 temperatures	 >45C	 or	 less	 than	 5C.	 They	 are	
small	diameter,	thinly	myelinated	Aδ	axons	(speed	5	to	30m/s).		
	
• Mechanical	nociceptors	–	activated	by	more	intense	pressure	(not	light	touch)	and	are	also	
thinly	myelinated	Aδ	axons.		
	
• Polymodal	nociceptors	–	are	activated	by	 chemical,	 thermal	and	high	 intensity	mechanical	
stimuli.	They	are	small	diameter	unmyelinated	C	axon	endings	conducting	at	slower	speeds	
of	1m/s.	
	
• Silent	 nociceptors	 –	 these	 are	 found	 in	 viscera,	 and	 they	 are	 not	 normally	 activated	 by	
noxious	 stimuli.	 Inflammation	 and	 chemical	 stimuli	 reduce	 their	 firing	 threshold,	 and	 they	
contribute	to	secondary	hyperalgeisa	and	central	sensitization.	
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The	 transient	 receptor	 potential	 vanilloid	 receptor	 family,	 and	 in	 particular,	 transient	
receptor	potential	vanilloid	receptor	1	(TRPV1)	is	expressed	in	oesophageal	epithelial	cells.	TRPV1	is	
activated	by	weak	acid	as	well	as	capsaicin	and	thermal	stimuli	(24).		
Weak	acid	 is	also	known	to	activate	the	acid-sensing	 ion	channels	(ASICs),	which	belong	to	
the	voltage-insensitive,	amiloride-sensitive	degenerin/epithelial	Na	channel	superfamily	 (25).	ASIC3	
in	particular,	is	known	to	be	expressed	on	human	oesophageal	epithelial	cells	(26).	
Another	 important	 receptor	 is	 Protease-activated	 receptor-2	 (PAR-2),	 also	 expressed	 in	
human	oesophageal	 epithelial	 cells.	 It	 is	 thought	 to	 increase	acid-induced	Adenosine	 triphosphate	
(ATP)	release.	ATP	behaves	as	a	neurotransmitter	in	the	central	and	peripheral	nervous	systems	and	
is	 involved	 in	 peripheral	 inflammation	 and	 transmission	 of	 pain	 (27),	 by	 inducing	 the	 secretion	 of	
platelet-activating	 factor	 (PAF),	 IL-8,	 eotaxins,	 monocyte	 chemoattractant	 protein-1	 (MCP-1),	 and	
macrophage	 inflammatory	 protein-1	 (MIP-1)	 that	 contribute	 to	 inflammation	 and	 injury	 of	 the	
oesophageal	 mucosa.	 ATP	 can	 also	 mediate	 the	 release	 of	 other	 neurotransmitters	 such	 as	
substance	P	and	CGRP	that	may	contribute	to	transmission	of	the	sensation	of	pain	(28).		
Wu	 et	 all	 demonstrated	 that	 acid	 induced	 ATP	 release	 was	 significantly	 reduced	 after	
pretreatment	of	human	oesophageal	epithelial	cells	with	both	5-iodoresiniferatoxin	(IRTX),	a	TRPV1-
specific	 antagonist,	 and	 with	 amiloride,	 a	 nonselective	 ASIC	 blocker.	 They	 also	 showed	 that	
pretreatment	 of	 human	 oesophageal	 epithelial	 cells	 with	 a	 PAR-2	 agonist	 enhanced	 weak	 acid-
induced	ATP	 release	 (29).	 These	 findings	 suggested	 that	 the	pathophysiology	of	 oesophageal	 pain	
hypersensitivity	may	be	associated	with	the	activation	of	PAR-2,	TRPV1,	and	ASICs.	
Prostaglandins	 are	 inflammatory	mediators	 associated	with	 inflammation	and	nociception,	
and	 of	 the	 prostaglandins,	 prostaglandin	 E2	 (PGE2)	 is	 known	 to	 be	 associated	 with	 nociception.	
When	 stimulated	 with	 chemical,	 thermal,	 mechanical	 or	 inflammatory	 stimuli,	 levels	 increase,	
causing	 peripheral	 sensitization	 of	 adjacent	 nerve	 endings	 via	 nociceptors	 such	 as	 TRPV1	 (30).	
Prostaglandins	bind	 to	EP	 receptors,	 and	PGE2	 in	particular,	binds	 to	4	 subtypes	of	EP	 receptors	 -		
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EP1,	 EP2,	 EP3	 and	EP4.	Of	 these	 subtypes,	 EP1	 receptors	 have	been	 shown	 to	be	 associated	with	
pain	 processing.	 Oesophageal	 acid	 exposure	 has	 been	 shown	 to	 increase	 PGE2	 levels	 (31),	 whilst	
antagonists	of	EP1	such	as	ZD6416	(32)	and	ONO	8539	(33)	have	been	shown	to	reduce	oesophageal	
hyperalgesia.		
There	 are	 other	 receptors	 and	 ion	 channels	 expressed	 in	 nociceptive	 sensory	 endings,	
although	not	 specifically	 identified	 yet	 in	 the	oesophagus.	 Those	expressing	 tetrodotoxin	 resistant	
Na	channels	(such	as	NaV1.7,	also	called	SCN9A)	were	discovered	in	patients	with	a	deletion	causing	
the	 inactivation	of	nav1.7,	 resulting	 in	a	complete	 inability	 to	sense	pain	 (34).	All	other	sensations	
are	normal	in	these	individuals.	Efforts	are	ongoing	to	assess	the	viability	of	NAV	1.7	as	a	target	for	
pain	modulating	therapies.		
MrgX2,	is	a	member	of	the	Mas-related	gene	(Mrgs)	family	(which	are	a	recently	identified	G	
protein-coupled	receptor	gene	family)	(35).	MrgX2	is	specifically	expressed	in	nociceptive	neurons	of	
the	dorsal	root	ganglia	and	trigeminal	ganglia,	suggesting	a	role	in	pain	processing,	with	potential	as	
another	target	for	pain	modulating	therapies.		
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Normal	oesophageal	physiology	
The	primary	function	of	the	oesophagus	 is	to	convey	 ingested	contents	from	the	mouth	to	
the	 stomach.	 This	 is	 achieved	 by	 a	 coordinated	 sequence	 of	 neuromuscular	 activity.	 Deglution	
involves	relaxation	of	the	upper	oesophageal	sphincter,	followed	shortly	by	relaxation	of	the	lower	
oesophageal	 sphincter,	with	 a	wave	 of	 peristaltic	 contraction	 propagating	 from	 proximal	 to	 distal	
oesophagus,	thus	allowing	the	bolus	to	be	admitted	to	the	stomach.			
	
	
	
	
	
	
	
Figure	1.2:	High	 resolution	manometry	 showing	 the	high	pressure	 zones	of	 the	upper	oesophageal	
sphincter	 (UOS)	 and	 the	 LOS.	 The	 colours	 on	 the	 heat	map	 represent	 pressure,	 the	 oesophagus	 is	
represented	on	the	y	axis	and	time	is	represented	on	the	x	axis.	
	
A	physiological	mechanism	for	venting	gas	from	the	stomach	exists,	and	involves	prolonged	
relaxations	 of	 the	 lower	 oesophageal	 sphincter,	 which	 occur	 independently	 to	 swallowing	 (36).	
These	 relaxations	 are	 termed	 transient	 lower	 oesophageal	 sphincter	 relaxations	 (TLOSRs)	 and	 are	
stimulated	by	gastric	distension,	especially	of	the	proximal	stomach.		
	
Upper	oesophageal	sphincter	
	
	
	
	
	
Lower	oesophageal	sphincter	
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Gastro	oesophageal	reflux	disease		
Gastro	 oesophageal	 reflux	 disease	 (GORD)	 is	 defined	 by	 the	 Montreal	 definition	 as	 a	
condition	 which	 develops	 when	 the	 reflux	 of	 gastric	 content	 causes	 troublesome	 symptoms	 or	
complications	(1).	GORD	is	then	further	classified	by	the	Montreal	classification	system	(Figure	1.4)	
into	categories	defined	by	investigations	that	form	the	usual	diagnostic	algorithm	(Figure	1.6)	for	a	
patient	with	suspected	GORD.		
Patients	 with	 no	 evidence	 of	 oesophageal	 injury	 are	 deemed	 to	 have	 a	 symptomatic	
syndrome.	 Symptoms	 may	 be	 typical	 or	 atypical,	 but	 in	 general,	 patients	 with	 the	 symptomatic	
syndrome	of	GORD	are	defined	as	having	non-erosive	reflux	disease	(NERD).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.4:	Overall	definition	of	GERD	and	its	constituent	syndromes	–	Montreal	classification.	
NERD 
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Epidemiology	
The	reported	prevalence	of	GORD	is	increasing	worldwide,	with	rates	of	up	to	almost	30%	in	
North	 America,	 almost	 26%	 in	 Europe,	 9%	 in	 East	 Asia,	 33%	 in	 the	 Middle	 East,	 almost	 12%	 in	
Australia	and	23%	in	South	America	(37).	In	contrast,	a	similar	analysis	undertaken	in	2005	reported	
much	 lower	 rates	 overall.	 For	 example,	 as	 a	whole,	 in	 the	Western	world,	 prevalence	 rates	were	
previously	 approximately	 20%	 (38).	 The	 cause	of	 this	 overall	 increase	 in	prevalence	 is	 not	 easy	 to	
elucidate.	The	high	economic	burden	of	GORD	 is	 therefore	only	 likely	 to	 rise.	Peery	et	al	 reported	
that	gastro	oesophageal	reflux	was	the	most	common	GI	diagnosis	made	in	the	United	States	in	their	
2012	update	(39),	with	cost	implications	due	to	investigations	(endoscopy)	and	treatment.	In	the	UK,	
direct	and	indirect	care	costs	of	reflux	disease	are	estimated	to	be	in	the	order	of	£2	billion	per	year	
(40).	
Non	erosive	reflux	disease	(NERD)	
Of	 the	 large	population	of	patients	with	GORD,	 those	diagnosed	with	NERD	make	up	70%	
(41).	 This	 group	 of	 patients	 is	 a	 heterogeneous	 one	 and	 definition	 of	 the	 constituent	 component	
groups	is	ongoing.		
	
	
	
	
	
Figure	1.5:	Patients	with	functional	heartburn	are	often	mistakenly	considered	as	NERD	until	 this	 is	
disproven	with	24	hour	multi	channel	intra	luminal	impedance	(MII)	pH	studies.	
	NERD	
True	NERD	 Reflux	hypersensitivity	 Functional	heartburn	/	chest	pain	
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As	shown	above,	those	patients	with	oesophageal	reflux	hypersensitivity	and	patients	with	
functional	heartburn	are	also	included	as	NERD	until	24	hour	multi	channel	intra	luminal	impedance	
(MII)	pH	studies	are	carried	out.	The	significance	of	this	is	shown	when	response	rates	to	PPI	therapy	
are	reviewed,	when	patient	with	FH	or	FCP	do	not	respond	to	anti	reflux	therapy		
True	NERD	
These	 are	 patients	 who	 have	 no	 macroscopic	 oesophageal	 injury	 at	 OGD	 and	 who	 have	
raised	oesophageal	acid	exposure	on	24	hour	pH	metry	alone.	The	proportion	of	 these	patients	 is	
not	as	high	as	previously	anticipated	with	the	advent	and	wider	use	of	MII	pH	metry	(42).	
Oesophageal	reflux	hypersensitivity	
These	 are	 patients	 who	 have	 no	 macroscopic	 oesophageal	 injury	 at	 OGD,	 and	 who	 have	
normal	oesophageal	acid	exposure	but	positive	reflux-symptom	association	at	MII	pH	metry.		
Functional	heartburn	and	functional	chest	pain	
These	 are	 patients	 who	 have	 no	 oesophageal	 injury	 at	 OGD	 and	 who	 have	 normal	
oesophageal	acid	exposure	as	well	as	negative	reflux-symptom	association	at	MII	pH	metry	(4).	 
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Diagnostic	tools	in	GORD	
On	 presenting	 to	 a	 clinician,	 a	 patient	 with	 symptoms	 of	 GORD	 currently	 will	 either	 be	
offered	 a	 trial	 of	 proton	 pump	 inhibitors	 (PPIs)	 or	 be	 referred	 for	 an	 oesophago-gastro-
duodenoscopy	(OGD).	As	mentioned	above,	most	OGD	examinations	yield	a	negative	finding	-	that	is	
they	show	a	macroscopically	normal	upper	gastrointestinal	 tract.	Oesophageal	biopsies	 to	 look	 for	
possible	 histological	 evidence	 of	 eosinophilic	 oesophagitis	 and	 microscopic	 oesophagitis	 can	 be	
performed	through	the	endoscope	at	the	same	time.	
Figure	1.6:	Classification	of	heartburn	in	the	context	of	a	normal	gastroscopy	as	per	Aziz	et	al	from	
the	ROME	 IV	oesophageal	disorders	 section,	highlighting	 the	use	of	pH	monitoring	 in	 classification	
(2).	
	
Prior	to	pH	metry,	patients	undergo	high-resolution	manometry	(HRM),	in	order	to	exclude	
major	 motility	 disorders,	 as	 well	 as	 to	 locate	 the	 upper	 border	 of	 the	 LOS.	 The	 next	 step	 in	
investigating	 these	 patients	 is	 by	 means	 of	 24	 hour	 pH	 monitoring,	 either	 using	 an	 oesophageal	
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catheter	 (with	 or	 without	 impedance	 recording)	 or	 wirelessly	 with	 a	 pH	 capsule	 attached	 to	 the	
distal	oesophagus.		
Recently,	the	length	of	pH	studies	has	come	under	scrutiny.	Sweis	et	al	(43)	took	38	patients	
who	had	a	negative	24	hour	catheter	based	pH	study	and	who	continued	to	have	symptoms.	They	
then	performed	prolonged	wireless	pH	studies	(up	to	96	hours,	with	a	median	of	72	hours)	on	these	
patients.	Average	versus	worst	day	analysis	demonstrated	that	oesophageal	acid	exposure	was	37%	
versus	 47%.	More	 strikingly,	when	 symptom	association	 probability	 (SAP)	was	 calculated,	 average	
versus	 worst	 day	 analysis	 showed	 a	 positive	 SAP	 in	 34%	 versus	 63%	 respectively.	 Overall,	 using	
average	and	worst	day	analyses,	61%	and	76%	of	these	patients	were	diagnosed	with	GERD.	This	not	
only	highlights	the	increased	tolerability	of	wireless	pH	studies,	but	also	considering	a	negative	SAP	
would	 confer	a	diagnosis	of	 functional	heartburn	or	 chest	pain,	 the	 concern	 is	 that	 these	patients	
may	be	erroneously	diagnosed	as	having	functional	heartburn	/	chest	pain,	and	not	GORD,	limiting	
their	access	to	potentially	helpful	treatments.	
Another	 area	 of	 debate	 is	 the	 reliability	 of	 calculating	 symptom	 association	 using	 either	
Symptom	Index	(SI),	symptom	specificity	index	(SSI)	or	SAP.	SI	and	SAP	are	more	commonly	used.	All	
three	are	a	means	of	reconciling	the	probability	of	a	reflux	event	and	an	episode	of	heartburn	and	
are	therefore	used	to	assess	reflux	symptom	association.	All	three	statistical	methods	of	calculating	
symptom	association	are	more	useful	when	patients	experience	higher	rates	of	reflux.	Slaughter	et	
al	concluded	that	SI	and	SAP	were	less	reliable	in	those	patients	with	low	numbers	of	reflux	events	
(less	than	10%	of	the	physiologically	accepted	number	of	reflux	episodes),	and	SI	and	SAP	were	also	
less	 reliable	 in	 those	who	 responded	poorly	 to	PPI	 therapy	 (44),	with	 the	effect	of	overestimating	
symptom	association.	Barriga-Rivera	et	al	used	the	Monte	Carlo	method	to	evaluate	reflux	symptom	
association,	and	concluded	in	particular	that	the	length	of	the	study	did	not	impact	on	SI	and	SSI,	and	
in	fact,	the	longer	the	study,	the	more	reliable	they	were.	However,	in	terms	of	SAP,	the	longer	the	
study	duration,	 the	higher	 the	value	of	 the	SAP	was	due	to	a	non	 linear	 relationship	between	SAP	
and	duration.	As	discussed	above,	 length	of	pH	 studies	 is	 a	 topic	of	 review	 recently,	 and	with	 the	
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advent	of	 longer	duration	studies,	 the	utility	of	 the	SAP	will	 increasingly	come	under	scrutiny	 (45).	
Therefore,	 it	 is	 important	 to	note	 these	 limitations	of	 the	current	available	methods	of	calculating	
reflux	symptom	association	when	interpreting	results.		
The	 Bernstein	 test	 was	 developed	 to	 diagnose	 reflux	 induced	 chest	 pain	 (46).	 It	 is	 still	
occasionally	used	to	diagnose	an	acid	sensitive	oesophagus	in	the	clinical	setting,	although	currently	
a	modified	version	is	often	used	in	the	research	setting	to	look	at	changes	in	the	acid	sensitivity	of	
the	oesophagus	 in	 relation	 to	 various	 therapies.	During	 this	 test,	 saline	 is	 initially	 infused	 into	 the	
lower	 oesophagus	 (10	 cm	 above	 the	 lower	 oesophageal	 sphincter)	 at	 a	 rate	 of	 10	 mL/min	 for	 2	
minutes.	Subsequently,	without	the	patient’s	knowledge,	0.1	M	hydrochloric	acid	solution	is	infused	
into	the	lower	oesophagus	for	10	minutes	at	the	same	rate.		
During	a	modified	Bernstein	test,	stimulus-response	functions	to	acid	are	quantified	by	 lag	
time	to	symptom	perception	(the	time	taken	for	subjects	to	report	when	retrosternal	discomfort	is	
perceived	during	acid	perfusion).	 In	the	context	of	research,	sensory	 intensity	rating	(at	the	end	of	
the	acid	perfusion)	and	APSS	(acid	perfusion	sensitivity	score)	are	often	calculated	(47).	 	
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Treatment	of	GORD	
	
PPIs	 Omeprazole,	lansoprazole,	rabeprazole,	pantoprazole	
Esomeprazole	
Dexlansoprazole	modified	release	
PPI	combinations	 IR	omeprazole	(combined	with	sodium	bicarbonate)	
H2	Receptor	antagonist	 Ranitidine	
Motility	agents	 Domperidone,	metoclopramide,	erythromycin	
Visceral	hypersensitivity	 Citalopram	
Surgical	therapies	 Nissen	Fundoplication	
Endostim	device		
Linx	device	
Endoscopic	therapies	 Stretta	procedure		
Endocinch	system		
Esophyx	device		
MUSE	TM	system	
	
Table	1.3:	Treatments	either	currently	available	or,	in	development,	for	the	treatment	of	GORD.		
	
Acid	suppression	therapy	
Proton	 pump	 inhibitors	 (PPIs)	 are	 currently	 the	 most	 commonly	 used	 pharmacological	
therapy	used	 for	 the	 treatment	of	GORD.	 	The	most	widely	used	PPIs	are	enteric	 coated,	 to	delay	
release	of	the	inactive	drug	until	it	is	in	the	small	bowel.	Once	in	the	small	bowel,	the	inactive	PPI	is	
quickly	 absorbed	 and	 redistributed	 to	 the	 acid	 filled	 canaliculus	 of	 an	 actively	 secreting	 gastric	
parietal	cell.	Here,	in	the	acidic	environment	of	the	canaliculus,	it	is	activated.	The	active	PPI	binds	to	
a	 cysteine	moiety	 in	 the	proton	pump,	 irreversibly	 stopping	acid	 secretion	 (48).	Newer	 isomers	of	
traditional	PPIs	such	as	esomeprazole	(49-51),	dexlanzoprazole	(52,	53)	and	S-pantoprazole	have	an	
increased	bioavailability	profile,	with	an	increased	area	under	the	plasma	concentration–time	curve.	
Extended	release	preparations	have	been	developed	to	increase	exposure	of	more	proton	pumps	to	
the	PPI.	 Extended	 release	 rabeprazole	 contains	 a	 combination	of	 a	 standard	enteric	 coated	 tablet	
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which	is	released	in	the	proximal	small	intestine,	and	four	pulsatile	release	tablets	that	are	released	
in	 the	 distal	 small	 intestine	 and	 the	 colon	 (54).	 Alevium	 (AGN201904-Z)	 is	 a	 chemically	 metered	
absorption	omeprazole	that	is	slowly	absorbed	throughout	the	length	of	the	small	intestine	resulting	
in	 a	 steady	 and	 prolonged	 plasma	 residence	 time	 (55).	 Immediate	 release	 (IR)	 PPIs	 are	 another	
avenue	 that	 have	been	explored.	 IR	omeprazole	 and	 IR	 esomeprazole	 are	non-enteric	 coated	 and	
combined	 with	 (54)	 sodium	 bicarbonate.	 The	 sodium	 bicarbonate	 prevents	 the	 PPI	 from	 being	
activated	 in	 the	stomach	as	 it	passes	 into	 the	small	 intestine.	Because	 it	does	not	have	an	enteric	
coat,	 the	 PPI	 is	 more	 rapidly	 absorbed.	 The	 sodium	 bicarbonate	 also	 stimulates	 acid	 secretion,	
enhancing	uptake	and	activation	of	the	inactive	PPI	(56).	PPIs	have	been	combined	with	other	agents	
to	 try	 to	 enhance	 their	 acid	 suppressive	 action.	 VECAM	 is	 omeprazole	 combined	 with	 VB101,	 a	
compound	 with	 pentagastrin	 like	 activity,	 which	 activates	 the	 parietal	 cell	 and	 stimulates	 acid	
secretion	from	the	proton	pump.	This	allows	more	PPI	to	be	taken	up	in	to	the	parietal	cell	canaliculi,	
enhancing	PPI	activity,	 thus	 reducing	 reliance	on	meal	 times	as	 the	proton	pump	 is	 independently	
activated	 (56).	 PPIs	 have	 been	 combined	 with	 nitric	 oxide,	 which	 is	 known	 to	 have	 an	 effect	 on	
mucosal	blood	flow	and	mucous	production,	with	H2RAs,	alginates	and	with	prokinetics	(56).	Other	
newer	 acid	 suppressants	 under	 development	 include	 tenatoprazole	 (an	 imidazopyridine	 with	 a	
longer	 half	 life	 than	 traditional	 PPIs)	 (57)	 and	 Ilaprazole	 (a	 modified	 benzimidazole	 that	 may	 be	
useful	in	poor	PPI	metabolizers	as	it	is	metabolized	via	a	different	pathway	than	the	usual	CYP2C19	
pathway)	(58).		
Potassium	 competitive	 acid	 blockers	 (PCABs)	 bind	 to	 the	 potassium-binding	 region	 of	 the	
proton	pump	in	a	competitive	reversible	manner	(59).	The	onset	of	action	is	also	much	faster	than	in	
traditional	PPIs.	Of	 the	PCABs	 recently	under	development,	 TAK	438	 (Vonoprazan)	 is	one	 that	has	
recently	completed	Phase	3	trials	at	present.	Although	previous	studies	demonstrated	noninferiority	
to	lanzoprazole	in	the	treatment	of	erosive	reflux	disease	(ERD)	(60),	at	doses	of	10	mg	and	20	mg,	
Vonoprazan	 was	 not	 superior	 to	 placebo	 in	 terms	 of	 proportion	 of	 days	 without	 heartburn	 in	
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patients	 with	 NERD.	 Severity	 of	 heartburn	 however	 was	 lower	 with	 vonoprazan	 compared	 to	
placebo	(61).		
Anti-reflux	agents		
Although	much	 progress	 has	 been	made	with	 acid	 suppression,	 it	 is	 clear	 that	 this	 is	 not	
likely	 to	 address	 all	 symptoms	 in	 GORD,	 particularly	 regurgitation	 and	 symptoms	 associated	with	
non-acid	 reflux.	 Reducing	 reflux	 per	 se	 is	 a	 more	 direct	 approach	 and	 is	 currently	 achieved	 by	
surgical	fundoplication.	Pharmacological	options	to	reduce	reflux	do	so	by	reducing	transient	lower	
oesophageal	 sphincter	 relaxations	 (TLOSRs).	 TLOSRs	 are	 a	 major	 mechanism	 of	 reflux	 in	 healthy	
subjects	 and	 in	 patients	 with	 GORD	 (62,	 63).	 They	 are	 prolonged	 relaxations	 of	 the	 lower	
oesophageal	sphincter	that	occur	independently	to	swallowing	and	are	a	means	by	which	gas	from	
the	stomach	is	vented	(36).	They	occur	more	in	the	upright	position	compared	to	the	supine	position	
(64),	and	they	are	more	likely	to	be	associated	with	acid	reflux	in	patients	with	GORD		(65).	TLOSRs	
are	stimulated	by	gastric	distension,	especially	of	the	proximal	stomach	(36).	This	distension	triggers	
vagal	 afferents	 that	 synapse	 in	 the	NTS,	which	 then	 activates	motor	 neurons	 in	 the	 dorsal	motor	
nucleus	 of	 the	 vagus	 nerve,	 leading	 to	 relaxation	 of	 the	 lower	 oesophageal	 sphincter.	 During	 a	
TLOSR,	there	is	also	associated	crural	diaphragmatic	inhibition,	contraction	of	the	costal	diaphragm	
and	 prolonged	 oesophageal	 shortening	 due	 to	 longitudinal	 muscle	 contraction	 in	 the	 distal	
oesophagus	(66),	and	these	all	contribute	to	the	occurrence	of	reflux.	Given	that	TLOSRs	are	a	major	
cause	of	GORD,	they	are	an	attractive	therapeutic	target,	and	several	agents	have	been	developed	in	
an	 attempt	 to	 reduce	 their	 frequency.	 The	 GABA(β)	 agonist,	 baclofen,	 is	 able	 to	 reduce	 TLOSR	
frequency	and	number	of	reflux	events	in	patients	with	GORD	(67).	Unfortunately	baclofen	crosses	
the	 blood	 brain	 barrier,	 and	 the	 subsequent	 central	 side	 effects	 (such	 as	 drowsiness)	 have	
prohibitively	 restricted	 its	 use	 in	 clinical	 practice.	 This	 has	 led	 to	 the	 search	 for	 better-tolerated	
TLOSR	 inhibitors.	 Recently,	 the	metabotropic	 glutamate	 receptor	 5	 (mGluR5)	 antagonist	 AZD2066	
was	 demonstrated	 to	 reduce	 TLOSRs	 and	 reflux	 episodes	 in	 healthy	 male	 volunteers	 in	 a	 dose	
dependant	fashion	(68),	but	a	study	in	patients	with	NERD	was	terminated	early	due	to	safety	issues	
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(ClinicalTrials.gov	 Identifier:	 NCT00939094).	 Previous	 mGluR5	 antagonists	 had	 issues	 with	 poor	
tolerability	and	hepatotoxicity.		
Recent	attempts	at	development	of	nitric	oxide	synthase	inhibitors	and	cannabinoid	agonists	
as	TLOSR	inhibitors	have	been	halted	due	to	issues	with	tolerability.	GABA(β)	agonists	with	improved	
side	 effect	 profiles	 are	 perhaps	 the	 most	 promising	 candidates	 for	 TLOSR	 inhibition	 in	 clinical	
practice.	Lesogaberan	and	AZD9343,	which	are	both	peripherally	acting	GABA(β)	agonists	have	been	
shown	 to	 reduce	 TLOSR	 frequency	 and	 acid	 reflux	 as	 well	 as	 increase	 LOS	 pressure	 (69-71).	
Lesogaberan	 particularly	 was	 shown	 to	 reduce	 episodes	 of	 reflux	 more	 than	 it	 reduced	 TLOSRs,	
suggesting	that	the	effect	of	Lesogaberan	on	other	mechanisms	associated	with	reflux	such	as	LOS	
pressure	 reduction	 are	 important	 as	well.	 Lesogaberan	 also	 appeared	 to	 have	 a	 greater	 effect	 on	
acid	reflux	events	compared	to	non-acid	or	weakly-acid	reflux	events.	This	effect	has	also	been	seen	
with	 Baclofen.	 The	 cause	 of	 this	was	 unclear,	 and	 although	 the	 use	 of	 Lesogaberan	 in	 acid	 reflux	
appeared	 promising,	 its	 potential	 use	 in	 oesophageal	 hypersensitivity	 in	 relation	 to	 non-acid	 and	
weakly-acid	 reflux	 could	also	have	been	considered	 (71).	Arbaclofen	Placarbil,	which	 is	 an	actively	
transported	 prodrug	 of	 the	 active	 R-isomer	 of	 the	 GABA(β)	 agonist	 baclofen	 was	 also	 shown	 to	
reduce	reflux	episodes	compared	to	placebo	in	initial	studies	(72).	Such	drugs	may	also	be	potential	
treatments	 in	 reducing	 belching	 related	 persistent	 reflux,	 due	 to	 their	 action	 on	 increasing	 LOS	
pressure.	 Lesogaberan	and	Arbaclofen	Placarbil	were	both	 taken	 further	 in	 larger	 studies	 (73,	74).	
Unfortunately,	although	they	do	reduce	TLOSR	frequency,	 increase	LOS	pressure	and	reduce	reflux	
episodes,	 clinical	 efficacy	 was	 limited	 in	 trials,	 and	 both	 have	 now	 been	 abandoned	 by	 their	
respective	pharmaceutical	companies	(71,	72,	75).	As	a	result,	at	present,	baclofen	remains	the	only	
clinically	 available	 TLOSR-inhibiting	 agent	 for	 patients	 with	 refractory	 disease.	 It	 is	 possible	 that	
patient	selection	was	a	significant	factor	in	failure	of	these	drugs	in	the	clinical	setting,	but	adverse	
events	 appeared	 to	 have	 played	 a	 role	 as	 well.	 In	 these	 trials,	 patients	 were	 not	 previously	
phenotyped	based	on	reflux	monitoring	and	so	 functional	heartburn	or	 functional	dyspepsia	could	
not	be	excluded	 from	 the	 studies.	 This	has	 implications	on	 the	outcome	of	 such	 trials	because,	 in	
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these	patients,	reducing	TLOSRs	may	not	have	been	expected	to	improve	their	symptoms.	More	care	
in	phenotyping	and	selection	of	patients	 for	 trials	of	TLOSR	 inhibitor	 therapy	may	yet	determine	a	
role	for	these	drugs	in	GORD	management.		
Alginates	and	prokinetic	agents		
The	importance	of	the	acid	pocket	(the	a	layer	of	unbuffered	acid	that	sits	on	top	of	gastric	
contents	in	the	postprandial	period)	in	GORD	has	been	increasingly	recognized	over	recent	years	(76,	
77).	 Modulation	 of	 the	 position	 or	 composition	 of	 the	 acid	 pocket	 is	 an	 interesting	 therapeutic	
modality.	Alginate	preparations	can	form	a	raft	on	top	of	gastric	contents,	and	have	been	shown	to	
be	 able	 to	 neutralize	 and	 displace	 the	 acid	 pocket	 in	 patients	 (78).	 It	 is	 possible	 that	 further	
exploitation	 and	modification	of	 this	 effect	may	be	useful	 in	 future	 therapies	 for	GORD.	Alginates	
may	also	have	a	secondary	beneficial	effect	 in	protecting	the	oesophageal	mucosa	against	noxious	
injury	 in	 reflux	 disease.	 This	 has	 been	 demonstrated	 ex	 vivo	 (79),	 and	 further	 exploration	 of	 this	
property	may	be	of	benefit	in	future	drug	development.		
Macrolides	 such	 as	 erythromycin	 have	 been	 known	 to	 increase	 gastrointestinal	 motility,	
acting	 via	 motilin	 receptors.	 They	 also	 increase	 proximal	 stomach	 tone	 and	 LOS	 pressure	 (80).	
Recently,	 azithromycin	was	 shown	 to	 reduce	 acid	 reflux	 events	 and	oesophageal	 acid	 exposure	 in	
patients	with	GORD.	Hiatus	hernia	 in	 these	patients	with	GORD	was	 reduced	 in	size	and	displaced	
more	distally,	moving	the	acid	pocket	more	distal	relative	to	the	diaphragm.	Newer	motility	agents	
such	as	mitemcinal	(GM-611)	have	shown	some	promise	but	are	still	in	the	development	phase	(81).		
Other	 prokinetic	 agents	 widely	 in	 use	 include	 domperidone	 and	 metoclopramide.	 Their	
utility	is	limited	in	the	longer	term,	due	to	QT	prolongation	which	is	a	well	recognised	phenomenon.		
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Mechanical	treatments	
Laparoscopic	 fundoplication	 techniques	 such	 as	 Nissen	 Fundoplication	 have	 become	
increasingly	popular	since	the	1990s,	with	minimal-access	approaches	improving	recovery	times	and	
comorbidity	 associated	with	 fundoplication.	 Concerns	 about	 long-term	morbidity,	 failure	 and	 side	
effect	of	laparoscopic	surgery	(particularly	abdominal	bloating,	inability	to	belch,	and	dysphagia)	(82)	
have	resulted	in	attempts	to	develop	even	less	invasive	surgical	procedures	and	devices.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.7:	Types	of	laparoscopic	fundoplication,	all	of	which	aim	to	increase	integrity	of	the	GOJ.	
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Another	method	 in	 use	 is	 a	 laparoscopically	 placed	magnetic	 ring	 (of	 interlinked	 titanium	
beads	with	magnetic	cores	connected	by	small	wires)	that	is	placed	around	the	distal	oesophagus.		
	
	
Figure	1.8:	The	LINX	reflux	management	system	(Torax	Medical	Inc,	Minnesota)	
http://www.toraxmedical.com/linx/	
	
This	device,	the	LINX	reflux	management	system	(Torax	Medical	Inc,	Minnesota),	essentially	
augments	LOS	pressure	by	constricting	the	LOS.	Several	studies	have	assessed	efficacy	in	long	term	
reduction	of	symptoms	of	GORD,	reduction	in	PPI	use	and	improvements	in	quality	of	life	(83,	84).	
	
The	device	augments	the	LOS.	 The	device	is	able	to	expand	to	
allow	passage	of	a	bolus.	
Due	to	action	of	the	magnets,	
the	device	closes	after	bolus	
transit.	
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Electrical	stimulation	
A	newer	mechanical	method	of	 treating	GORD	 is	 an	 LOS	 stimulation	device,	 the	EndoStim	
(BV,	The	Hague,	Netherlands).	This	was	developed	on	 the	principle	 that	gastro	oesophageal	 reflux	
results	from	the	failure	of	the	barrier	function	of	the	GOJ,	a	major	component	of	which	is	the	LOS.	
Acute	and	chronic	electrical	stimulation	of	the	LOS	in	animal	models	has	shown	increased	LOS	basal	
pressures	(85)	(86,	87).	A	short-term	study	in	human	subjects	was	published	in	2012	by	Rodriguez	et	
al	 (88),	 where	 patients	 with	 GORD	 undergoing	 laparoscopic	 cholecystectomy,	 had	 a	 temporary	
electrode	 inserted	 into	 the	 LOS	 at	 the	 time	 of	 surgery.	 Oesophageal	manometry	 was	 carried	 out	
before	 and	 during	 30	 min	 periods	 without	 LOS	 electrical	 stimulation,	 and	 this	 showed	 that	
stimulation	 increased	 resting	 LOS	 pressure,	whilst	 peristaltic	 amplitude	 and	 residual	 LOS	 pressure	
(during	swallowing)	was	not	affected.	Therefore,	the	GOJ	is	augmented,	resulting	in	less	reflux,	and	
consequently	 reduced	 exposure	 of	 oesophageal	 mucosa	 to	 acid	 (as	 well	 as	 non	 acid)	 reflux.	 The	
same	 group	 further	 examined	 this	 technique	with	 a	 2	 year	 open-label	 pilot	 trial	 of	 long-term	 LOS	
electrical	 stimulation	 with	 a	 permanently	 implanted	 stimulator	 in	 24	 patients	 with	 GORD	 (89),	
followed	 by	 a	 further	 year	 of	 follow	 up	 in	 a	 multicenter	 registry	 trial,	 showing	 significant	 and	
sustained	improvement	in	distal	oesophageal	acid	exposure,	GORD	symptoms	and	PPI	use	(90).		
	
	
	
	
	
	
	
	
	
Figure	 1.9:	 The	 Endostim	 device	 delivers	 mild	 electrical	 stimulation	 the	 LOS	 for	 pre-programmed	
periods,	increasing	LOS	pressure	without	diminishing	LOS	relaxation.	
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Endoscopic	therapies		
Endoscopic	anti-reflux	therapies	are	gaining	popularity	as	an	even	 lesser	 invasive	means	of	
treating	 GORD	 mechanically.	 Stretta	 is	 an	 endoscopic	 thermal	 ablation	 technique	 where	 heat	 is	
applied	 to the	 lower	 oesophageal	 musculature	 via	 specialised	 needles	 attached	 to	 a	 catheter.	
Although	GORD symptoms	are	reduced,	distal	oesophageal	acid	exposure	is	not,	suggesting	that	the	
improvement	 is more	 likely	due	 to	 thermal	neurolysis	of	 sensory	nerves	 in	 the	 lower	oesophagus	
(91).		
Several	 trans	 oral	 incisionless	 fundoplication	 systems	 have	 been	 developed	 of	 recent,	
although	with	 little	success	 in	terms	of	 long	term	efficacy	apart	 from	the	EsoPhyx	device.	A	recent	
long-term	 efficacy	 study	 assessing	 the	 an	 updated	 version	 of	 the	 Esophyx	device	 over	 a	 6 year	
period,	showed	reduced	PPI	use,	improved	symptom	scores	and	reduced	reflux	episodes	(92).	
	
 
 
 
Figure	1.10:	Transoral	incisionless	fundoplication	with	the	EsoPhyx	device	(93).	
A	retractor	engages	the	
mucosa	of	the	oesophagus	
and	the	stomach	at	the	
level	of	the	GOJ.		
The	tissue	mold	component	
is	closed,	opposing	the	
oesophageal	and	gastric	
walls	to	recreate	the	angle	
of	His.	Transmural	
fasteners	secure	the	join.	
The	resulting	trans	oral	
incisionless	fundoplication.	
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Treatment	of	oesophageal	hypersensitivity		
In	reflux	disease	there	may	be	a	heightened	perception	to	the	gastro	oesophageal	refluxate,	
and	 this	 may	 be	 via	 peripheral,	 central	 or	 psychoneuroimmune	 sensitization.	 Visceral	
hypersensitivity	 is	 increasingly	being	considered	as	an	 important	aspect	of	GORD	pathophysiology,	
particularly	 in	non-erosive	disease	(94).	Subsequently	 it	 is	 increasingly	seen	as	a	therapeutic	target	
for	 treatment	of	GORD.	Peripheral	 sensitization	 is	where	direct	noxious	 stimuli	 such	as	acid	 cause	
the	activation	of	nociceptive	channels	 leading	to	pain	hypersensitivity	at	the	site	of	 injury	(primary	
hyperalgesia).	 This	 can	be	mediated	via	direct	or	 indirect	activation	of	 local	nociceptive	 receptors,	
and	 in	 the	 oesophagus,	 the	 acid-sensitive	 TRPV1	 receptor	 is	 a	 strong	 candidate	 for	 therapeutic	
targeting	(28).	As	well	as	chemical	and	thermal	activation,	the	TRPV1	receptor	can	also	be	activated	
by	even	mild	acidification	(95),	and	therefore	an	antagonist	may	be	useful	in	visceral	hypersensitivity	
TRPV1	antagonists	has	been	keenly	 sought	 (96-98).	AZD1386	 is	 a	TRPV1	antagonist	 that	 increased	
oesophageal	 pain	 thresholds	 to	 heat	 in	 healthy	 volunteers	 (99).	 Unfortunately,	 it	 has	 now	 been	
shown	to	have	no	analgesic	effect	on	oesophageal	pain	thresholds	in	NERD	patients	with	partial	PPI	
response	(100).		
Central	sensitization	occurs	with	repetitive	stimulation	of	peripheral	nociceptors,	leading	to	
hypersensitivity	 in	 areas	 remote	 from	 the	 area	 of	 peripheral	 sensitization	 (101).	 This	 is	 called	
secondary	 hyperalgesia	 (102).	 Increased	 visceral	 hypersensitivity	 has	 been	 demonstrated	 in	 the	
upper	 oesophagus	 of	 patients	 with	 GORD	when	 the	 lower	 oesophagus	was	 stimulated	with	 acid.	
Similarly,	 proximal	 oesophageal	 and	 chest	 wall	 hyperalgesia	 has	 been	 demonstrated	 in	 healthy	
volunteers	 following	 distal	 oesophageal	 acidification	 (103,	 104).	 This	 secondary	 hyperalgesia	 is	
attenuated	 by	 prostaglandin	 E2	 receptor-1	 (EP-1)	 antagonism	 (105),	 as	 was	 shown	with	 the	 EP-1	
antagonist	ZD6416.	Further	development	of	 this	was	been	halted	due	 to	adverse	events.	A	newer	
EP-1	 receptor	antagonist,	ONO	8539	has	been	developed.	A	Phase	 IIb	clinical	 trial	evaluating	ONO	
8539	is	the	subject	of	Chapter	3	in	this	thesis.		
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Targeting	 central	 sensitization	 remains	 an	 important	 area	 for	 future	 drug	 development	 in	
patients	with	 reflux	 symptoms,	 since	 central	 sensitization	may	 play	 an	 important	 role	 in	 not	 only	
NERD,	but	also	functional	heartburn.	
Few	 other	 drugs	 have	 been	 evaluated	 in	 reflux	 hypersensitivity.	 Viazis	 et	 al	 looked	 at	
citalopram	 as	 a	 treatment	 RH,	 and	 demonstrated	 that	 citalopram	 reduced	 heartburn	 symptoms	
significantly	compared	to	placebo	(P	=	0.021)	(106).	Prior	to	this,	Broekaert	et	al	demonstrated	that	
in	the	acute	setting,	Citalopram	20mg	administered	 intravenously	significantly	 increased	sensitivity	
and	discomfort	threshold	during	balloon	distention	of	the	oesophagus.	Citalopram	also	significantly	
increased	lag	time	to	perception	of	heartburn	during	distal	oesophageal	acid	perfusion	(107).		
Overlap	between	GERD,	NERD,	RH	and	FH		
With	the	introduction	of	ROME	IV,	the	understanding	that	there	is	likely	an	overlap	between	
GORD,	 NERD,	 RH	 and	 functional	 oesophageal	 disorders	 is	 an	 important	 consideration	 in	 the	
evaluation	 of	 therapies.	 Therefore,	 considering	 that	 a	 patient	 with	 ERD	may	 have	 an	 element	 of	
oesophageal	hypersensitivity,	if	they	are	refractory	to	anti	reflux	and	acid	suppression	therapies,	this	
increases	 the	 therapeutic	 options	 available	 for	 this	 patient	 for	 the	 treatment	 of	 their	 refractory	
symptoms.	
Treatments	 for	 functional	 oesophageal	 disorders,	 such	 as	 functional	 chest	 pain	 and	
functional	heartburn	are	summarised	in	table	1.3.	Most	have	been	evaluated	for	use	in	non	cardiac	
chest	 pain,	 which	 is	 used	 as	 an	 umbrella	 term	 for	 chest	 pain	 of	 oesophageal	 origin.	 Although	
functional	chest	pain	is	considered	to	fall	within	this	category,	GORD	as	a	cause	of	non	cardiac	chest	
pain	is	not	ruled	out.	The	varied	response	rates	of	these	treatments	may	add	weight	to	the	idea	that	
diagnoses	causing	symptoms	of	heartburn	and	chest	pain	may	lie	on	a	spectrum	ranging	from	ERD	to	
FH	and	FCP.	
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Table	 1.4:	 Pain	 modulating	 therapies	 evaluated	 for	 the	 treatment	 of	 functional	 oesophageal	
disorders	(2).		
Other	 therapies	 evaluated	 in	 the	 treatment	 of	 functional	 oesophageal	 disorders	 include	
Imipramine	(108)	and	Amitriptyline	(109)	which	are	both	tricyclic	antidepressants	(TCAs),	and	have	
demonstrated	 benefit	 in	 terms	 of	 symptoms	 over	 placebo	 and	 Rabeprazole	 respectively.	 As	
mentioned	 above,	 the	 SSRI	 Citalopram	 has	 been	 shown	 to	 confer	 some	 benefit	 in	 RH	 (106,	 110).	
Similarly,	 Paroxetine	 (110)	 and	 Sertraline	 (111)	 have	 been	 evaluated	 in	 non	 cardiac	 chest	 pain	 as	
potential	 therapies.	 Trazodone	 (112,	 113)	 and	 Venlafaxine	 (a	 selective	 norepinephrine	 reuptake	
inhibitor	 (SNRI))	have	both	been	shown	to	modestly	 improve	symptoms	 in	non	cardiac	chest	pain.	
Theophylline	 has	 been	 evaluated	 in	 non	 cardiac	 chest	 pain,	 showing	 improvement	 in	 symptom	
scores	 (114).	 This	 work	 was	 based	 on	 studies	 showing	 that	 patients	 who	 were	 pretreated	 with	
intravenous	 aminophylline	 (an	 antagonist	 of	 adenosine	 P1-receptors)	 showed	 reduced	 adenosine	
induced	chest	pain	compared	to	placebo	(115).	
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The	oesophageal	pain	hypersensitivity	model	
Our	 group	 has	 developed	 a	 model	 in	 which	 infusion	 of	 0.15M	 hydrochloric	 acid	 into	 the	
healthy	distal	oesophagus	(figure	1.11	and	figure	1.12)	reduced	pain	threshold	not	only	 in	the	acid	
exposed	 region	 (due	 to	 peripheral	 sensitization	 of	 afferent	 nerves),	 but	 also	 in	 the	 adjacent	
unexposed	region	due	to	central	sensitization	of	spinal	dorsal	horn	neurones	(103)	(figure	1.12).	
Evidence	of	the	facilitation	of	afferent	sensory	pathways	in	the	model	has	been	obtained	by	
a	cortical	evoked	potential	study	demonstrating	a	decrease	in	latency	and	increase	in	amplitude	of	
the	 response	 after	 acid	 infusion	 in	 comparison	 to	 saline	 (116).	 The	 factors	 that	 mediate	 post-
acidification	 oesophageal	 sensitization	 are	 incompletely	 understood	 but	 physiological	 factors	 are	
likely	to	be	involved.			
	
	
	
	
	
	
Figure	1.11:	A	catheter	is	placed	in	the	oesophagus,	which	has	a	proximal	pH	probe	&	silver	bipolar	
electrical	stimulation	electrodes	to	measure	oesophageal	pain	sensitivity	and	a	distal	pH	probe	&	
infusion	port	(12).
15cm	
pH	in	distal	
oesophagus	
pH	in	proximal		
oesophagus	
Catheter		
pH	probe	and	silver	
bipolar	electrical	
stimulating	electrodes	
		
pH	probe	and	acid	
infusion	port	
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Figure	1.12:		Subjects	are	randomised	to	receive	either	a	saline	or	acid	infusion.	As	expected	when	
saline	is	infused	there	is	no	change	in	pH	in	either	the	proximal	or	distal	oesophagus,	whereas	there	is	
a	demonstrable	drop	in	pH	in	the	distal,	but	not	in	the	proximal,	oesophagus	during	acid	infusion	
(12).	
	
For	 instance,	 it	 has	 been	 demonstrated	 that	 oesophageal	 acidification	 is	 associated	with	 a	 rise	 in	
sympathetic	 nervous	 system	 (SNS)	 activity	 and	 a	 fall	 in	 parasympathetic	 nervous	 system	 (PNS)	
activity,	 with	 subjects	 who	 withdrew	 their	 parasympathetic	 tone	 the	 most,	 developing	 the	 most	
heightened	sensitivity	(117)	(figure	1.13).	
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FIGURE 3 - A schematic representation of the esophageal pain hypersensitivity model. From left to right:- A - a catheter is 
placed in the esophagus which has a proximal pH probe & silver bipolar electrical stimulation electrodes to measure 
esophageal pain sensitivity and a distal pH probe & infusion port. B - subjects are randomised to received either a saline or 
acid infusion. As expected when saline is infused there is no change in pH in either the proximal or distal esophagus, 
whereas there is a demonstrable dr p in pH in the distal, but n  in the proximal, esopha us during acid infusion. C - Pain 
thresholds in the proximal esophagus, which has not been exposed to acid, show decreased pain sensitivity (shaded green 
area) due to habituation following saline infusion but following acid infusion there is increased pain sensitivity (shaded red 
area) due to central sensitisation. Adapted from Sarkar, Aziz et al. Lancet 2000.
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Figure	1.13:		Pain	thresholds	in	the	proximal	oesophagus,	which	has	not	been	exposed	to	acid,	show	
decreased	pain	sensitivity	(shaded	green	area)	due	to	habituation	following	saline	infusion.	Following	
acid	infusion	there	is	increased	pain	sensitivity	(shaded	red	area)	due	to	central	sensitization	(12).	
	
ANS	modulation	of	oesophageal	pain	
The	autonomic	nervous	system	(ANS)	is	thought	to	play	a	role	modulating	pain.	This	occurs	
via	 its	 interaction	with	the	peripheral	and	central	nervous	system.	It	 is	thought	that	dysfunction	of	
the	ANS	is	likely	to	play	a	role	in	pain	perception	(118).	An	increasing	body	of	evidence	from	animal	
studies	 has	 proposed	 the	 importance	 of	 the	 PNS,	 or	 as	 is	 more	 commonly	 referred	 to	 in	 the	
literature,	 “cholinergic	 tone”,	 as	 a	 critical	 mediator	 the	 inflammatory/anti-inflammatory	 balance	
(119).	
The	 oesophageal	 pain	 hypersensitivity	 model,	 developed	 and	 validated	 by	 our	 group	
demonstrates	that	 in	the	event	of	distal	oesophageal	acidification,	the	proximal	oesophagus	which	
has	not	been	exposed	directly	to	acid	exhibits	a	lowered	pain	threshold	due	to	central	sensitisation	
as	described	above.	Botha	et	 al	 studied	 the	modulation	of	 the	ANS	and	 its	 effect	on	oesophageal	
pain	hypersensitivity	(12)	in	healthy	volunteers.	They	demonstrated	that	parasympathetic	tone	was	
increased	with	slow	deep	breathing	compared	to	unpaced	sham	breathing	(figure	1.14).	This	had	an	
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effect	 on	 central	 sensitization,	 increasing	 proximal	 oesophageal	 pain	 threshold	 after	 distal	
oesophageal	acid	exposure	(figure	1.15).		
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.14:	The	effect	of	sham/un-paced	breathing	(shaded	black)	and	deep	breathing	(unshaded)	
on	cardiac	vagal	tone	(mean±SE)	(parasympathetic	tone)	and	skin	conductance	response	(mean±SE)	
(sympathetic	tone).	*Statistically	significant	at	p<0.03	(12).	
	
	
Figure	1.15:	The	effect	of	sham	breathing	(▪)	and	deep	breathing	(●)	on	the	development	of	central	
sensitisation,	derived	from	the	paired	change	in	pain	thresholds	(mean±SE	of	the	mean),	in	the	
proximal	oesophagus	at	T60,	T90	and	T120,	with	mixed	effects	regression	showing	a	coefficient	of	
effect	for	deep	breathing	of	9.94	(CI	8.3	to	11.6,	p	=	0.0001	(12).
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Botha	et	al	clarified	this	further	by	using	atropine,	which	is	known	to	block	parasympathetic	
tone.	This	was	elegantly	shown	to	abolish	 the	central	 sensitizing	blocking	effect	of	deep	breathing	
after	distal	oesophageal	acid	exposure	(figure	1.16).	
	
	
Figure	1.16:	The	effect	of	atropine/deep	breathing	(▪)	and	placebo/deep	breathing	(●)	on	the	
development	of	central	sensitisation,	in	comparison	with	the	screening	visit	(♦),	derived	from	the	
paired	change	in	pain	thresholds	(mean±SE	of	the	mean),	in	the	proximal	oesophagus	at	T60,	T90	
and	T120.	Mixed	effects	regression	showed	a	significant	effect	for	atropine	(coefficient	−3.5	mA/unit	
time	(CI	−6.8	to	−0.06),	p=0.046).	(12)	
.
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The	remaining	questions	addressed	by	this	thesis		
1. What	 characteristics	 “best”	 define	 patients	 diagnosed	 with	 oesophageal	 reflux	
hypersensitivity?	
There	is	currently	a	paucity	of	data	with	regards	to	the	characteristics	of	patients	with	a	
diagnosis	of	oesophageal	reflux	hypersensitivity.	Although	the	definition	of	oesophageal	
reflux	 hypersensitivity	 is	 evolving,	 a	 better	 awareness	 of	 the	 characteristics	 of	 these	
patients	will	help	in	work	to	further	understand	the	pathophysiology	of	this	condition	as	
well	as	inform	efforts	assessing	potential	therapies.		
2. What	 is	 the	prevalence	 and	what	 are	 the	 characteristics	 of	 patients	with	oesophageal	
reflux	hypersensitivity	in	our	institution	(Royal	London	Hospital)?	
Current	 studies	 looking	 at	 the	 prevalence	 of	 oesophageal	 reflux	 hypersensitivity	 are	
limited.	 Looking	 at	 the	 prevalence	 and	 characteristics	 of	 our	 local	 population	will	 not	
only	 address	 this	 issue,	 but	 also	would	 be	 extremely	 useful	 in	 order	 to	 ensure	 better	
service	provision	for	our	local	population.			
3. Can	we	treat	reflux	hypersensitivity	pharmacologically	with	newly	developed	drugs?		
4. Can	 we	 treat	 reflux	 hypersensitivity	 non-pharmacologically	 by	 modulation	 of	 the	
autonomic	nervous	system	(ANS)		
There	 is	 a	 clear	 gap	 in	 therapeutics	 with	 regards	 to	 oesophageal	 pain	 that	 is	 fully	 or	
partially	 refractory	 to	 currently	available	 therapy.	Therefore,	 continuing	 the	 search	 for	
viable	 alternatives,	 be	 they	 pharmacological	 or	 non-pharmacological	 is	 a	 worthy	
exercise.	Using	our	current	understanding	of	the	pathophysiology	of	oesophageal	pain,	
and	current	advances	in	drug	discovery	as	well	as	non	invasive	therapeutic	techniques,	
further	work	 is	 required	to	assess	potential	 treatment	strategies	 for	oesophageal	pain,	
and	therefore	oesophageal	reflux	hypersensitivity		
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Aim	of	this	PhD	research	project		
1. To	 review	 the	 current	 definitions	 and	 pathophysiology	 of	 oesophageal	 reflux	
hypersensitivity,	and	to	assess	the	prevalence	of	oesophageal	reflux	hypersensitivity	
at	the	Royal	London	Hospital.	
2. To	assess	pharmacological	treatment	of	RH	in	patients	with	NERD	using	a	selective	
prostaglandin	EP1	receptor	antagonist		
3. To	assess	the	effect	of	modulation	of	the	ANS	on	oesophageal	pain	hypersensitivity	
in	healthy	subjects	and	patients	with	NERD	using			
a) transcutaneous	vagal	nerve	stimulation		
b) deep	slow	breathing		
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Chapter	2			
Reflux	 hypersensitivity,	 definitions,	 pathophysiology	 and	
prevalence	at	the	Royal	London	Hospital	
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Introduction	
What	is	reflux	hypersensitivity?	
Oesophageal	 reflux	hypersensitivity	 (RH)	 is	defined	as	an	 increased	sensitivity	of	 the	
human	 oesophagus	 to	 mechanical,	 chemical	 and	 electrical	 stimuli	 in	 the	 absence	 of	 any	
macroscopic	 pathology	 or	 increased	 oesophageal	 acid	 exposure	 or	 reflux	 (2).	 This	 is	 not	
expected	in	the	oesophagus	of	a	healthy	subject.		
The	concept	of	a	hypersensitive	oesophagus	has	been	around	since	the	1990s	with	
the	 advent	 of	 ambulatory	 oesophageal	 pH	 testing	 and	 reflux	 symptom	 association	
calculations.	This	was	 in	 response	to	 the	realisation	that	a	population	of	patients	suffering	
with	 typical	 GORD	 symptoms	 did	 so	 in	 the	 presence	 of	 physiological	 levels	 of	 distal	
oesophageal	acid	exposure.	This	group	of	patients	with	 typical	GORD	symptoms	that	were	
related	 to	physiological	 reflux	was	 included	as	new	category	of	non	erosive	 reflux	disease	
(NERD)	in	the	ROME	III	criteria	published	in	2006	(120).		
ROME	is	an	 international	consensus	effort	to	define,	classify	and	foster	research	 in	
functional	gastrointestinal	disorders	(FGIDs).	The	ROME	IV	consensus	document,	released	in	
2016,	updated	diagnostic	criteria	for	FGIDs.	
In	 Rome	 IV	 in	 2016	 (2),	 Aziz	 et	 al	 reviewed	 the	 status	 of	 the	 hypersensitive	
oesophagus,	placing	it	back	in	the	realm	of	functional	oesophageal	disorders,	defining	it	as	
oesophageal	reflux	hypersensitivity	(RH).	The	rationale	for	this	was	due	to	the	fact	that	the	
underlying	pathophysiological	process	was	thought	to	be	more	consistent	with	a	functional	
disorder.		
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ROME	IV	diagnostic	criteria	for	RH		
It	is	stipulated	that	as	RH	is	considered	a	chronic	condition,	the	following	diagnostic	
criteria	must	be	fulfilled	for	the	past	3	months	with	symptom	onset	at	least	6	months	before	
diagnosis	with	a	frequency	of	at	least	twice	a	week.		
1. Retrosternal	symptoms	including	heartburn	and	chest	pain.		
2. Normal	endoscopy	and	absence	of	evidence	 that	eosinophilic	oesophagitis	 (EoE)	 is	
the	cause	for	symptoms.		
3. Absence	of	major	oesophageal	motor	disorders	(achalasia/GOJ	outflow	obstruction,	
diffuse	oesophageal	spasm,	jackhammer	oesophagus,	absent	peristalsis).		
4. Evidence	of	 triggering	of	 symptoms	by	 reflux	events	despite	normal	acid	exposure	
on	 pH	 or	 pH–impedance	 monitoring	 (response	 to	 antisecretory	 therapy	 does	 not	
exclude	the	diagnosis).	
The	pathophysiology	of	reflux	hypersensitivity	
Oesophageal	 biopsies	 of	 patients	 defined	 as	 having	 oesophageal	 hypersensitivity	
may	 have	 microscopic	 changes	 in	 the	 form	 of	 dilated	 intercellular	 spaces	 as	 well	 as	
microscopic	oesophagitis.	In	patients	with	increased	oesophageal	acid	exposure	or	increased	
reflux	episodes	but	without	macroscopic	oesophageal	injury	(i.e.	non-erosive	reflux	disease),	
microscopic	 oesophageal	 injury	 is	 seen	 in	 a	majority	 of	 patients	 compared	 to	 controls	 as	
shown	in	a	review	by	Dent	et	al	(121).	The	predominant	finding	consistent	with	oesophageal	
injury	 was	 dilated	 intercellular	 spaces	 as	 well	 as	 basal	 cell	 hyperplasia	 and	 papillary	
elongation.	 Inflammatory	 cell	 infiltration	 was	 less	 consistent.	 Of	 interest,	 these	 changes	
responded	to	acid	suppressive	therapy	(121).	The	lack	of	resolution	of	symptoms	however	is	
likely	 to	 relate	 to	 the	 longer	 lasting	 effects	 of	 peripheral	 and	 central	 sensitization	 in	 this	
instance.	Therefore,	although	PPIs	may	address	a	component	of	the	pathophysiology	of	RH,	
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part	of	the	pathophysiological	process	remains	untreated,	hence	the	limited	utility	of	PPIs	in	
RH.		
Although	 there	 is	 no	direct	 evidence	 for	neurogenic	 inflammation	 in	RH,	ROME	 IV	
suggests	that	abnormalities	in	transient	receptor	potential	vanilloid	1	(TRPV1),	acid-sensing	
ion	channel	3,	protease-activated	receptor	2	(PAR2),	neuropeptides	such	as	substance	P	and	
CGRP,	 and	 their	 receptors	 such	 as	 neurokinin	 1	 receptor	 (NK1R)	 and	 receptor	 activity-
modifying	protein-1	may	play	a	role	in	the	pathophysiology	of	RH	(26)	(2).		
In	addition	 to	 this,	ROME	 IV	 recognises	 that	 symptom	perception	 in	RH	 is	 likely	 to	
involve	peripheral	and	also	perhaps	central	sensitisation	as	well	as	other	factors	involved	in	
the	gut	brain	axis	such	as	autonomic	state,	altered	central	processing	of	visceral	stimuli	and	
psychological	factors,	triggered	by	physiological	reflux.		
	
	
	
	
	
	
	
	
	
Figure	2.1:	The	interplay	between	esophageal	hypersensitivity	and	acid	exposure	in	the	reflux	
symptom	spectrum	(2).	
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Diagnosis	of	reflux	hypersensitivity	
High	resolution	manometry	
	
	
	
	
Figure	2.2	–	This	figure	shows	progression	of	a	single	Clouse	plot	with	a	pressure	(at	each	
position	of	the	catheter)	v	time	graph	for	each	individual	sensor	to	an	aggregation	of	all	36	
sensors	on	a	pressure	v	time	plot	with	sensor	position	on	the	z	axis.	Pressure	is	then	divided	
into	colour	groups	with	high	pressure	reading	as	red	and	low	pressure	reading	as	blue.	The	y	
axis	pressures	are	then	coloured	in	with	the	respective	corresponding	pressure/colour	
groups.	The	3	dimensional	(pressure	v	time	v	catheter	position)	graph	is	then	collapsed	down	
to	a	2	dimensional	(time	v	catheter	position)	x	v	z	axis	graph	with	the	y	axis	(pressure)	
represented	by	colour,	akin	to	a	topography	map.	 	
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The	 current	 the	 gold	 standard	 test	 for	 assessing	 oesophageal	 motility	 is	 high	
resolution	manometry	(HRM)	(122).		
In	 the	 diagnostic	 algorithm	described	 in	 chapter	 1,	 HRM	 is	 performed	 prior	 to	 pH	
studies	 initially	to	exclude	major	oesophageal	motility	disorders	as	the	cause	of	presenting	
symptoms.	 HRM	 is	 also	 useful	 to	 define	 the	 upper	 border	 of	 the	 LOS	 to	 ensure	 correct	
placement	of	the	oesophageal	and	gastric	pH	sensors	for	accurate	24	hour	pH	studies.	
The	 data	 acquired	 by	 the	 HRM	 catheter	 is	 analysed	 by	ManoScan®	 software,	 and	
parameters	are	calculated	using	the	latest	Chicago	Classification	system	version	3.0	(123)	for	
oesophageal	 motility	 disorders.	 This	 then	 allows	 for	 the	 diagnosis	 of	 major	 and	 minor	
oesophageal	motility	disorders,	which	may	have	a	bearing	on	the	diagnosis	of	GORD,	as	well	
as	helping	elucidate	possible	causative	or	contributory	factors	such	as	hiatus	hernia	or	poor	
oesophageal	motility.	
24	hour	oesophageal	pH	and	impedance	testing	
pH-metry	 is	 considered	 to	 be	 the	 gold	 standard	 investigation	 for	 the	 diagnosis	 of	
GORD	(124).		Currently,	this	may	be	performed	with	a	catheter	or	a	capsule	based	method.	
Adding	 impedance	measurements	 allows	 for	 the	 quantification	 of	 non	 acid	 reflux	 and	 gas	
events	as	well	as	more	detailed	information	on	direction	of	travel	of	oesophageal	contents.	
As	 mentioned	 previously,	 adding	 impedance	 measurements	 allows	 for	 the	 possibility	 of	
diagnosing	GORD,	and	also	RH,	FH	and	FCP.	
The	 24	 hour	 pH	 and	MII	 pH	 testing	 system	 used	 at	 the	 Royal	 London	 Hospital	 GI	
physiology	unit	 is	a	catheter	based	system.	The	MII	pH	system	consist	of	a	catheter	with	2	
antimony	 pH	 sensors	 (gastric	 and	 distal	 oesophageal)	 as	 well	 as	 6	 impedance	 sensing	
segments,	each	2cm	in	length,	sited	at	3,	5,	7,	9,	15,	and	17	cm	above	the	proximal	border	of	
the	 LOS	 as	 defined	 by	 HRM.	 The	 catheter	 in	 both	 systems	 is	 single	 use.	 A	 compact	 flash	
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memory	 card	 is	 set	 up	with	 the	 required	 testing	 details	 and	 inserted	 into	 the	 data	 logger	
box.	The	data	logger	box-catheter	unit	is	then	calibrated	using	pre	prepared	pH	solutions.		
Patients	 were	 instructed	 to	 keep	 a	 simple	 diary	 of	 meals	 and	 periods	 of	 being	
recumbent.	Changes	in	position	from	upright	to	recumbent	affect	LOS	pressure.	Considering	
meal	times,	delayed	gastric	emptying	for	example	has	a	bearing	on	gastric	acid	pH.	A	data	
logger	carried	by	 the	patient	allowed	for	 the	patient	 to	record	meals	and	periods	of	being	
recumbent.	
In	general,	 typical	symptoms	of	 reflux	were	assessed	with	regards	 to	 the	assessing	
the	 possibility	 of	 association	 with	 reflux	 episodes.	 	 Atypical	 symptoms	 were	 occasionally	
assessed	if	they	were	particularly	bothersome	to	a	patient,	and	reflux	was	thought	to	be	a	
possible	cause.		During	a	24	hour	pH	or	MII	pH	study,	patients	were	given	the	opportunity	to	
record	upto	three	different	symptoms.	They	were	instructed	to	press	a	particular	“symptom	
button”	as	soon	as	they	started	to	experience	a	particular	symptom.	This	data	was	logged	in	
the	 data	 logger	 box	 carried	 by	 the	 patient	 for	 the	 duration	 of	 the	 recording	 as	 described	
previously.	
The	 patient	 was	 able	 to	 go	 home	 after	 the	 above	 and	 continue	 with	 their	 usual	
activities	of	daily	 living,	 including	going	to	work	 if	 feasible.	They	were	asked	to	have	meals	
and	 drinks	 as	 usual,	 but	 to	 avoid	 frequent	 snacking	 or	 ingesting	 acidic	 drinks.	 They	 were	
asked	 to	 continue	 to	 avoid	 acid	 suppression	 therapy,	 and	 to	 avoid	 antacids,	 alginates	 and	
other	 medications	 for	 reflux/GORD.	 	 The	 patient	 returned	 24	 hours	 later	 to	 have	 the	
catheter	removed	after	which	the	data	from	the	data	logger	was	downloaded	on	to	a	secure	
network	 for	 analysis.	 The	 patient	 was	 debriefed	 and	 any	 questions	 or	 queries	 were	
addressed.		
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With	 pH	metry,	 only	 acid	 reflux	 events	 and	 symptoms	 are	 apparent.	With	MII	 pH	
metry	 however,	 reflux	 events	 (liquid/gas/mixed)	 and	 their	 proximal	 extent,	 swallows,	
belches	 (gastric	 or	 supragastric)	 and	 their	 numbers	 are	 apparent	 as	 is	 the	 acidity	 of	 the	
refluxate	(acid/non	acid).	The	number	and	timing	of	symptoms,	meal	periods	and	recumbent	
periods	are	also	apparent	on	the	tracing.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	2.3:	24	hour	pH	metry/MII	pH	metry	catheter	and	data	logger	(ZepHr®	Impedance/pH	
Reflux	Monitoring	System).	
	
24	hour	Multichannel	Intraluminal	pH	(MII	pH)	metry	
As	described	above,	 impedance	 is	 the	best	 technique	 for	detection	of	 reflux	while	
pH	metry	 characterizes	 acidity.	 Hence	 the	 combination	 of	 both	 techniques	 is	 superior	 to	
either	being	used	alone	(65).	
Both	pH	metry	 and	 impedance	pH	metry	 catheter	 systems	 are	 attached	 to	 a	 data	
logger	box	that	is	carried	by	the	patient	over	the	24	hour	period	for	which	the	catheter	is	in	
situ.	On	completion	of	the	study,	the	data	 is	downloaded	onto	a	computer	and	the	data	 is	
analysed	using	proprietary	software	(Sleuth®,	Sandhill	Scientific,	Inc.).	
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Figure	2.4:	Abnormal	multichannel	impedance	pH	study	with	high	oesophageal	pH	levels	
seen	in	the	oesophageal	pH	channel	and	predominantly	acidic	pH	levels	seen	in	the	gastric	
pH	channel.	This	patient	had	an	oesophageal	pH	of	less	than	4	for	13.2%	of	the	total	study.	
He	had	many	symptoms	and	many	reflux	events.	
	
	
Reflux	monitoring	-	parameters	measured		
Percentage	 of	 time	where	 distal	 oesophageal	 acid	 exposure	 to	 a	 pH	 <4	 is	 used	 to	
diagnose	GORD.	A	value	of	distal	 acid	exposure	 time	 (AET)	of	 greater	 that	4.2%	over	a	24	
hour	time	period	is	used	in	the	GI	Physiology	Unit	at	the	Royal	London	Hospital.	The	recent	
Lyon	Consensus	Group	state	that	a	distal	AET	>6%	is	conclusive	of	GORD.	Conversely,	a	distal	
AET	of	<4%	makes	a	diagnosis	of	GORD	very	unlikely.	They	recommend	that	a	distal	AET	of	4-
6%	 on	 its	 own	 is	 inadequate	 for	making	 a	 diagnosis	 of	 GORD,	 and	 supportive	 evidence	 is	
required	in	order	to	make	a	diagnosis	of	GORD.		
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The	algorithm	used	 to	calculate	 reflux	episodes	 in	 impedance	pH	studies	 identifies	
retrograde	movement	of	contents	(gas,	liquid	or	mixed).	This,	in	combination	with	pH	of	the	
distal	oesophageal	pH	sensor	data	is	used	to	identify	acid	as	well	as	non	acid	reflux	episodes.	
Impedance	pH	metry	 tracings	are	 reviewed	manually	 to	ensure	artefactual	 reflux	episodes	
are	not	included	in	the	final	analysis.		
The	 consensus	 for	 a	 pathological	 number	 of	 reflux	 events	 is	 >80	 over	 a	 24	 hour	
recording	 period.	 40	 or	 fewer	 reflux	 events	 over	 a	 24	 hour	 period	 is	 thought	 to	 be	
physiological,	 and	 therefore,	 40-80	 reflux	 events	 alone	 is	 inadequate	 to	 be	 classed	 as	
pathological	per	se	(125).			
On	 the	 whole,	 as	 mentioned	 previously,	 the	 vast	 majority	 of	 symptoms	 assessed	
using	 the	 portable	 data	 logger,	 were	 typical	 GORD	 symptoms	 –	 heartburn,	 regurgitation,	
chest	pain	and	epigastric	pain.	Atypical	symptoms	were	assessed	only	occasionally.	Patients	
were	 instructed	 on	 the	 importance	 of	 pressing	 a	 symptom	button	 as	 soon	 as	 a	 particular	
symptom	began.	They	were	instructed	to	only	press	the	button	once	for	a	single	episode	of	a	
particular	symptom.	Occasionally	a	patient	would	press	the	button	several	times	in	a	cluster	
and	 in	 this	 situation,	 using	 a	 pragmatic	 approach,	 the	 standard	 practice	 would	 be	 to	
preserve	the	first	symptom	marker	of	the	cluster	and	to	edit	out	the	subsequent	markers.	If	
there	were	several	symptom	markers	and	reflux	events	clustered	together,	a	note	would	be	
made	on	the	report	of	the	study	as	hypervigilance	would	likely	be	playing	a	role	the	patients	
symptomatology.		
In	terms	of	numbers	of	symptoms	recorded,	accurately	recorded	increased	numbers	
of	symptoms	increases	the	statistical	significance	with	regards	to	reflux	symptom	association	
calculations.	For	the	purposes	of	this	study,	we	used	a	cut	off	number	of	5	symptom	markers	
per	 symptom	 type,	 although	 an	 update	 of	 the	 previous	 consensus	 document	 for	 the	
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diagnosis	 of	 GORD,	 the	 Porto	 Consensus,	 recommended	 that	 for	 reliability	 for	 reflux	
symptom	association	calculations,	at	least	3	symptom	events	should	be	recorded	(126).		
Reflux	symptom	association	
The	 most	 widely	 used	 methods	 for	 calculating	 reflux	 symptom	 association	 are	
Symptom	Index	(SI)	and	Symptom	Association	Probability	(SAP),	which	are	both	used	in	our	
Department,	and	for	the	purposes	of	this	study.	Other	methods	of	assessing	reflux	symptom	
association	 such	 as	 the	 Symptom	 Sensitivity	 Index	 (SSI)	 and	 the	 Binomial	 Symptom	 Index	
(BSI)	have	not	been	used.		
The	SI	was	 the	 first	method	proposed	 to	calculate	 if	a	 symptom	was	 related	 to	an	
episode	 of	 reflux	 (127).	 Here	 the	 number	 of	 reflux	 episodes	 related	 to	 a	 reflux	 event	
compared	to	the	total	number	of	symptoms	is	expressed	as	a	percentage.		Relatedness	of	a	
symptom	 to	 a	 reflux	 event	 is	 defined	 as	 occurring	 within	 2	 minutes	 of	 a	 reflux	 event.	
Receiver	operating	characteristic	analysis	has	suggested	that	the	optimal	threshold	for	the	SI	
would	be	50%	(128).	A	disadvantage	of	the	SI	 is	the	fact	that	 it	does	not	take	into	account	
the	total	number	of	reflux	events.	
The	SSI	is	defined	as	the	proportion	of	reflux	episodes	that	are	symptomatic	and	this	
is	also	expressed	as	a	percentage	(129).	For	the	SSI	5	or	10%	has	been	arbitrarily	used	as	a	
cut-off	(128).	An	obvious	disadvantage	of	the	SSI	is	a	disproportionately	high	positivity	if	the	
number	of	recorded	symptoms	is	high.		
Because	 of	 the	 complex	 nature	 of	 symptom	 association,	 SAP	 (130)	 and	 BSI	 were	
developed,	 which	 both	 use	 more	 statistically	 sophisticated	 methods	 to	 calculate	 reflux	
symptom	association.	They	both	use	a	P	<0.05	as	a	cut	off	for	positivity,	and	if	positive,	the	
probability	of	reflux	symptom	association	is	unlikely	to	have	occurred	by	chance.	
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	The	SAP	 is	based	on	a	Fisher’s	exact	 test	performed	on	a	 two-by-two	contingency	
table	in	which	the	number	of	two-minute	periods	with	reflux-related	symptoms,	with	reflux-
unrelated	symptoms,	with	symptom-free	reflux	episodes,	and	with	symptom-	eliciting	reflux	
episodes	 is	 entered.	 The	 BSI	 calculates	 the	 probability	 that	 symptoms	 are	 related	 to	 acid	
reflux	by	 summating	 the	partial	probability	 for	each	 individual	 symptom	that	 is	acid	 reflux	
related	 (128).	 Of	 note,	 the	 BSI	 is	 of	 more	 use	 with	 longer	 duration	 studies.	 Also,	 in	 the	
context	 of	 small	 number	 of	 symptoms,	 the	 statistical	 analysis	 becomes	 underpowered,	
undermining	its	accuracy.		
					
	
Figure	2.5:	The	calculation	of	SAP	is	represented	schematically.	The	recording	is	divided	into	
2-	minute	segments.	Here,	two	of	them	contain	a	reflux	episode.	The	patient	has	also	pressed	
the	symptom	button	on	two	occasions	denoted	by	the	symptom	onset	marker.	Acid	reflux	(R)	
precedes	the	first	symptom	(S)	(that	is,	S+R+),	but	not	the	second	symptom	(S+R−).		
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Previous	work	on	the	subject		
The	first	real	attempt	at	characterising	the	hypersensitive	oesophagus	category	was	
by	Savarino	et	al	in	2008	(131).	They	prospectively	assessed	150	patients	with	NERD	(typical	
symptoms	 of	 GORD	 and	 a	 normal	 gastroscopy)	 referred	 for	 24	 hour	 combined	 MII-pH	
monitoring.	 They	 compared	 their	 patient	 data	with	 that	 of	 48	healthy	 volunteers.	 In	 their	
population	 of	 NERD	 patients,	 they	 identified	 87	 patients	 who	 had	 physiological	 levels	 of	
distal	oesophageal	acid	exposure.	Of	these	87	patients,	48	had	positive	symptom	association	
probability	 (SAP),	which	 differentiated	 them	 from	 those	 patients	who	 had	 a	 negative	 SAP	
and	 thus	 a	 diagnosis	 of	 a	 functional	 disorder.	 They	 further	 categorised	 the	 SAP	 positivity	
with	 acid/non-acid/mixed	 reflux,	 demonstrating	 that	 patients	 with	 a	 hypersensitive	
oesophagus	do	also	perceive	typical	GORD	symptoms	in	response	to	non	acid	reflux.		
Prior	 to	 this,	 in	 2002,	 Kuran	 et	 al	 demonstrated	 that	 on	 review	 of	 44	 patients	
referred	for	MII	pH	monitoring,	7	were	classed	as	having	a	hypersensitive	oesophagus	(132).		
More	 recently,	 Frazzoni	 et	 al	 have	 demonstrated	 the	 use	 of	 post	 reflux	 swallow-
induced	peristaltic	wave	(PSPW)	index	and	the	mean	nocturnal	baseline	impedance	(MNBI)	
as	 a	means	 to	 characterize	 RH	 independently	 of	 SAP	 and	 SI	 (133).	 They	 assessed	MII	 pH	
tracings	 from	 125	 patients	 with	 NERD	 (defined	 as	 gastroscopy	 negative,	 PPI-responsive	
heartburn	with	an	abnormal	distal	oesophageal	acid	exposure	time),	108	with	RH	(defined	as	
gastroscopy	 negative,	 PPI-responsive	 heartburn	 with	 a	 normal	 distal	 oesophageal	 acid	
exposure	time),	and	70	patients	with	FH	(gastroscopy	negative	and	PPI	non	responsive	with	
normal	distal	oesophageal	acid	exposure	time).	They	showed	a	lower	PSPW	index	and	MNBI	
in	patients	with	NERD	compared	to	hypersensitive	oesophagus.	The	patients	with	FH	in	turn	
had	 the	 highest	 values.	 In	 combination,	 the	 area	 under	 the	 curve	 on	 receiver	 operating	
characteristic	 analysis	 was	 0.957.	 	 The	 SAP	 and/or	 SI	 was	 positive	 in	 67	 of	 the	 108	 RH	
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patients,	but	impressively,	the	PSPW	index	and/or	MNBI	was	abnormal	in	99	of	the	108	HE	
patients	(92	%;	P	<	0.0001).	
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Reflux	hypersensitivity	at	the	Royal	London	Hospital	
Study	design	and	objectives	
This	 was	 a	 retrospective	 cohort	 study	 conducted	 in	 the	 GI	 physiology	 unit	 of	 the	
Royal	London	Hospital,	with	a	prospective	component.	Our	aim	was	to	assess	the	incidence	
of	RH	in	the	Gastro-Intestinal	Physiology	Department	at	the	Royal	London	Hospital.		
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	2.6:	Schematic	of	study	design.
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Data	was	collected	from	an	internal	database,	collated,	and	ordered	by	date	of	tests.	
Data	was	checked	for	accuracy	by	comparing	patient	notes	and	the	Central	Records	System	
(CRS)	of	the	National	Health	Service	(NHS).		
	
Definitions	of	pathology	specified	in	terms	of	pH/MII	pH	studies	
GORD	was	defined	as		
• Typical	reflux	symptoms	(heartburn,	chest	pain,	epigastric	pain	and	regurgitation)		
• At	least	5	recorded	episodes	of	a	symptom	
• Increased	acid	exposure	time	off	PPI	(>4.2%)	
	
Reflux	hypersensitivity	was	defined	as	
• Typical	reflux	symptoms	(heartburn,	chest	pain,	epigastric	pain	and	regurgitation)		
• At	least	5	recorded	episodes	of	a	symptom	
• Normal	acid	exposure	time	(<4.2%)	
• Positive	SI	or	SAP	
	
Functional	heartburn	(FH)	and	functional	chest	pain	(FCP)	were	defined	as	
• Symptoms	of	heartburn	or	chest	pain	respectively		
• At	least	5	recorded	episodes	of	a	symptom	
• Normal	acid	exposure	time	(<4.2%)	
• Negative	SI	and	SAP	
	
A	normal	study	was	defined	as		
• Normal	acid	exposure	time	(<4.2%)	
• Negative	SI	and	SAP	
• Less	than	5	episodes	of	a	symptom	recorded	
	
	
	
	
	 90	
Methods	
Data	ordinarily	collected		
All	 patients	 referred	 to	 the	 GI	 physiology	 unit	 complete	 a	 pre	 procedure	
questionnaire	 about	 demographics,	 type	 and	 frequency	 of	 symptoms,	 as	well	 as	 past	 and	
current	 medical	 history	 and	 medication	 history.	 Before	 the	 written	 informed	 consent	
process,	the	GI	physiologist	reviews	this	questionnaire	and	fills	out	any	missing	data	before	
proceeding	for	safety	reasons	and	to	ensure	the	test	is	tailored	to	their	symptoms.		
Demographic	data		
The	 following	 demographic	 data	 are	 ordinarily	 collected	 from	 patients	 when	 they	
attend	the	GI	physiology	Unit	as	part	of	service	evaluation.		
• Age	
• Gender		
• Ethnicity	
• Catchment	area	(local	to	Barts	and	the	London	NHS	Foundation	Trust	or	not)		
Medical	history	data	and	reflux	symptom	data	
The	 following	medical	history	and	reflux	symptom	data	are	ordinarily	collected	 for	
safety	reasons	and	to	ensure	the	test	is	tailored	to	their	symptoms.		
• Type,	frequency	and	duration	of	symptoms	to	be	evaluated		
• Current	medication	
• Medical	history	and	medication	history	
• Presence	of	oesophageal	and	extra-oesophageal	symptoms	
• Weight	and	height	
• Hypermobility	score	
• Anti-reflux	 medications	 such	 as	 proton	 pump	 inhibitors	 (PPI)	 and	 H2	 receptor	
antagonists	(H2RA)	used	before	pH	study	
• Pain	modulator	and	antidepressant	use.	
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Characteristics	of	cohort	evaluated	
All	patients	included	in	the	study	had	been	referred	for	assessment	of	symptoms	of	
GORD	 from	 local	or	 regional	 referral	hospitals	by	a	gastroenterologist	or	a	gastrointestinal	
surgeon.	From	January	2010	to	December	2015,	3000	records	of	patients	referred	to	the	GI	
Physiology	Unit	at	the	Royal	London	Hospital	were	identified	from	the	upper	GI	Physiology	
Database.	Medical	 records	 for	 these	 patients	were	 assessed	 based	 on	 pH/MII	 pH	 data	 to	
phenotype	 them	 into	 4	 groups	 –	GORD,	RH,	 FH/FCP	 and	normal	 using	 the	 criteria	 set	 out	
above.		
Studies	done	whilst	on	acid	suppression	therapy	were	not	included.	Patients	with	a	
history	of	upper	gastro-intestinal	surgery	and	severe	motility	disorders	were	excluded	from	
the	analysis.		
Patients	 with	 at	 least	 one	 typical	 symptom	 of	 GORD	 (heartburn,	 chest	 pain,	
epigastric	 pain	 and	 regurgitation)	 lasting	 for	 more	 than	 6	 months	 were	 included	 in	 the	
analysis.	 The	 specific	 atypical	 symptoms	 (in	 addition	 to	 typical	 reflux	 symptoms)	 of	 throat	
burning,	cough	and	belching	were	recorded.		
Of	 note,	 findings	 of	 an	 oesophago-gastro-duodenoscopy	 (OGD)	 were	 not	 always	
available	 and	 therefore	 were	 recorded	 only	 if	 available.	 For	 the	 patients	 included	 in	 the	
analysis,	 a	 great	 deal	 of	 effort	 was	 made	 to	 source	 the	 OGD	 result.	 Those	 with	 erosive	
oesophagitis,	 Barrett’s	 oesophagus,	 eosinophilic	 oesophagitis,	 oesophageal	 or	 upper	 GI	
malignancy	were	excluded	from	the	cohort	being	studied.	The	timing	of	the	gastroscopy	was	
not	 always	 available	 and	 was	 therefore	 not	 recorded.	 In	 terms	 of	 Helicobacter	 pylori	 (H	
pylori),	the	pattern	of	where	H	pylori	related	gastritis	is	seen,	appears	to	have	a	bearing	on	
the	extent	of	acid	secretion	that	occurs.	Therefore,	 this,	 in	combination	with	other	 factors	
such	as	TLOSRs,	appears	to	contribute	to	the	generation	of	symptoms	of	reflux	(134).		There	
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is	limited	evidence	assessing	the	effect	of	H	pylori	on	oesophageal	hypersensitivity	and	none	
assessing	the	effect	of	H	pylori	on	RH.	There	was	no	facility	to	record	H	pylori	status	for	any	
of	the	patients	and	therefore	I	did	not	evaluate	this.		
RH	cohort	
All	patient	fulfilling	criteria	for	RH	were	included	in	the	analysis.		
NERD	and	FH/FCP	cohort	
As	shown	in	the	study	design	section,	I	selected	a	cohort	of	patients	with	true	NERD	
and	with	FH/	FCP.	The	rationale	for	these	two	comparison	groups	was	to	assess	RH	in	terms	
of	 known	 characteristics	 of	 patients	 with	 GORD	 and	 FH/FCP.	 Comparison	 of	 GORD	
phenotypes	may	also	inform	classification	strategies	such	as	ROME	IV.			
These	 patients	 were	 selected	 prospectively	 from	 the	 GI	 physiology	 database,	 in	 a	
consecutive	manner,	to	avoid	selection	bias.		
32	patients	with	NERD	and	31	patients	with	FH/FCP	were	selected	out	of	a	group	of	
995	and	276	respectively.	The	2	previous	studies	presented	in	the	literature	(by	Savarino	et	
all	 and	 Frazzoni	 et	 al)	 both	 had	 representative	 groups	 of	 true	 NERD	 and	 FH/FCP.	 The	
numbers	in	my	study	were	comparable	to	the	above	studies.		
Manometry	and	pH	metry	data		
None	 of	 the	 studies	 were	 longer	 than	 24	 hours	 (ie:	 pH	 capsule	 studies	 (eg	 Bravo	
studies)	 were	 not	 included	 as	 they	 are	 not	 routinely	 performed	 in	 our	 Department.	
Following	completion	of	high	resolution	manometry	testing	and	24	hour	pH	testing	(with	or	
without	 impedance	 measurements),	 the	 following	 data	 were	 collected.	 Length	 of	 study	
(excluded	if	<20	hours	as	deemed	an	incomplete	study).	
• Supine,	upright	and	total	acid	exposure	
• Acid	reflux	episodes	[reflux	episodes	detected	by	impedance	with	a	pH	<4]	
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• Non-acid	reflux	episodes	[reflux	episodes	detected	by	impedance	with	a	pH>4]	
• Total	acid	reflux	episodes		
• Proximal	reflux	episodes	
• Reflux	diagnoses	
• Manometry	diagnoses	
Statistical	analysis	
Continuous	 data	 that	 was	 not	 normally	 distributed	 was	 analysed	 using	 the	 non	
paramentric	Mann	Whitney	 test.	 Proportions	were	 compared	using	 χ2	 tests.	 Results	were	
considered	statistically	significant	when	P<0.05.	
Statistical	 analysis	 was	 carried	 out	 using	 proprietary	 software	 (GraphPad	 Prism	
version	7.00	for	Windows,	GraphPad	Software,	La	Jolla	California	USA,	www.graphpad.com).	
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Results	
Of	 the	 patients	 referred	with	 typical	 reflux	 symptoms	 to	 our	 unit,	 a	 total	 of	 1869	
patients	were	 included	 in	 the	 analysis.	 211	 patients	met	 the	 criteria	 for	 RH	 and	 data	was	
analysed	for	all	211	of	these	patients	(65%	female,	mean	age	44.4	years,	age	range	19	to	82,	
media	age	44	years).	As	control	populations,	31	consecutive	patients	who	met	 the	criteria	
for	FH/FCP	and	32	patients	who	met	the	criteria	for	NERD	were	analysed.		
• 211	fulfilled	criteria	for	reflux	hypersensitive	oesophagus,		
• 995	fulfilled	criteria	for	GORD	(including	NERD	and	ERD),		
• 276	fulfilled	criteria	for	functional	heartburn	and	functional	chest	pain,		
• The	 remaining	 386	were	 deemed	 to	 have	 a	 normal	 study,	 defined	 as	 normal	 acid	
exposure	time	(<4.2%),	negative	SI	and	SAP	or	fewer	than	5	episodes	of	a	symptom	
recorded.		
	
	
	
	
	
	
	
	
Figure	2.7:	Diagnoses	of	patient	referred	to	the	GI	physiology	unit	at	the	Royal	London	
Hospital	with	typical	GORD	symptoms.
n	=	1868
GORD	(including	NERD	and	ERD)	
(n	=	995)
RH	(n	=	211)
Func9onal	(n	=	276)
Normal	(n	=	386)
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Comparison	groups		
As	mentioned	 in	the	study	design	section,	 I	selected	a	cohort	of	patients	with	true	
NERD	 and	with	 either	 FH	 or	 FCP.	 These	 patients	were	 selected	 prospectively	 from	 the	GI	
physiology	database,	in	a	consecutive	manner,	to	avoid	selection	bias.		
The	representative	cohort	of	patients	from	the	995	patients	with	GORD	made	up	the	
true	NERD	group	with	32	patients	(33%	female,	mean	age	51.15	years,	age	range	29	to	77,	
median	 age	 54	 years),	 after	 review	 of	 gastroscopy	 and	 pH	 study	 results.	 A	 representative	
cohort	of	patients	from	the	276	patients	identified	with	FH/FCP	made	up	the	FH	group	with	
31	patients	(67%	female,	mean	age	51.15	years,	age	range	18	to	73,	median	age	47	years).	
Gender	characteristics	
The	RH	group	had	a	predominance	of	female	patients	compared	to	the	NERD	group,	
but	a	 similar	percentage	of	 females	 to	 the	FH/FCP	group.	As	noted	above,	 the	majority	of	
patients	with	RH	were	female	(65%).	A	similar	trend	is	noted	in	the	FH/FCP	group	(65%).	This	
is	strikingly	different	from	the	NERD	group,	is	characterized	by	male	predominance	(67%).	
	
	
	
	
	
Figure	2.8:	Distribution	of	sex	in	the	three	cohorts	assessed.	
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Age	characteristics	
In	terms	of	age	characteristics,	the	RH	group	of	patients	were	significantly	younger	
than	 the	 NERD	 group	 (p	 =	 0.0089).	 There	 was	 no	 significant	 difference	 between	 the	 age	
difference	between	 the	RH	and	FH/FCP	group	 (p=	0.4955).	 Patient	with	RH	and	FH/FCP	 in	
the	population	I	assessed	were	younger	than	those	with	NERD.		
	
	
	
	
	
	
	
Figure	2.9:	Age	distribution	for	the	three	groups.	There	was	a	significant	difference	in	the	
median	age	of	the	RH	group	compared	to	the	NERD	group	(p	=	0089).	
	
Symptom	characteristics		
Typical	reflux	symptoms	
Distribution	of	typical	symptoms	of	GORD	was	evaluated	in	our	RH	study	population.	
Data	 was	 available	 for	 all	 211	 patients	 with	 RH	 included	 in	 the	 study.	 All	 patients	
volunteered	at	least	1	typical	symptoms	of	GORD	such	as	heartburn,	regurgitation,	epigastric	
pain	 or	 chest	 pain.	 Heartburn	 was	 the	 most	 common	 symptom	 with	 154/211	 patients	
recording	it	as	a	significant	symptom.	This	was	closely	followed	by	regurgitation,	recorded	as	
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a	 significant	 symptom	by	153/211	patients.	32/211	patients	 complained	of	 chest	pain	and	
25/211	complained	of	epigastric	or	abdominal	pain.	
In	the	NERD	group,	heartburn	was	the	most	common	symptom	with	23/32	patients	
recording	it	as	a	significant	symptom.	This	was	closely	followed	by	regurgitation,	recorded	as	
a	significant	symptom	by	19/32	patients.	4/32	patients	complained	of	chest	pain	and	5/32	
complained	of	epigastric	or	abdominal	pain.		
In	 the	 FH/FCP	 group,	 heartburn	 was	 the	 most	 common	 symptom	 with	 20/31	
patients	 recording	 it	 as	 a	 significant	 symptom.	 This	was	 closely	 followed	 by	 regurgitation,	
recorded	 as	 a	 significant	 symptom	by	 10/31	 patients.	 16/31	 patients	 complained	 of	 chest	
pain	and	11/31	complained	of	epigastric	or	abdominal	pain.		
	
	
	
	
	
	
	
	
	
	
	
	
Figure	2.10:	Proportion	of	typical	symptoms	of	GORD	experienced	by	patients	in	each	of	the	
three	groups	studied,	expressed	as	a	percentage.	
	
Reflux	characteristics		
In	the	RH	group,	35/211	(17%)	underwent	pH	metry	alone	whilst	the	rest	underwent	
MII	pH	metry.	 In	the	NERD	group,	all	 the	patients	underwent	MII	pH	metry.	 In	the	FH/FCP	
group,	11/31	(35%)	underwent	pH	metry	alone.		
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Total	 median	 distal	 oesophageal	 acid	 exposure	 (figure	 2.11)	 was	 1.3%	 in	 the	 RH	
group	 (0.6	 –	 2.3%),	 12.1%	 (8.35	 –	 18.35%)	 in	 the	NERD	 group	 and	 0.6	 (0.2	 –	 1.4%)	 in	 the	
FH/FCP	 group.	 The	 difference	 between	 the	 RH	 and	 NERD	 group	 was	 significant	 at	 p	 =	
<0.0001,	whilst	the	difference	between	the	RH	and	FH/FCP	group	was	also	significant	at	p	=	
0.0048,	confirming	that	subjects	within	each	of	the	groups	were	correctly	allocated.	
	
	
	
	
	
	
Figure	2.11:	Median	distal	oesophageal	acid	exposure	time	was	significantly	different	
between	the	RH	and	NERD	groups	and	the	RH	and	FH/FCP	groups	(p	=	<0.0001	and	p	=	
0.0048	respectively),	confirming	that	subjects	within	each	of	the	groups	were	correctly	
allocated..	
	
Comparing	median	supine	distal	acid	exposure,	 the	NERD	group	had	a	significantly	
greater	supine	distal	oesophageal	acid	exposure	at	10%	(0.4	–	22.1%)	compared	to	the	RH	
and	FH/FCP	groups,	which	had	a	median	supine	distal	oesophageal	acid	exposure	of	0%	(0	–	
0.4%)	and	0	–	2.4%	respectively).	Median	upright	distal	oesophageal	acid	exposure	was	also	
significantly	higher	in	the	NERD	group	at	14.1%	(8.1	–	18.85%),	with	the	RH	group	having	a	
median	of	2.1%	(0.9	–	3.9%)	and	the	FH/FCP	group	having	a	median	of	1%	(0	–	2.4%).	This	
again	 confirmed	 that	 the	 NERD	 group	 experienced	 pathological	 distal	 supine	 as	 well	 as	
upright	acid	exposure,	as	compared	with	the	RH	and	FH/FCP	groups,	as	expected.		
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In	terms	of	reflux	episodes	(figure	2.12),	total	reflux	episodes	were	recorded	for	all	
studies	 as	 this	 is	 always	 recorded	 in	 both	 pH	 metry	 and	 MII	 pH	 metry	 studies.	 Median	
number	of	reflux	episode	during	the	recording	period	was	38	(25	–	58)	for	the	RH	group	and	
54	(43	–	75)	for	the	NERD	group,	which	was	significantly	different	(p	=	<0.0001).	The	FH/FCP	
group	 had	 a	 median	 number	 of	 total	 reflux	 episodes	 of	 28	 (12	 -	 35),	 which	 was	 also	
significantly	different	to	the	RH	group	(p	=	0.0004).	
	
	
	
	
	
	
	
Figure	2.12:	Total	number	of	reflux	episodes	was	significantly	different	between	the	RH	and	
NERD	groups	as	well	as	the	RH	and	FH/FCP	groups	(p	=	0.0001	and	0.0004	respectively).	
	
	
When	analysing	the	MII	pH	data,	it	is	evident	that	the	NERD	group	have	the	highest	
median	number	of	acid	reflux	events	(43,	28	-	59),	compared	to	the	RH	group	(18,	8	-	33)	and	
the	FH/FCP	group	(8,	1	-	18).	The	difference	between	the	numbers	of	acid	reflux	events	for	
the	RH	group	compared	to	the	NERD	groups	is	significant	(p	=	<0.0001).	In	fact	the	difference	
between	the	RH	and	FH/FCP	groups	is	also	significant	at	p	=	0.0019)	(figure	2.13).	
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Figure	2.13:	Total	number	of	acid	reflux	episodes	was	significantly	different	between	the	RH	
and	NERD	groups	as	well	as	the	RH	and	FH/FCP	groups	(p	=	0.0001	and	0.0004	respectively)	
	
Considering	non	acid	reflux,	the	RH	group	had	the	highest	number	of	non	acid	reflux	
events	 (18,	 range	 0	 to	 123),	 compared	 to	 the	 NERD	 group	 (12,	 range	 0	 to	 109)	 and	 the	
FH/FCP	 group	 (15,	 range	 1	 to	 41).	 The	 difference	 between	 the	 RH	 and	 NERD	 group	 was	
significant	at	p	=	0.0411,	whilst	 the	difference	between	the	RH	and	FH/FCP	group	was	not	
significant	(p	=	0.1868).		
	 RH	 NERD	 FH/FCP	
Proportion	of	heartburn	episodes	 49%	 50%	 20%	
Proportion	of	regurgitation	episodes	 43%	 34%	 11%	
Proportion	of	chest	pain	episodes	 4%	 5%	 13%	
Proportion	of	epigastric	pain	
episodes	
3%	 11%	 55%	
	
Table	2.1:	Proportion	of	typical	symptoms	relative	to	total	symptoms	in	patients	with	RH	(n	=	
211),	NERD	(n	=	32)	and	FH/FCP	(n	=	31).
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Dyspeptic	symptoms		
Patients	 in	 the	 RH	 group	 also	 complained	 of	 dyspeptic	 symptoms,	 although	 these	
were	not	evaluated	as	part	of	the	reflux	symptom	association	element	of	their	24	hour	pH	or	
MII	pH	study.	Considering	patients	with	functional	disorders	are	more	likely	to	complain	of	
dyspeptic	type	symptoms	(2),	evaluation	of	the	distribution	of	these	symptoms	was	thought	
to	be	of	use	when	attempting	to	phenotype	patients	with	RH.	
• Bloating		
In	our	study	population,	patients	with	RH	complained	of	bloating	and	indeed	it	was	a	
prominent	symptom	in	the	RH	group,	with	66%	volunteering	it	as	a	symptom.	In	comparison,	
NERD	 patients	 (63%)	 had	 less	 bloating	 compared	 to	 the	 RH	 group	 whilst	 patients	 in	 the	
FH/FCP	group	complained	of	bloating	the	most	with	84%	reporting	bloating	as	a	symptom.		
• Belching			
62%	 of	 patients	 in	 the	 RH	 group	 complained	 of	 belching.	 By	 comparison,	 77%	 of	
patents	 in	 the	FH/FCP	group	also	complained	of	belching.	 Interestingly,	79%	of	patients	 in	
the	NERD	group	also	complained	of	belching.		
• Nausea		
Among	 the	 RH	 patient	 group,	 32%	 complained	 of	 nausea.	 This	 was	 similar	 to	 the	
FH/FCP	group	where	35%	had	nausea	(p=0.0528).	But	only	21%	of	the	NERD	group	revealed	
nausea	as	a	symptom,	which	was	significantly	lower	in	comparison	to	RH	(p=0.0269).		
• Vomiting	
In	 the	 RH	 group,	 29%	 complained	 of	 vomiting	 as	 a	 symptom.	 This	 was	 similar	 to	
patients	in	the	FH/FCP	groups	where	32%	complained	of	vomiting.	Vomiting	in	patients	with	
NERD	(24%)	was	less	common	than	either	the	RH	or	FH/FCP	groups.	
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Medications		
On	review	of	medications	taken	by	the	patients	 in	our	cohort,	 I	 reviewed	acid	suppression	
medications,	 including	proton	pump	 inhibitors	 (PPIs)	and	histamine-2	 receptor	antagonists	
(H2RAs).	 In	 addition	 to	 the	 gastric	 acid	 neutralisation	 effects	 of	 these	 preparations,	 I	 also	
looked	 at	 neuromodulator	 use,	 in	 particular,	 tricyclic	 antidepressants	 (TCAs)	 and	 selective	
serotonin	receptor	inhibitor	(SSRI)	use.		
• Acid	suppressants	
Most	 patients	 evaluated	were	 on	 a	 PPI,	 although	 doses	 and	 regimes	were	 varied.	
89%,	97%	and	90%	of	patients	with	RH,	NERD	and	FH/FCP	were	on	a	PPI	respectively.		
	
	
	
	
	
	
	
	
	
Figure	2.14:	Percentage	of	PPI	use	in	the	RH	group	(n=211),	NERD	group	(n=33)	and	the	
FH/FCP	group	(n=31)	
	
	
	
	
	
	
	
	
Figure	2.15:	Percentage	of	H2RA	use	in	the	RH	group	(n=211),	NERD	group	(n=33)	and	the	
FH/FCP	group	(n=31)
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Use	of	neuromodulators		
Patients	 with	 symptoms	 of	 GORD	 refractory	 to	 acid	 suppression	 therapy	
unsurprisingly	 end	 up	 being	 prescribed	 classes	 of	 drugs	 thought	 to	 reduce	 perception	 of	
pain.	 These	 commonly	 include	 tricyclic	 antidepressants,	 SSRIs	 and	 pregabalin.	 36/211	
patients	(17%)	in	the	RH	group	were	on	one	of	the	above	neuromodulation	agents	(although	
other	 reasons	 for	 being	 prescribed	 these	medications	 cannot	 be	 ruled	 out).	 	 In	 the	NERD	
group	4/33	patients	 (12%)	were	 taking	neuromodulation	 agents	 and	 in	 the	 FH/FCP	group,	
this	was	7/31	(23%).		
	
	
	
	
Figure	2.16:	Percentage	of	neuromodulator	use	in	the	RH	group	(n=211),	NERD	group	(n=33)	
and	the	FH/FCP	group	(n=31).	
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Summary	
In	 summary,	 I	 have	 demonstrated	 that	 in	 our	 cohort	 of	 patients	 referred	 for	
investigation	 of	 typical	 symptoms	 of	 GORD,	 patients	 with	 RH	 account	 for	 11%	 of	 our	
population	(211/1868).	Patients	confirmed	as	having	GORD	accounted	for	53%	and	patients	
with	 functional	heartburn	and	 chest	pain	accounted	 for	15%.	The	male:female	 ratio	 in	RH	
was	similar	to	the	ratio	in	FH/FCP	as	opposed	to	NERD.	They	were	also	significantly	younger	
than	the	NERD	group.	The	pattern	of	typical	reflux	symptoms	was	however	more	similar	to	
the	NERD	group	than	the	FH/FCP	group.			
Median	distal	oesophageal	 acid	exposure	was	 significantly	higher	 than	 the	FH/FCP	
group	and	significantly	lower	than	the	NERD	group.	Total	number	of	reflux	episodes	as	well	
as	 acid	 reflux	 episodes	 was	 also	 similarly	 significantly	 higher	 than	 the	 FH/FCP	 group	 and	
lower	than	the	NERD	group.	Distribution	of	type	of	typical	GORD	symptoms	showed	that	RH	
and	 NERD	 patients	 volunteered	 a	 larger	 proportion	 of	 heartburn	 and	 regurgitation	
symptoms,	 whilst	 FH/FCP	 patients	 predominantly	 reported	 symptoms	 of	 chest	 and	
epigastric	pain.		
When	 considering	dyspeptic	 symptoms,	patients	with	 FH/FCP	 complained	of	more	
bloating,	nausea	and	vomiting.	Belching	was	seen	most	in	the	NERD	group.	
In	 terms	 of	 medications,	 most	 patients	 in	 all	 three	 groups	 were	 on	 a	 PPI.	 Fewer	
patients	were	on	H2RAs	but	of	the	three	groups,	more	patients	in	the	FH/FCP	group	were	on	
H2RAs	compared	to	the	other	2	groups.	Neuromodulator	use	was	similar	in	all	three	groups,	
albeit	slightly	higher	in	the	FH/FCP	group.		
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Discussion	
Based	 on	 my	 summary	 findings,	 patients	 with	 RH	 have	 characteristics	 similar	 to	
NERD	in	some	respects	and	similar	to	FH/FCP	in	some	respects.	Considering	the	male:female	
ratio	in	our	cohort,	RH	had	a	higher	proportion	of	female	patients	which	is	consistent	with	
the	literature,	in	terms	of	hypersensitive	oesophagus,	where	the	consensus	based	on	limited	
studies	have	shown	a	slight	female	preponderance	in	RH	(135).	I	have	also	showed	a	female	
preponderance	in	FH/FCP.	Functional	chest	pain,	in	the	tertiary	care	setting	at	least,	shows	a	
female	preponderance	similar	to	my	findings,	whereas	in	the	general	population,	males	and	
females	present	with	functional	chest	pain	equally	(136)	(137).	Functional	heartburn	is	also	
equally	seen	in	male	and	female	patients.	The	general	perception	that	more	female	patients	
suffer	with	functional	disorders	may	stem	from	patterns	in	other	disorders	such	as	irritable	
bowel	 syndrome	 (IBS)	 (138).	 Therefore,	 although	 the	 male:female	 distribution	 has	 been	
evaluated	 in	 the	 literature	 for	 GORD	 and	 FH/FCP,	 with	 some	 previous	 work	 in	 RH,	 the	
male:female	distribution	in	RH	has	not	been	previously	been	evaluated	in	a	group	as	large	as	
this.	
I	 have	 shown	 that	 heartburn	 and	 regurgitation	were	more	 significantly	 prominent	
symptoms	 in	RH,	compared	to	chest	pain	and	epigastric	pain.	This	has	not	been	evaluated	
previously	and	adds	to	the	understanding	of	the	phenotype	of	the	RH	patient.		
ROME	 IV	 clearly	 defines	 RH	 as	 a	 separate	 entity	 to	 FH	 and	 FCP.	 In	 terms	of	 distal	
oesophageal	acid	exposure	as	well	as	total	number	of	reflux	episodes	and	total	number	of	
acid	reflux	episodes	in	RH,	I	have	demonstrated	that	RH	is	clearly	a	distinct	entity.	This	may	
explain	 the	microscopic	 difference	 seen	 in	RH	when	 compared	 to	 FH/FCP	 (121)	 as	well	 as	
differenced	 seen	 in	 baseline	 impedance	 (133).	 The	 implication	 of	 the	 results	 for	 non	 acid	
reflux	 are	 not	 easy	 to	 explain.	 It	 may	 be	 that	 the	 increased	 proportion	 of	 acid	 reflux	
compared	 to	 non	 acid	 reflux	 in	 patients	 with	 NERD	 allows	 for	 the	 relatively	 higher	
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proportion	of	non	acid	versus	physiological	acid	reflux	in	RH	to	appear	as	significant,	when	in	
fact	this	 is	not	so.	Comparing	the	RH	group	with	a	group	of	healthy	volunteers	 in	terms	of	
non	 acid	 reflux	 and	 physiological	 acid	 reflux	may	 help	 clarify	 the	 significance	 of	 non	 acid	
reflux	 in	 this	 case.	 The	 non-significance	 of	 non-acid	 reflux	 episodes	 between	 the	 RH	 and	
FH/FCP	group	may	does	not	really	inform	us	further	either,	and	a	comparison	with	a	groups	
of	healthy	 volunteers	may	be	useful	 here	as	well.	 Either	way,	non	acid	 reflux	may	be	 less	
significant	than	has	been	suggested	in	previous	studies	(139).		
When	 considering	 dyspeptic	 symptoms,	 again	 the	 RH	 group	 in	 our	 cohort	 were	
similar	 to	 the	 NERD	 group	 with	 66%	 vs	 63%.	 The	 FH/FCP	 group	 however	 complained	 of	
significantly	 more	 bloating	 with	 84%	 volunteering	 bloating	 as	 a	 bothersome	 symptom.	
Nausea	and	vomiting,	although	not	common	were	seen	 in	marginally	more	patients	 in	 the	
RH	 and	 FH/FCP	 group	 compared	 to	 the	 NERD	 group.	 The	 contribution	 of	 visceral	
hypersensitivity	 in	 the	pathophysiology	of	 all	 three	 conditions	 (2)	 is	 likely	 to	explain	 these	
not	insignificant	levels	of	dyspepsia	in	all	thee	groups	studied.	
Belching	 however	 was	 clearly	 more	 common	 in	 patients	 with	 NERD,	 which	 is	
possibly	due	to	the	contribution	of	TLOSRs	in	the	pathophysiology	of	reflux	(66).	The	levels	
of	 belching	 in	RH	and	 FH/FCP	were	not	 insignificant	 though	 at	 62%	and	77%	 respectively.	
Belching	was	not	 specifically	 investigated	during	 impedance	metry	 for	 the	vast	majority	of	
patients,	although	a	few	who	complained	of	significant	belching	affecting	quality	of	life	were	
reviewed	in	terms	of	belching	during	their	MII	pH	study.	The	predominant	rationale	for	this	
was	 to	 look	 for	 potential	 supragastric	 belching,	 especially	 since	 our	 unit	 was	 trialling	
behavioural	therapy	as	a	treatment	for	problematic	supragastric	belching	(140).			
Despite	being	on	a	PPI,	all	patients	still	complained	of	at	least	1	typical	symptoms	of	
GORD	to	qualify	 for	 inclusion	 into	this	study,	hence	referral	 to	a	tertiary	centre	for	 further	
investigation	 of	 their	 symptoms.	 This	 fact	 reinforces	 the	 need	 for	 improvement	 in	 the	
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diagnosis	and	treatment	for	those	patients	who	are	either	partially	or	fully	refractory	to	acid	
suppression	therapy.		
Increasing	evidence	for	the	use	of	SSRIs	and	gabapentin	in	FH	and	FCP	(4)	has	lead	
increased	prescribing	of	these	medications	when	clinicians	suspect	a	functional	component	
to	 the	 symptoms	 experienced	 by	 a	 patient.	 Despite	 this	 however,	 it	 is	 interesting	 to	 note	
that	 despite	 23%	 of	 the	 FH	 group	 already	 being	 on	 either	 amitriptyline,	 an	 SSRI	 or	
pregabalin,	they	presumably	did	not	have	sufficient	relief	of	their	symptoms,	culminating	in	
a	tertiary	referral	for	further	investigation	of	their	symptoms.		
The	 body	 of	 this	 work	 represents	 the	 largest	 group	 of	 patient	 studied	 with	 RH,	
previously	 termed	 hypersensitive	 oesophagus,	 as	 classified	 by	 ROME	 III	 criteria.	 Although	
ROME	 IV	 reclassified	RH	as	 a	 functional	 oesophageal	 disorder	 as	 opposed	 to	 a	 subtype	of	
NERD,	 the	only	 real	 change	 in	 terms	of	diagnostic	 criteria	was	 the	 fact	 that	 specific	 reflux	
symptom	 association	 parameters	 were	 removed,	 although	 evidence	 of	 “triggering	 of	
symptoms	 by	 reflux	 events	 despite	 normal	 acid	 exposure	 on	 pH	 or	 pH–impedance	
monitoring”	forms	part	of	the	current	diagnostic	criteria.	This	 is	currently	not	quantified	 in	
the	ROME	IV	consensus	document,	which	is	unusual	in	a	parameter	driven	environment	that	
surrounds	 the	 study	 of	 GORD.	 The	 rationale	 given	 is	 the	 uncertainty	 of	 the	 “true	 clinical	
value”	 of	 reflux	 symptom	 association.	 In	 effect	 however,	 confirming	 that	 a	 symptom	 is	
“triggered”	by	a	reflux	event	 is	a	component	of	reflux	symptom	association.	Therefore	our	
cohort	of	patients	still	falls	within	the	diagnostic	criteria	for	RH.		
As	would	be	expected,	there	are	some	concerns	including	those	raised	by	Frazzoni	et	
al,	that	RH	is	better	characterised	as	it	was	previously,	as	a	subtype	of	NERD	(141)	and	they	
argue	that	the	classification	of	RH	as	a	functional	disorder	is	not	justified	at	present.	 	Their	
argument	proposes	that	newer	impedance	parameters	such	as	the	PSPW	index	and	MNBI,	in	
addition	to	reflux	symptom	association	would	better	define	patients	with	RH.	Of	note,	 the	
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same	 authors	 have	 demonstrated	 that	 both	 these	 parameters	 have	 been	 shown	 increase	
diagnostic	yield	 in	NERD	(142).	 	This	highlights	the	need	for	better	phenotyping	of	patients	
diagnosed	with	RH.		
In	summary,	 it	 is	clear	that	my	findings	contribute	to	the	understanding	of	RH	and	
inform	the	following	chapters	in	this	thesis.	This	work	also	affords	improved	phenotyping	of	
patients,	 which	 is	 especially	 useful	 when	 assessing	 novel	 therapies	 for	 the	 treatment	 of	
GORD	and	oesophageal	pain.		
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Chapter	3	
Treatment	 of	 oesophageal	 hypersensitivity	 in	 patients	 with	
NERD:	effect	of	a	prostaglandin	EP1	receptor	antagonist	
	 	
	
	
	 110	
Introduction	
The	pathophysiology	of	symptom	generation	in	NERD	is	thought	to	involve	central	as	
well	 as	 peripheral	 sensitisation.	 Pathological	 and	 also	 physiological	 acid	 exposure	 to	 the	
distal	 oesophagus	 is	 thought	 to	 sensitise	 local	 nerves	 (possibly	 via	 dilated	 intercellular	
spaces)	as	well	as	dorsal	horn	nuclei,	 leading	 to	 increased	sensitivity	of	 the	distal	and	also	
the	proximal	oesophagus	to	acid	(94).		
In	 general,	 assessment	 of	 oesophageal	 sensitivity	 in	 NERD	 patients	 has	 yielded	
evidence	 for	 reduced	 perception	 thresholds	 for	 painful	 stimuli.	 Miwa	 et	 al	 evaluated	
stimulus	response	functions	to	acid	in	patients	with	NERD,	compared	with	ERD	and	FH,	using	
an	 acid	 perfusion	 model.	 They	 demonstrated	 that	 NERD	 patients	 had	 lower	 perception	
thresholds	for	pain,	especially	compared	with	normal	controls,	but	also	compared	to	those	
with	erosive	oesophagitis	and	Barrett’s	oesophagus	(143).		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	3.1:	Mechanisms	underlying	sensitization.	Luminal	factors	and	mediators	released	in	
response	to	ischemia,	injury,	and	inflammation	act	on	the	sensory	endings	to	drive	
sensitization.	These	peripheral	mechanisms	are	reinforced	by	central	mechanisms	in	the	
spinal	cord	and	CNS.	ATP,	adenosine	triphosphate;	LIF,	leukaemia	inhibitory	factor;	NGF,	
nerve	growth	factor;	PGE,	prostaglandin	E;	TNF,	tumour	necrosis	factor	(94).
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Several	mediators	involved	in	this	process	of	oesophageal	pain	hypersensitivity	have	
been	identified	recently,	including	prostaglandin	E2,	TRPV1,	PAR-2	and	ASICS	as	discussed	in	
chapter	 1	 of	 this	 thesis	 (24-27).	 Identification	 of	 such	 target	 mediators	 and	 a	 means	 of	
manipulating	them	in	order	to	treat	oesophageal	pain	comprises	one	strategy	to	address	the	
gap	in	therapies	for	patients	with	refractory	GORD.	
In	this	chapter,	I	investigated	the	effect	of	a	compound	that	is	a	potent	and	selective	
prostaglandin	 EP1	 receptor	 antagonist	 as	 a	 therapy	 for	 oesophageal	 pain	 in	 patients	with	
NERD.		
Prostaglandin	E2	
The	 prostanoid	 prostaglandin	 E2	 (PGE2)	 is	 an	 important	 mediator	 of	 both	 central	
and	 peripheral	 sensitisation	 and	 the	 prostaglandin	 E	 receptor	 1	 (EP1)	 appears	 to	 have	 a	
major,	 but	 not	 exclusive,	 role	 in	 mediating	 the	 contribution	 of	 PGE2	 to	 both	 peripheral	
and	 central	 sensitisation	(144-147).	PGE2	exerts	its	cellular	effects	through	four	different	G	
protein-coupled	receptors	encoded	by	separate	genes,	termed	EP1,	EP2,	EP3	and	EP4	(148).	
Among	the	four	subtypes,	EP1	receptors	appear	to	have	a	major	role	 in	processing	of	pain	
(146,	149).		
ONO-8539	
ONO-8539	 is	 a	 potent	 and	 selective	 prostaglandin	 EP1	 receptor	 antagonist	
developed	 by	 ONO	 Pharmaceutical	 Co.,	 Ltd.	 Preclinical	 data	 generated	 in	 a	 distal	
oesophageal	acidification	model	in	the	monkey	demonstrated	that	ONO-8539	is	effective	in	
increasing	 pain	 tolerance	 threshold	 following	 electrical	 stimulation	 of	 the	 proximal	
oesophagus.	Their	data	suggested	that	ONO-8539	might	therefore	be	an	effective	modulator	
of	oesophageal	pain	hypersensitivity.	Previous	clinical	studies	have	shown	it	to	be	safe	and	
well	tolerated	in	humans	(150).	The	most	frequently	reported	GI-related	adverse	event	was	
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diarrhoea	 and	 the	 majority	 of	 adverse	 events	 seen	 were	 mild	 and	 resolved	 without	
intervention	(151).	
Study	design	 	
This	was	a	randomised,	two	centre	(London,	UK	and	Leuven,	Belgium),	double-blind,	
placebo-controlled,	two-period,	crossover	study	design.	The	main	objective	was	to	evaluate	
ONO-8539	on	a	model	of	oesophageal	pain	hypersensitivity	in	patients	with	NERD.	Subjects	
with	a	 confirmed	diagnosis	of	NERD	on	a	 stable	dose	of	PPI	were	enrolled	 into	 the	 study.	
ONO-8539	 or	 placebo	 was	 dosed	 as	 an	 add-on	 therapy	 to	 a	 stable	 dose	 of	 PPI.	 ONO	
Pharmaceutical	 designed	 the	 protocol,	 in	 collaboration	 with	 the	 Principal	 investigators	 of	
both	 sites	 and	 their	 respective	 research	 groups.	 I	 was	 involved	 in	 the	 latter	 part	 of	 the	
refining	process.		
Each	 subject	was	 randomised	 to	ONO-8539	 300	mg	 bid	 or	 placebo	 bid	 in	 the	 first	
treatment	 period	 and	 the	 alternate	 treatment	 in	 the	 second	 treatment	 period.	 	 Each	
treatment	period	lasted	28	days	(±	1	day).		There	was	a	washout	of	≥	13	days	between	each	
treatment	period.		Subjects	were	randomised	to	treatment	sequence	in	a	1:1	ratio.	Subjects	
were	enrolled	for	a	total	of	approximately	19	weeks	from	the	screening	visit	(visit	1)	to	the	
follow-up	 visit	 (visit	10)	 and	 attended	 the	 clinic	 for	 a	maximum	of	 10	visits.	 Subjects	were	
outpatients	and	therefore	no	overnight	stays	were	required.		
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Figure	3.	2:	Schematic	of	study	design.	
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Study	medication	
The	study	medication	consisted	of	either	300mg	of	ONO-8539	or	matching	placebo,	
that	 was	 taken	 orally	 with	 water	 twice-daily.	 As	 ONO-8539	 is	 a	 weak	 inhibitor	 of	 the	
cytochrome	 P450	 (CYP)	 isoenzyme	 CYP3A4,	 a	 list	 of	 contraindicated	 medications	 was	
formulated	to	ensure	co	administration	was	avoided,	thus	reducing	the	risk	of	inadvertently	
increased	drug	levels.		
Medications	 affecting	 PGE2	 levels	 such	 as	 non-steroidal	 anti-inflammatory	 drugs,	
COX-2	inhibitors	and	Prostaglandin	drugs	were	also	prohibited	during	the	study.	
Inclusion	and	exclusion	criteria	
As	expected	with	a	 clinical	 trial	 involving	an	 investigational	medicinal	product,	 the	
inclusion	and	exclusion	criteria	were	extensive	and	rigorous.		
Inclusion	criteria	
1. Able	to	give	written	informed	consent.	
2. Male	or	female	subjects	aged	18	to	70	years	inclusive.	
3. Confirmed	GORD	according	to	the	Montreal	definition	(1)	
4. Confirmed	normal	oesophageal	mucosa	on	endoscopy.		
5. On	a	stable	dose	of	a	PPI	for	at	least	4	weeks	prior	to	Visit	4.			
6. Moderate	intensity	heartburn	on	at	least	2	days	a	week	for	at	least	8	weeks	prior	to	
Visit	3,	as	reported	by	the	patient	on	direct	questioning.					
7. Scoring	of	 intensity	of	their	symptoms	at	 least	 ‘very	mild’	 (≥5.3cm)	following	distal	
oesophageal	acid	perfusion	using	a	previously	validated	verbal	descriptor	scale.	
8. If	male,	an	agreement	to	use	a	highly	effective	method	of	contraception	from	Visit	4	
until	3	months	after	their	follow	up	study	visit.	
9. If	 female,	 and	 of	 child-bearing	 potential,	 an	 agreement	 to	 use	 a	 highly	 effective	
method	of	contraception	for	a	period	of	at	least	28	days	before	Visit	4	until	at	least	1	
month	after	the	follow	up	visit.		
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10. The	subject	was	able	to	meet	the	study	restrictions.		
11. The	 subject	 was	 capable	 of	 independently	 completing	 the	 study	 diaries	 and	
questionnaires.		
Exclusion	criteria  
1. Any	present	or	past	history	of	any	significant	disease	or	disorder	that	would	increase	
the	 risk	 for	 the	 subject	 if	 they	 were	 enrolled	 in	 the	 study,	 or	 would	 affect	 study	
procedures	or	outcomes.		
2. Presence	of	oesophageal	motility	disorders,	as	identified	by	HRM	at	screening.	
3. Inability	 to	 tolerate	oesophageal	 acid	perfusion,	oesophageal	electrical	 stimulation	
or	oesophageal	intubation.			
4. A	 history	 of	 GI,	 renal	 or	 hepatic	 disease,	 prior	 endoscopic	 anti-reflux	 procedure,	
major	 GI	 surgery	 or	 any	 other	 condition	 that	 may	 have	 interfered	 with	 drug	
absorption,	distribution,	metabolism	or	excretion.			
5. Normal	 oesophageal	 acid	 exposure	 (total	 time	 pH<4	 less	 than	 or	 equal	 to	 4.2%)	
during	24	h	MII-pH	monitoring,	and	both	a	negative	SI	and	SAP.	
6. Any	acute	gastro-intestinal	symptoms	within	14	days	of	Visit	4	with	the	exception	of	
GORD	symptoms	and	constipation.		
7. An	identified	endoscopic	or	manometric	abnormality.		
8. Any	 clinically	medical	 issue	 within	 4	 weeks	 of	 Visit	 4	 which	 in	 the	 opinion	 of	 the	
Investigator	 would	 place	 the	 subject	 at	 undue	 risk,	 could	 influence	 the	 results	 or	
ability	of	the	subject	to	participate	in	the	study.			
9. A	history	of	alcoholism	or	drug	abuse.	
10. A	clinically	significant	laboratory	abnormality.	
11. Cardiovascular	conditions	within	6	months	prior	to	Visit	1.		Abnormal	blood	pressure	
unless	well	controlled.	Prolonged	QT	interval.		
12. A	positive	drugs	of	abuse,	hepatitis	B,	hepatitis	C	or	human	immunodeficiency	virus	
(type	I	or	II)	test	at	Visit	1.		
13. A	 history	 of	 hypersensitivity	 to	 any	 of	 the	 drug	 constituents	 as	 listed	 in	 the	
investigators	brochure	(IB).		
14. Participation	 in	 a	 clinical	 trial	 involving	 an	 investigational	medicinal	 product	 (IMP)	
within	3	months	or	five	half-lives	of	the	IMP	(whichever	is	longer)	of	Visit	1.	
15. Unable	to	use	a	PPI	or	on	any	contraindicated	medication	that	could	 influence	the	
efficacy	of	the	PPI	or	the	ability	to	continue	their	use	of	a	PPI.		
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16. Taking	 any	 prohibited	 concomitant	 medication	 within	 the	 defined	 period	 prior	 to	
screening	Visit	1.	
17. Changing	the	dose	of	a	permitted	medication	required	to	be	at	a	stable	dose,	within	
the	defined	period	prior	to	screening	Visit	1.		
18. Taking	 any	 medication,	 which	 in	 the	 opinion	 of	 the	 Investigator	 would	 place	 the	
subject	 at	 undue	 risk,	 could	 influence	 the	 results	 or	 ability	 of	 the	 subject	 to	
participate	in	the	study.		
19. Donating	 blood	 and/or	 received	 blood	 or	 blood	 products	 within	 the	 previous	 3	
months	prior	to	screening	Visit	1		
20. Pregnancy,	lactating	or	planning	to	become	pregnant	during	the	course	of	the	study.		
21. Inadequate	vision	or	manual	dexterity	to	complete	the	subject	diary.		
22. Difficulty	swallowing	tablets.		
23. Unable	 to	 cooperate	 fully	 with	 study	 staff,	 difficulty	 following	 some	 study	
requirements,	or	otherwise	not	qualified	for	the	study.		
24. Previously	received	ONO-8539.		
25. Vulnerable,	imprisoned	or	institutionalized	by	regulatory	or	court	order.		
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Study	Objectives	
Primary	Objective	
The	 primary	 objective	 of	 the	 study	 was	 to	 evaluate	 the	 effect	 of	 ONO-8539	 on	
oesophageal	pain	hypersensitivity	to	oesophageal	acid	perfusion.			
Secondary	Objectives	
1. To	 evaluate	 the	 effect	 of	 ONO-8539	 on	 subject-reported	 symptoms	 of	 GORD	
(severity	and	frequency)	
2. To	assess	the	safety	and	tolerability	of	ONO-8539	
Exploratory	Objective(s)	
1. To	 investigate	 the	 effect	 of	 ONO-8539	 on	 oesophageal	 pain	 hypersensitivity	 to	
electrical	stimulation	
2. To	evaluate	the	effect	of	ONO-8539	on	quality	of	life	
3. To	investigate	the	pharmacokinetics	of	ONO-8539	
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Methods	
Baseline	data	collection	
The	 following	 demographic	 data	 and	 medical	 history	 were	 taken	 at	 screening.	
Baseline	assessments	were	also	conducted.	
• Date	of	birth,	  gender,	  race	 
• A	 full	 medical	 history,	 including	 GORD	 symptoms,	 medication	 history,	 smoking	
history,	alcohol	consumption	history	and	systemic	enquiry.	 
• Endoscopy	 
• HRM	and	MII	pH	monitoring	 
• Physical	examination	(including	weight	and	height)	   
• Vital	signs	and	12-lead	ECG		 
• Clinical	laboratory	tests	(including	viral	screen)	 
• As	 part	 of	 screening,	 baseline	 oesophageal	 pain	 threshold	 was	 recorded	 using	
electrical	stimulation	of	the	oesophagus. 
• Baseline	 response	 to	 oesophageal	 acid	 exposure	 was	 recorded	 using	 a	 Modified	
Bernstein	test 
• Baseline	 personality	 trait,	 anxiety	 levels,	 symptom	 scores,	 quality	 of	 life	 scores	 as	
well	as	fear	of	pain	scores	are	recorded. 
Study	procedures	
Endoscopy	 
Gastroscopy	 was	 performed	 at	 screening	 to	 review	 the	 presence	 of	 mucosal	
abnormalities	in	the	upper	GI	tract.	
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Oesophageal	Manometry	and	24	hour	MII	pH	monitoring 
Oesophageal	 manometry	 was	 undertaken	 at	 screening.	 Motility	 disorders	 where	
reviewed	with	regards	to	inclusion	and	exclusion	criteria.	The	upper	border	of	the	LOS	was	
recorded.	A	24	hour	MII-pH	study	was	also	undertaken	to	confirm	NERD	and	exclude	FH	and	
FCP.		
Oesophageal	pain	threshold	measurement	
Oesophageal	electrical	stimulation	was	performed	using	a	bespoke	catheter	with	a	
distal	oesophageal	electrode.	The	electrode	was	placed	5cm	above	the	LOS	and	oesophageal	
pain	threshold	was	determined	by	increasing	the	electrical	stimulation	intensity	in	steps	of	2	
mA,	 until	 the	 subject	 first	 reported	 pain.	 The	mean	 of	 three	 separate	measurements	was	
recorded	as	the	pain	threshold.	The	duration	of	the	electrical	stimulus	pulse	was	200μs	and	
the	frequency	of	presentation	0.5	Hz.			
Modified	Bernstein	Test	
Several	 studies	 investigating	 various	 aspects	 of	 GORD,	 use	 the	 Bernstein	 test,	 or	
modifications	of	it,	to	investigate	the	effect	an	agent	on	the	perception	of	acid	(or	non	acid)	
reflux	 (152-154).	 The	 modification	 used	 in	 this	 study	 was	 the	 use	 of	 the	 perception	 of	
“slightest	discomfort”	instead	of	“typical	symptoms”	as	an	endpoint	for	the	test.	
Prior	to	starting	the	modified	Bernstein	test	(MBT),	a	standard	instruction	script	was	
read	 out	 in	 order	 to	 standardise	 instructions.	During	 the	MBT,	 saline	 of	 0.9%	was	 initially	
infused	 into	 the	 oesophagus	 through	 an	 infusion	 port	 10cm	 above	 the	 LOS	 at	 a	 rate	 of	
10ml/minute.	After	2	minutes,	the	infusion	was	changed	to	one	on	0.1	M	Hydrochloric	acid	
(HCL)	at	a	rate	of	10ml/minute,	for	a	period	or	10	minutes.	The	patient	was	unaware	of	the	
switch	and	was	asked	to	alert	the	investigator	when	they	first	felt	“the	slightest	discomfort”.	
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Quantification	of	stimulus-response	to	acid		
This	was	quantified	by	three	parameters:		
• Lag	 time	 to	 symptom	 perception	 (defined	 as	 the	 time,	 in	 seconds,	 to	 initial	
discomfort	perception	following	the	MBT).		
• Sensory	 intensity	rating	(an	assessment	of	the	 intensity	of	symptoms	at	the	end	of	
the	MBT,	made	using	a	previously	validated	verbal	descriptor	scale.).	
• APSS	(acid	perfusion	sensitivity	score)		
	
The	APSS	was	 calculated	 from	 lag	 time	 (T)	expressed	 in	 seconds	 (sec)	and	 sensory	
intensity	rating	(I)	expressed	 in	centimeters	(cm).	The	figure	obtained	 is	divided	by	100	for	
convenience:		APSS	=	(I)	x	(T)/100	(cm	x	sec/100)	(152-155).		
The	verbal	descriptor	scale	consisted	of	a	20-cm	vertical	bar	flanked	by	descriptors	
of	 increasing	 intensity	 (no	 sensation,	 very	 weak,	 faint,	 weak,	 very	 mild,	 mild,	 moderate,	
barely	strong,	slightly	 intense,	strong,	 intense,	very	 intense,	extremely	 intense).	Placement	
of	 words	 along	 the	 scale	 was	 determined	 from	 their	 relative	 log	 intensity	 rating	 in	 a	
normative	study.	The	validity	of	these	scales	for	assessing	the	perceived	intensity	of	visceral	
sensation	has	been	previously	confirmed	(156,	157).		
The	APSS	was	chosen	as	a	 suitable	endpoint	 in	view	of	previous	validation	 studies	
where	 it	was	utilised	by	Fass	et	al	 to	assess	chemosensitivity	 to	acid	 in	healthy	volunteers	
and	patients	with	GORD	(152).	They	also	used	it	to	assess	chemosensitivity	to	acid	in	older	
and	younger	patinets	with	GORD	(155)	more	recently	they	used	it	to	evaluate	the	response	
of	patients	with	GORD	to	auditory	stress	(158).	In	this	last	study,	the	APSS	was	able	to	clearly	
differentiate	 GORD	 patients	 from	 healthy	 volunteers	 at	 baseline,	 and	 after	 the	 active	
intervention	versus	the	control.		
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Questionnaires	
Subjects	 were	 asked	 to	 complete	 several	 questionnaires	 at	 defined	 time	 points	
during	the	study	to	assess	symptoms,	anxiety	and	depression.	
Reflux	Symptom	Questionnaire	7	Day	Recall		
This	 is	 a	well-validated	questionnaire	 used	 in	 patients	with	GORD	who	experience	
only	a	partial	 response	to	PPI	 therapy.	 It	 is	brief	and	easy	 to	complete	and	 is	 intended	 for	
use	 in	 routine	 clinical	 care.	 It	 consists	 of	 13	 items	 incorporating	 oesophageal	 and	 extra	
oesophageal	 symptoms	 of	 GORD,	 and	 requires	 the	 patient	 to	 document	 frequency	 and	
intensity	 of	 symptoms	 over	 the	 previous	 7	 days.	 It	 is	 frequently	 used	 in	 clinical	 trials	
assessing	 new	 therapies	 for	 the	 treatment	 of	 GORD	 and	 it	 was	 therefore	 a	 suitable	
questionnaire	to	study	the	effect	of	treatment	on	symptoms	of	GORD	(159).		
State-Trait	Anxiety	Inventory		
This	 is	 a	 widely	 used	 self-report	 questionnaire	 to	 assess	 anxiety,	 which	 has	 good	
reliability	 and	 has	 been	 validated	 extensively	 (160).	 As	 one	 may	 expect,	 the	 state	
questionnaire	 asks	 how	 the	 subject	 feels	 at	 the	 present	 moment,	 whereas	 the	 trait	
questionnaire	enquires	about	 longer	 term	 feelings	of	anxiety.	The	 subject	was	 required	 to	
select	how	closely	they	identified	with	20	different	emotions	at	that	point	in	time	on	a	scale	
of	1	 (“not	at	all”)	 to	4	 (“very	much	so”).	The	Trait	Anxiety	Questionnaire	examines	 longer-
term	traits	 toward	anxiety	than	the	State	Anxiety	Questionnaire.	The	subject	was	required	
to	 select	 how	 frequently	 they	 associated	with	 20	 different	 traits	 on	 a	 scale	 of	 1	 (“almost	
never”)	to	4	(“almost	always”).		
Patient	Health	Questionnaire–15	 
This	questionnaire	is	self-administered	and	comprises	15	somatic	symptoms	derived	
from	the	full	Patient	Health	Questionnaire.	Each	symptom	is	scored	0	(“not	bothered	at	all”),	
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1	 (“bothered	 a	 little”),	 or	 2	 (“bothered	 a	 lot”).	 The	 PHQ-15	 examines	 how	much	 subjects	
have	been	affected	by	 the	15	different	somatic	 symptoms	over	 the	previous	4	weeks.	The	
results	of	this	questionnaire	indicate	if	the	subject	is	experiencing	somatisation	disorder	and	
at	what	level	(161).	
Hospital	Anxiety	and	Depression	Scale	
The	 HADS	 is	 a	 short	 self-administered	 questionnaire	 that	 takes	 approximately	 5	
minutes	 to	 complete.	 It	 is	 designed	 to	 screen	medical	 patients	 for	 anxiety	 and	depression	
and	 is	well	validated	 (162).	There	are	seven	 items	on	the	questionnaire	relating	 to	anxiety	
and	 seven	 relating	 to	 depression.	 The	 subject	 indicated	 how	 closely	 they	 related	 to	 each,	
and	a	score	of	0–3	is	generated	for	each	answer.	An	overall	 figure	(out	of	21)	 is	generated	
for	both	anxiety	and	depression	(163),	with	higher	scores	corresponding	to	higher	levels	of	
anxiety	and	depression.	
Fear	of	Pain	Questionnaire	(FPQ) 
The	 FPQ	 is	 a	 self-	 administered	 assessment	 which	 outlines	 different	 scenarios	 in	
which	a	subject	could	potentially	experience	pain	and	asks	how	much	they	would	 fear	 the	
pain	in	each	scenario	on	a	scale	of	1	(“not	at	all”)	to	5	(“extreme”)	(164).	 
Quality	of	Life	Assessment	-	Inhibition	(QOLRAD-RI)		
This	is	a	well-validated	questionnaire	used	in	patients	with	dyspepsia	and	heartburn	
predominant	 reflux	 (165),	 (166),	 (167).	 It	 measures	 the	 effect	 of	 upper	 gastro-intestinal	
symptoms	over	the	previous	week	on	various	aspects	of	quality	of	 life	 including	emotional	
well-being,	sleep,	vitality,	eating	and	drinking	and	physical	and	social	functioning	(166).	
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Statistical	Methods	
Determination	of	sample	size	
The	 sample	 size	 for	 this	 study	 was	 selected	 based	 on	 feasibility,	 as	 this	 was	 an	
exploratory	study.	As	there	was	no	defined	and	accepted	pharmacodynamic	endpoint	in	this	
population,	 considering	 the	 mechanism	 of	 action	 of	 ONO-8539,	 there	 was	 a	 paucity	 of	
information	 to	 facilitate	 establishing	 formal	 powering.	 	 Thus,	 a	 sample	 size	 of	 30	subjects	
was	selected	on	the	basis	of	comparability	to	other	exploratory	studies	in	this	population	in	
the	 literature.	 	 Assuming	 a	withdrawal	 rate	 of	 between	 10–20%,	 this	was	 still	 considered	
sufficient	to	provide	data	to	assess	the	pharmacodynamics	of	ONO-8539	as	an	exploratory	
study.	
Statistical	analysis	
Continuous	variables	are	presented	as	mean	and	standard	deviation,	or	medians	and	
inter-quartile	 ranges,	 dependent	 on	 data	 distribution.	 Categorical	 variables	 were	
summarised	by	the	mean	and	standard	deviation.	
ONO	Pharmaceuticals	 carried	out	 statistical	 analysis	on	pre-defined	 sets.	 This	data	
was	reanalysed	by	me	as	well.	The	full	set	analysis	(FAS)	comprised	all	randomised	subjects	
who	 received	 ≥	1	dose	 of	 study	 drug	 and	 who	 had	 ≥	1	 valid	 post-randomisation	
pharmacodynamic	evaluation.	The	FAS	was	the	secondary	analysis	population	for	this	study	
and	it	was	used	for	analysis	of	the	primary	endpoint.	The	per	protocol	set	(PPS)	Included	all	
subjects	in	the	FAS	who	did	not	deviate	from	any	major	entry	criteria,	did	not	deviate	from	
the	protocol	between	randomisation	and	study	completion	and	met	criteria	for	compliance	
to	the	study	drug.		The	PPS	was	defined	on	a	period-by-period	basis.		In	addition	an	overall	
PPS	was	defined	that	included	subjects	in	both	the	PPS	for	treatment	period	1	and	the	PPS	
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for	treatment	period	2.	The	PPS	was	the	primary	analysis	population	for	pharmacodynamic	
and	quality	of	life	endpoints.			
The	primary	endpoint	of	change	from	baseline	in	the	APSS	was	due	to	be	analysed	
using	analysis	of	covariance	(ANCOVA)	to	compare	the	results	in	the	ONO-8539	group	with	
those	in	the	placebo	group.		This	analysis	was	due	to	be	performed	on	the	PPS.	The	primary	
analysis	was	also	due	to	be	repeated	for	the	lag	time	and	sensory	intensity	rating.	It	should	
be	noted	 that	because	 the	 target	 sample	 size	was	not	 achieved,	 it	was	 felt	 that	 statistical	
analysis	 of	 the	 primary	 endpoint	would	 be	 underpowered	 and	 therefore	 differences	were	
described	instead.		
The	 secondary	 endpoint	 was	 based	 on	 the	 PPS.	 Absolute	 value	 and	 change	 from	
baseline	were	summarised	descriptively	by	 treatment	and	 time-point	 (baseline	and	end	of	
treatment	period).		
Analyses	 performed	 used	 proprietary	 software	 (GraphPad	 Prism	 version	 7.00	 for	
MAC,	GraphPad	Software,	La	Jolla	California	USA,	www.graphpad.com).	P<0.05	was	adopted	
as	the	level	of	statistical	significance.	
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Results	
Demographic	characteristics	
Although	 it	 was	 planned	 to	 randomise	 a	 total	 of	 30	subjects,	 due	 to	 recruitment	
difficulties	only	14	subjects	were	randomised	to	treatment.	All	these	subjects	were	recruited	
from	the	Queen	Mary	University	of	London	site.	Due	to	the	length	and	invasive	nature	of	the	
study,	 local	 recruitment	was	 difficult	 and	 so	 an	 amendment	was	 sought	 to	 advertise	 City	
wide	in	the	printed	media.	Just	under	2000	subjects	were	screened	by	a	research	nurse	and	
myself	in	order	to	randomise	the	above	14	subjects.		
All	subjects	received	at	least	1	dose	of	study	drug.	2	subjects	discontinued	the	study	
prematurely	 (sciatica	 requiring	 NSAID	 therapy	 and	 mild	 ECG	 abnormality	 referred	 to	
cardiology).	
Overall,	 the	 median	 age	 of	 subjects	 was	 53.0	(33-62)	years.	 	 Most	 subjects	 were	
male	 (8	subjects	[57.1%])	 and	 white	 (10	subjects	[71.4%]).	 	 The	 median	 BMI	 was	
28.030	(18.70-47.00)	kg/m².	 Demographic	 characteristics	 were	 similar	 between	 the	
2	treatment	 sequences.	 All	 patients	 included	 in	 the	 analysis	 fulfilled	 the	 inclusion	 and	
exclusion	criteria.	Of	note,	they	were	confirmed	to	have	a	negative	OGD	as	well	as	a	positive	
24	hour	MII	pH	study	(12	subjects	confirmed	as	pathological	GORD	and	2	as	RH).		
Compliance	data		
Median	 compliance	 was	 100%	 for	 ONO-8539	 and	 placebo.	 With	 respect	 to	 PPI,	
median	 compliance	 was	 96.55%	 in	 both	 the	 ONO-8539	 and	 placebo	 groups.	 Six	 subjects	
used	 lansoprazole	 (at	 doses	 of	 30	mg	 daily	 [4	subjects],	 15	mg	 twice	 daily	 [1	subject],	 or	
15	mg	three	times	per	day	[1	subject]),	5	subjects	used	omeprazole	(at	doses	of	20	mg	once	
daily	 [3	subjects]	 or	 20	mg	 twice	 daily	 [2	subjects])	 and	 1	subject	 used	 esomeprazole	 (at	 a	
dose	of	40	mg	twice	daily).		
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Oesophageal	hypersensitivity	assessments	
Acid	perfusion	sensitivity	score	(APSS)	
The	 primary	 endpoint	 in	 this	 study	 was	 the	 change	 from	 baseline	 in	 the	 APSS,	
following	oesophageal	acid	perfusion	after	28	days	of	treatment.		
At	 baseline,	 the	 mean	 APSS	 was	 higher	 in	 the	 ONO-8539	 treatment	 group	 at	
75.424	(±35.154)	compared	with	the	placebo	group	at	61.391	(±28.471).		
After	 28	days	 of	 treatment,	 the	mean	 change	 from	baseline	 in	 APSS	 showed	 a	 directional	
change	 in	 favour	 of	 ONO-8539;	 however,	 the	magnitude	 of	 the	 change	was	 very	 small	 in	
both	 treatment	 groups,	 -15.471	(±48.144)	 in	 the	 ONO-8539	 treatment	 group	 and	 -
12.622	(±30.790)	 in	 the	placebo	group.	 	An	analysis	of	 the	change	 from	baseline	 (adjusted	
for	 baseline)	 showed	 a	 smaller	 change	 in	 the	 ONO-8539	 treatment	 group	 and	 a	 greater	
change	 in	 the	placebo	 group	 (LS	 (least	 squares)	means:	 -11.8	 and	 -16.3,	 respectively);	 the	
differences	between	treatments	were	not	statistically	significant	(p=0.757).	The	mean	APSS	
at	baseline	was	higher	in	treatment	period	1	than	in	treatment	period	2.		
The	APSS	data	obtained	in	this	study	were	comparable	with	those	obtained	in	NERD	
patients	in	previous	studies	(152).		
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Figure	3.	3:	This	plot	illustrates	the	lack	of	a	consistent	response	in	APSS	within	each	
treatment	group.	The	large	within	and	inter	subject	variability	is	demonstrated	as	well.	The	
data	in	red	indicate	the	mean	(SD)	at	each	visit.
Treatment	period	1	–	ONO	8539																Treatment	period	2	-	placebo		
AP
SS
	
Treatment	period	1	–	placebo	 	 Treatment	period	2	–	ONO	8539	
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Sensory	intensity	rating		
	
	
	
Figure	3.4:	This	plot	illustrates	the	lack	of	a	consistent	response	within	each	treatment	group	
in	sensory	intensity	rating.	A	large	within	and	inter	subject	variability	is	also	demonstrated.	
The	data	in	red	indicate	the	mean	(SD)	at	each	visit.
Treatment	period	1	-	ONO	8539		 Treatment	period	2	-	Placebo	
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At	 baseline,	 the	 mean	 sensory	 intensity	 rating	 was	 higher	 in	 the	 ONO-8539	
treatment	group	at	13.36	(±4.06)	cm	compared	with	the	placebo	group	at	11.65	(±4.34)	cm.		
After	 28	days	 of	 treatment,	 the	 mean	 change	 from	 baseline	 in	 sensory	 intensity	 rating	
showed	a	directional	change	in	favour	of	ONO-8539;	however,	the	magnitude	of	the	change	
was	small	in	both	treatment	groups,	-1.66	(±4.85cm	in	the	ONO-8539	treatment	group	and	-
0.96	(±3.94)	cm	in	the	placebo	group.		An	analysis	of	the	change	from	baseline	(adjusted	for	
baseline)	 had	 similar	 results	 (LS	 means:	 -1.6	cm	 in	 the	 ONO-8539	 treatment	 group	 and	 -
1.0	cm	 in	 the	 placebo	 group).	 	 The	 differences	 between	 treatments	 were	 not	 statistically	
significant	(p=0.742).		
In	 addition,	 the	mean	 sensory	 intensity	 rating	at	baseline	was	higher	 in	 treatment	
period	1	than	in	treatment	period	2,	suggesting	an	effect	of	learning	on	the	baseline	values	
between	treatment	period	1	and	2.	Thus,	there	appeared	to	be	an	order	effect.					
Lag	time	
At	 baseline,	 the	mean	 lag	 time	was	 shorter	 in	 the	 ONO-8539	 treatment	 group	 at	
66.2	(±183.51)	sec	 compared	with	 the	placebo	group	at	 90.5	(±74.53)	sec.	After	 28	days	of	
treatment,	the	mean	change	from	baseline	in	lag	time	showed	a	directional	change	in	favour	
of	 ONO-8539	 at	 118.3	(±286.12)	sec	 in	 the	 ONO-8539	 treatment	 group	 and	
73.1	(±214.12)	sec	in	the	placebo	group.		An	analysis	of	the	change	from	baseline	(adjusted	
for	baseline)	had	very	similar	results	(LS	means:	110.0	sec	in	the	ONO-8539	treatment	group	
and	 81.5	sec	 in	 the	 placebo	 group).	 	 The	 differences	 between	 treatments	 were	 not	
statistically	significant	(p=0.779).		
In	addition,	similar	to	mean	baseline	sensory	 intensity	rating,	the	mean	lag	time	at	
baseline	 was	 lower	 in	 treatment	 period	1	 than	 in	 treatment	 period	2,	 also	 suggesting	 an	
order	effect.		
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Figure	3.5:	This	plot	illustrates	the	lack	of	a	consistent	response	within	each	treatment	group	
in	sensory	intensity	rating.	Similar	to	the	previous	two	stimulus	response	measures,	a	large	
within	and	inter	subject	variability	is	demonstrated.	The	data	in	red	indicate	the	mean	(SD)	at	
each	visit;	a	negative	time	indicates	that	the	discomfort	occurred	during	the	saline	perfusion.	
Treatment	period	1	-	ONO	8539		 		Treatment	period	2	-	placebo	
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Reflux	symptom	questionnaire	analysis	
Changes	 from	 baseline	 in	 each	 of	 the	 four	RESQ-7	 domains	 (i.e.,	 burping,	 cough,	
heartburn	 and	 regurgitation;	 each	 assessed	 for	 frequency	 and	 intensity)	 were	 generally	
greater	 following	treatment	with	ONO-8539	compared	with	placebo,	although	none	of	the	
changes	 were	 statistically	 different	 compared	 with	 placebo.	 	 Of	 note,	 mean	change	 from	
baseline	in	burping	frequency	score	was	-1.25	(±1.631)	following	treatment	with	ONO-8539	
compared	 to	 -0.33	(±1.451)	 following	 treatment	with	 placebo	 (p=0.270).	 Burping	 intensity	
score	was	-1.33	(±1.155)	following	treatment	with	ONO-8539	versus	-0.58	(±1.782)	following	
treatment	with	placebo	(p=0.159).	
No	clear	pattern	was	observed	in	relation	to	the	changes	in	the	RESQ-7	categories.	
None	 of	 the	 observed	 differences	 in	 change	 from	 baseline	 in	 RESQ-7	 categories	 were	
statistically	significantly	different	between	treatments.	
Pain	threshold	analysis	
None	of	 the	 observed	 differences	 in	 change	 from	baseline	 in	 pain	 threshold	were	
statistically	significantly	different	between	treatments	(p=0.409).		
Pharmacokinetic	analysis	
Mean	 pre-dose	 ONO-8539	 plasma	 concentration	 was	 100.608	(±104.6350)	ng/mL	
for	 the	 mid	 study	 period	 (week	 2)	 and	 86.083	(±58.3468)	ng/mL	 at	 the	 end	 of	 the	 study	
period	 (week	4).	These	plasma	concentrations	observed	were	consistent	with	 results	 from	
previous	studies	with	ONO-8539	(151).	
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Quality	of	life,	anxiety,	depression	and	health	questionnaire	analysis	
None	 of	 observed	 differences	 in	 change	 from	 baseline	 in	 any	 of	 the	 QOLRAD-RI	
domains	 (i.e.,	 emotional	 distress,	 food/drink	 problems,	 physical/social	 functioning,	 sleep	
disturbance	 and	 vitality)	 were	 statistically	 significantly	 different	 between	 treatments	
(p=0.545,	p=0.942,	p=0.949,	p=0.411	and	p=0.857,	respectively).		
At	 baseline,	 the	 STAI-T	 was	 lower	 in	 the	 ONO-8539	 treatment	 group	 (36.0)	
compared	with	the	placebo	group	(39.5);	the	STAI-S	was	higher	in	the	ONO-8539	treatment	
group	 (36.7)	 compared	 with	 the	 placebo	 group	 (33.8).	 	 No	 clinically	 relevant	 changes	 in	
mean	 STAI-S	 scores	 were	 observed	 on	 Day	28	 compared	 to	 baseline	 following	 treatment	
with	ONO-8539	or	placebo.	The	difference	in	change	from	baseline	in	total	STAI-S	score	was	
not	statistically	significantly	different	between	treatments.	
None	of	the	observed	differences	in	change	from	baseline	in	PHQ-15	questionnaire	
score	 were	 statistically	 different	 between	 treatments	 (p=0.371).	 None	 of	 the	 observed	
differences	 in	 change	 from	 baseline	 in	 HADS	 anxiety	 score	 were	 statistically	 different	
between	treatments	(p=0.128).	Overall,	the	mean	total	fear	of	pain	(FPQ)	score	was	lower	in	
the	 ONO-8539/placebo	 treatment	 sequence	 (57.7	(±11.84)	 compared	 with	 the	
placebo/ONO-8539	 (62.7	(±11.45).	 	 Individual	 subject	 responses	 to	 the	FPQ	showed	a	high	
degree	of	variation.	
Response	rates	to	measured	endpoints		
The	 number	 of	 responders	 for	 APSS,	 sensory	 intensity	 rating	 and	 lag	 time	 were	
generally	higher	following	treatment	with	ONO-8539	compared	with	placebo.		
Although	 the	 mean	 changes	 from	 baseline	 tended	 to	 demonstrate	 a	 directional	
change	 in	 favour	 of	 ONO-8539	 compared	with	 placebo,	 the	 effect	 of	 ONO-8539	 on	 APSS,	
sensory	intensity	rating	and	lag	time	was	not	statistically	significantly	different	from	placebo	
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when	 adjusted	 for	 baseline.	 A	 similar	 pattern	 was	 also	 observed	 in	 secondary	 and	
exploratory	analyses.	
The	 number	 of	 responders	 for	 APSS,	 sensory	 intensity	 rating	 and	 lag	 time	 were	
generally	 higher	 following	 treatment	 with	 ONO-8539	 compared	 with	 placebo.	 However,	
differences	between	treatment	groups	 in	the	numbers	of	 responders	were	small,	and	only	
one	 of	 the	 differences	 was	 statistically	 significant.	 When	 considering	 the	 number	 of	
responders	 with	 a	 50%	 reduction	 in	 lag	 time,	 there	 were	 significantly	 more	 responders	
during	treatment	with	ONO-8539	than	during	placebo.			
Changes	in	all	4	RESQ-7	domains	(burping,	cough,	heartburn	and	regurgitation;	each	
assessed	 for	 frequency	 and	 intensity)	 were	 generally	 greater	 following	 treatment	 with	
ONO-8539	 (i.e.,	 indicating	a	greater	 improvement	versus	baseline)	compared	with	placebo	
although	none	of	the	differences	were	statistically	or	clinically	significant.			
None	of	the	changes	in	QOLRAD-RI,	STAI-S,	PHQ-15	and	HADS	(with	the	exception	of	
HADS	 depression)	 questionnaire	 scores	 were	 statistically	 significantly	 different	 following	
treatment	with	ONO-8539	compared	with	placebo.	
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	 ONO-8539	
N=12	
n	(%)	
Placebo	
N=12	
n	(%)	
p-value	
APSS	%	reduction	from	baseline	 	 	 	
30%	 5	(41.7)	 4	(33.3)	 0.656		
40%	 5	(41.7)	 3	(25.0)	 0.395		
50%	 4	(33.3)	 2	(16.7)	 0.237		
Sensory	intensity	rating	%	reduction	
from	baseline	
	 	 	
30%	 2	(16.7)	 2	(16.7)	 0.775		
40%	 2	(16.7)	 1	(8.3)	 0.634		
50%	 2	(16.7)	 1	(8.3)	 0.634		
Time	from	start	of	acid	perfusion	to	
first	perception	of	the	slightest	
discomfort	%	reduction	from	baseline	
	 	 	
30%	 4	(33.3)	 4	(33.3)	 0.970		
40%	 4	(33.3)	 3	(25.0)	 0.498		
50%	 4	(33.3)	 1	(8.3)	 0.042		
Sensory	intensity	rating	scale	AND	lag	
time,	%reduction	from	baseline	
	 	 	
30%	 2	(16.7)	 1	(8.3)	 0.799		
40%	 2	(16.7)	 1	(8.3)	 0.799		
50%	 2	(16.7)	 1	(8.3)	 0.799		
	
Table	3.1:	Summary	of	Responders	–	PPS.		
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Adverse	Events	
The	 overall	 incidence	 of	 total	 adverse	 events	 (TEAs)	 was	 numerically	 higher	 after	
treatment	with	ONO-8539	(11	subjects	[84.6%])	compared	with	placebo	(8	subjects	[61.5%]).	
The	 majority	 of	 TEAEs	 were	 mild	 in	 intensity	 (headache,	 nausea	 and	 mild	 abdominal	
discomfort).	ONO-8539	300	mg	bid	administered	for	28	days	was	shown	to	be	safe	and	well	
tolerated.		
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Summary		
This	 randomised,	 double-blind,	 two	 centre,	 placebo-controlled,	 two-period,	
crossover	study	in	subjects	with	a	diagnosis	of	NERD	was	designed	to	investigate	the	effect	
of	ONO-8539	on	oesophageal	pain	hypersensitivity	to	acid	perfusion	using	a	MBT.	
Mean	decreases	in	APSS	and	sensory	intensity	rating,	and	mean	increase	in	lag	time	
to	 symptom	 perception	 demonstrated	 a	 directional	 change	 in	 favour	 of	 ONO-8539	
compared	 with	 placebo.	 The	 magnitude	 of	 the	 change	 seen	 was	 very	 small	 in	 both	
treatment	 groups,	 and	 none	 of	 the	 differences	 were	 statistically	 significantly	 different	
compared	with	placebo	when	adjusted	for	baseline.		At	baseline,	APSS	and	sensory	intensity	
rating	were	higher	and	lag	time	was	lower	in	the	ONO-8539	treatment	group	compared	with	
placebo.	
A	large	within	and	inter	subject	variability	was	observed	in	the	change	from	baseline	
in	APSS,	sensory	intensity	rating	and	lag	time.		When	change	from	baseline	in	APSS,	sensory	
rating	and	lag	time	was	analysed	per	treatment	period,	the	effect	of	ONO-8539	was	greater	
during	 treatment	 period	1	 than	 in	 treatment	 period	2.	 	 A	 similar	 pattern	 was	 observed	
across	 secondary	 and	 exploratory	 analyses,	 where	 a	 directional	 change	 in	 favour	 of	
ONO-8539	 was	 observed,	 but	 only	 one	 of	 the	 observed	 changes	 from	 baseline	 was	
statistically	 significant.	 For	 the	 number	 of	 responders	 with	 a	 50%	 reduction	 in	 lag	 time,	
where	 there	 were	 significantly	 more	 responders	 during	 treatment	 with	 ONO-8539	 than	
during	placebo.			
Exposure	 to	 ONO-8539	 300	mg	bid	 in	 this	 study	 was	 consistent	 with	 previously	
obtained	 human	 data	 at	 this	 dose	 and	 a	 directional	 trend	 was	 evident	 between	 higher	
plasma	 concentrations	 of	 ONO-8539	 and	 greater	 improvement	 in	 APSS,	 sensory	 intensity	
rating	and	lag	time	(151).	 	
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Discussion	
It	 was	 initially	 planned	 to	 randomise	 a	 total	 of	 30	subjects,	 however,	 due	 to	
recruitment	 difficulties,	 only	 14	subjects	 were	 randomised	 and	 12	subjects	 completed	 the	
study	(and	were	included	in	the	PPS).		Therefore,	although	this	was	an	exploratory	study,	the	
study	 was	 likely	 underpowered	 to	 detect	 any	 statistical	 differences	 between	 treatments.		
The	reduced	sample	size	led	to	a	number	of	statistical	analyses	not	being	performed.		
Recruitment	difficulties	were	 likely	due	to	several	 reasons.	Firstly,	 the	 invasiveness	
of	 the	 study	 (4	 MBTs	 over	 the	 entire	 study	 period)	 was	 a	 significant	 factor.	 Aside	 from	
attempting	 to	 avoid	 the	 order	 effect	 mentioned	 above,	 reducing	 the	 number	 of	 invasive	
components	of	a	study	such	as	this	is	likely	to	improve	recruitment	as	such	a	study	may	be	
perceived	as	more	appealing.	 This	would	also	have	an	added	advantage	of	 shortening	 the	
length	of	the	study,	which	may	also	help	improve	recruitment.	Recruitment	was	affected	by	
the	extremely	tight	 inclusion	and	exclusion	criteria	as	well	as	study	restrictions	specified	in	
the	 protocol	 for	 this	 study.	 In	 order	 to	 preserve	 the	 integrity	 of	 the	 scientific	 method,	 a	
careful	 balance	 must	 be	 achieved	 between	 applying	 a	 pragmatic	 approach	 and	 trying	 to	
achieve	 the	 most	 carefully	 phenotyped	 idealistic	 study	 population.	 Perhaps	 in	 this	 study,	
reducing	the	number	of	endpoints	would	have	allowed	for	fewer	restrictions	and	facilitated	
a	more	achievable	set	of	inclusion	and	exclusion	criteria.			
Although	the	use	of	the	MBT	has	been	reported	in	the	literature,	its	use	as	a	primary	
endpoint	 in	 a	 therapeutic	 intervention	 study	 is	 limited.	 	 Therefore,	 the	 sensitivity	 of	 this	
endpoint	to	detect	differences	between	active	and	placebo	treatment	 in	oesophageal	pain	
hypersensitivity	is	not	fully	understood.		In	addition	to	this,	some	patients	were	not	able	to	
complete	all	12	minutes	of	the	MBT,	which	is	likely	to	have	had	a	bearing	on	the	VAS	sensory	
intensity	score,	and	therefore	the	APSS.		
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The	 APSS	 itself	 has	 limitations	 in	 terms	 of	 being	 a	 function	 of	 two	 different	
subjective	 stimulus	 responses.	 Therefore,	 if	 either	 lag	 time	 or	 sensory	 intensity	 rating	 are	
influenced	 by	 factors	 that	 have	 not	 been	 controlled	 for,	 the	 reliability	 of	 the	 APSS	 is	
diminished.	 This	 is	 therefore	 a	 potential	 argument	 to	 support	 the	 use	 of	 one	 stimulus	
response	such	as	lag	time	as	a	stimulus	response	measure	instead	of	APSS.	
Lag	time	has	its	limitations	as	well,	as	perception	of	“slightest	discomfort”	might	be	
seen	 as	 more	 subjective	 compared	 to,	 for	 example	 pain	 tolerance	 threshold	 to	 electrical	
stimulation.	That	said,	I	was	not	able	to	show	a	difference	in	pain	tolerance	threshold	before	
and	after	each	treatment	period	for	either	treatment.		
The	placebo	response	in	this	study	was	high	which	is	not	unexpected	in	a	group	of	
subjects	 with	 a	 high	 unmet	medical	 need.	 	 High	 placebo	 responses	 have	 been	 previously	
demonstrated	 in	 pain	 studies	 (168)	 and	 several	 factors	 are	 recognised	 to	 increase	 the	
magnitude	 of	 the	 placebo	 response	 (e.g.,	 number	 of	 tablets	 taken,	 subjects’	 expectations	
that	 they	 would	 see	 an	 effect,	 clinicians’	 warmth,	 prestige,	 and	 positive	 attitude).	 	 The	
placebo	 effect,	 paired	 with	 the	 reduced	 sample	 size,	 likely	 compromised	 the	 ability	 to	
demonstrate	 whether	 or	 not	 ONO-8539	 demonstrated	 a	 clear	 therapeutic	 benefit	 over	
placebo.		
I	 have	 demonstrated	 what	 appeared	 to	 be	 an	 order	 effect	 in	 this	 study	 with	 a	
difference	in	baseline	observed	between	treatment	period	1	and	2.	A	learning	effect	linked	
to	subjects	becoming	more	aware	of	what	to	expect	during	the	MBT	could	not	be	excluded	
as	 the	 subject’s	became	more	accustomed	upon	 repeating	 the	MBT.	 This	has	 a	 significant	
bearing	 on	 how	 the	MBT	 is	 used	 in	 studies	 evaluating	 oesophageal	 pain.	 Previous	 studies	
using	the	MBT	have	at	most	used	2	MBTs	one	day	apart	(152)	or	in	quick	succession	(169).	
These	studies	did	not	assess	for	an	order	effect	as	a	single	baseline	was	used.	Thus,	the	use	
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of	several	MBTs	over	the	course	of	a	single	study	had	not	been	tested	previously,	which	was	
a	significant	limitation	of	this	study.		
As	per	 inclusion	criterion	7,	subjects	had	to	rate	the	intensity	of	their	symptoms	as	
at	least	very	mild	(5.3	cm);	however,	there	was	no	restriction	relating	to	the	lag	time,	which	
may	 explain	 the	 greater	 difference	 in	 baseline	 lag	 time	 compared	 with	 the	 difference	 in	
baseline	 intensity.	 This	 may	 therefore	 have	 accounted	 in	 part	 to	 the	 variability	 in	 the	
response	seen	in	the	study	for	lag	time,	which	in	turn	likely	contributed	to	the	lack	of	ability	
to	observe	statistical	differences	between	ONO-8539	and	placebo.	
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Chapter	4	
A	 randomized	 single	 blinded	 crossover	 study	 to	 investigate	 the	
effect	 of	 physiological	 modulation	 of	 the	 ANS	 using	
transcutaneous	 vagal	 nerve	 stimulation	 on	 oesophageal	 pain	
hypersensitivity	in	healthy	volunteers	
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Introduction	
As	 described	 in	 this	 thesis	 thus	 far,	 GORD	 is	 recognised	 as	 a	 significant	 cause	 of	
morbidity,	healthcare	seeking	and	reduction	in	quality	of	life	(38,	39).	In	particular,	patients	
who	 have	 NERD,	 who	 are	 refractory	 to	 current	 available	 therapy	 (to	 varying	 extents)	
represent	a	sizable	proportion	of	patients	with	GORD	(3).	
In	 chapter	 1,	 I	 discussed	 pharmacological,	 electrical	 stimulation	 and	 mechanical	
therapies	for	GORD,	as	well	as	therapies	for	RH	and	functional	oesophageal	disorders.	I	also	
discussed	 the	 therapeutic	 gap	 for	 patients	who	 are	 refractory	 to	 current	 therapies,	 hence	
the	 importance	 of	 evaluating	 newer	 therapies	 to	 address	 the	 symptoms	 experienced	 by	
these	patients.		
Autonomic	modulation	in	visceral	pain	perception	
Patients	 with	 both	 true	 NERD	 (with	 no	 evidence	 of	 oesophageal	 injury	 at	
gastroscopy,	and	pathological	distal	oesophageal	acid	exposure	on	24	hour	pH	studies)	and	
oesophageal	RH	often	display	heightened	 sensitivity	 to	 intra-oesophageal	 stimuli,	which	 is	
referred	to	as	oesophageal	pain	hypersensitivity	(170).		
The	proposed	pathophysiology	of	this	visceral	pain	hypersensitivity	includes	–		
• peripheral	sensitization	of	primary	afferent	nerves	at	the	site	of	injury	and		
• central	sensitization	where	repeated	stimulation	of	peripheral	nociceptors,	leads	to	
sensitization	of	spinal	dorsal	horn	neurons,	with	an	increase	in	the	receptive	field	of	
these	neurons,	leading	to	hypersensitivity	in	areas	remote	from	the	area	of	injury.		
The	experience	of	oesophageal	pain	however,	is	highly	individual	with	a	multitude	of	
factors	proposed	to	account	 for	this	variability,	 in	particular,	dysfunction	of	 the	ANS	(171).		
The	ANS	is	thought	to	play	a	critical	role	 in	the	modulation	of	pain	through	its	 interactions	
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with	 the	 nociceptive	 system	 at	 the	 level	 of	 the	 periphery,	 spinal	 cord,	 brainstem	 and	
forebrain	(172,	173).		
Oesophageal	pain	hyperalgesia	due	to	distal	oesophageal	acid	infusion	is	correlated	
with	a	increase	in	sympathetic	tone	(as	measured	by	a	rise	in	cardiac	sympathetic	index	and	
skin	 conductance	 response),	 as	well	 as	a	 reduction	 in	parasympathetic	 tone	 (measured	by	
cardiac	vagal	tone	and	cardiac	sensitivity	to	the	Baroreflex)	(174).	Ness	et	al	demonstrated	
that	 low	 intensity	 vagal	 nerve	 stimulation	 reduced	 pain	 threshold	 to	 cutaneous	 thermal	
stimulation	 (175).	 Botha	 et	 al	 demonstrated	 that	 deep	 slow	 breathing	 prevented	
oesophageal	hyperalgesia	due	to	an	increase	in	parasympathetic	tone,	with	a	corresponding	
decrease	 in	 sympathetic	 tone,	 an	 effect	 that	was	 reversed	 by	 the	 vagolytic	 drug	 atropine	
(176).	 Iovino	 et	 al	 demonstrated	 that	 by	 increasing	 sympathetic	 tone	 per	 se	 (using	 lower	
body	 negative	 pressure,	 which	 produces	 venous	 pooling	 in	 the	 lower	 body,	 and	 a	
subsequent	 circulatory	 response	 as	 a	 result	 of	 sympathetic	 activation),	 they	were	 able	 to	
show	to	significantly	increased	visceral	sensitivity	(demonstrated	as	increased	perception	of	
duodenal	 distention)	 compared	 to	 somatic	 stimulation	 (transcutaneous	 electrical	
stimulation	of	the	dorsum	of	the	non	dominant	hand)	(177).		
Thus,	increasing	PNS	tone	has	a	broadly	anti-nociceptive	effect	whilst	increasing	SNS	
tone	appears	to	have	pro-nociceptive	effects.	Thus,	raising	PNS	tone	is	more	likely	to	cause	a	
general	 anti	 nociceptive	 effect	 than	 an	 organ	 specific	 effect.	 It	 is	 also	 likely	 then	 that	 a	
balance	of	sympathetic	and	parasympathetic	tone	is	required	for	“normal”	pain	perception,	
with	wider	reaching	impacts	on	visceral	pain	and	inflammation	in	particular	(178).		
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The	oesophageal	pain	hypersensitivity	model	
As	mentioned	 in	Chapter	1	of	this	thesis,	our	group	has	developed	and	validated	a	
human	model	of	oesophageal	pain	hypersensitivity	in	healthy	volunteers	(103),	where	distal	
oesophageal	 acidification	 reduced	 pain	 threshold	 to	 electrical	 stimulation	 in	 the	 non	 acid	
exposed	proximal	oesophagus.		Sharma	et	al	used	this	model	to	demonstrate	an	increase	in	
sympathetic	 tone	 as	 well	 as	 a	 decrease	 in	 parasympathetic	 tone,	 in	 response	 to	 distal	
oesophageal	 acid	 infusion	 (174).	 Botha	 et	 al	 then	 used	 this	 model	 to	 demonstrate	 that	
increasing	parasympathetic	 tone	using	slow	deep	breathing	had	an	anti-nociceptive	effect,	
with	 a	 reduction	 in	 oesophageal	 pain	 hyperalgesia	 caused	 by	 distal	 oesophageal	 acid	
perfusion	(176).	
Vagal	nerve	stimulation	
Stimulation	of	neurons	using	electrical	impulses	or	magnets	has	been	used	in	various	
circumstances,	from	deep	brain	stimulation	to	sacral	nerve	stimulators.	The	stimulus	alters	
function	 or	 properties	 of	 the	 synapse,	 and	 although	 the	 exact	mechanism	 of	 such	 neuro-
modulation	 in	 not	 entirely	 clear,	 there	 is	 evidence	 to	 suggest	 that	 parasympathetic	
activation	may	be	a	contributing	factor	(175).		
In	addition	to	this,	there	 is	evidence	to	show	that	neurotransmitter	concentrations	
at	 the	 synapse	 are	 altered,	 with	 excitatory	 or	 inhibitory	 effects.	 In	 particular,	 there	 is	
evidence	 to	 show	 that	 levels	 of	 noradrenaline	 and	 gamma-Aminobutyric	 acid	 (GABA)	 are	
increased	 by	 vagal	 nerve	 stimulation	 (179).	 The	 significance	 of	 this	 lies	 in	 the	 role	 of	
noradrenaline	 and	GABA	 in	 neuromodulation	 of	 cognitive	 processes	 such	 as	memory	 and	
perception.		
Development	 of	 new	 circuits	 or	 even	 changing	 the	 output	 of	 existing	 circuits	 has	
been	 described	 (180).	 Many	 neurons	 have	 ionotropic	 and	 metabotropic	 receptors	 to	 the	
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same	neurotransmitters;	therefore	modification	of	either	of	these	types	of	receptors	is	also	
likely	to	have	an	effect	on	neutrotransmitter	release,	and,	therefore	neuronal	activity	(181,	
182).		
Neurostimulation	 has	 also	 been	 shown	 to	 activate	 neruronal	 reflex	 circuitries,	 a	
phenomenon	 known	 as	 the	 cholinergic	 anti-inflammatory	 pathway,	 which	 is	mediated	 by	
the	 vagus	 nerve	 and	 the	 α7	 subunit	 of	 the	 nicotinic	 acetylcholine	 receptor	 expressed	 on	
cytokine	 producing	 cells	 (183).	 Activation	 of this	 pathway	 by	 electrical	 stimulation	 of	 the	
vagus	nerve	or	administration	of	α7	selective	drugs,	is	effective	in	ameliorating	inflammation	
by	 reducing	 TNF	 α	 and	 IL6	 levels,	 improving	 survival	 in	 experimental	 models	 of	 sepsis,	
haemorrhagic	shock,	pancreatitis,	postoperative	ileus	and	endothelial	cell	activation	(183).		
Vagal	 nerve	 stimulation	 is	 well	 established	 as	 a	 therapy	 for	 conditions	 such	 as	
epilepsy	(14)	and	depression	(15).	The	evidence	for	its	use	in	other	conditions	such	as	sepsis	
and	inflammation	as	described	in	the	previous	paragraph,	is	emerging	(18).	In	the	context	of	
pain,	 vagal	 nerve	 stimulation	 has	 been	 used	 to	 treat	 fibromyalgia	 (19)	 and	migraine	 (20)	
although	 the	 mechanisms	 of	 the	 anti-nociceptive	 effect	 here	 is	 not	 well	 elucidated.	 As	
mentioned	 above,	 vagal	 nerve	 stimulation	 may	 be	 a	 viable	 means	 of	 increasing	
parasympathetic	tone,	harnessing	this	anti-nociceptive	effect	for	the	treatment	of	pain.	
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Vagal	nerve	stimulating	devices	
Vagal	 nerve	 stimulation	 devices	 are	made	 up	 of	 a	 power	 supply,	 a	 programmable	
electrical	pulse	generator,	and	electrodes.	Stimulation	parameters	depend	on	the	particular	
device,	 and	 validated	 protocols	 have	 been	 developed	 for	 example	 in	 epilepsy.	Most	 vagal	
nerve	stimulators	approved	for	use	in	epilepsy	at	present	are	implanted	stimulators,	similar	
to	 cardiac	 pacemakers,	with	 the	 electrode	 usually	wrapped	 around	 the	 left	 cervical	 vagus	
nerve	(119)	(figure	4.1).	Use	of	the	right	vagus	has	been	shown	to	reduce	heart	rate	due	to	
right	 vagal	 innervation	of	 the	 sino	 atrial	 (SA)	 node	 in	 rats,	 so,	 the	 left	 vagus	 is	 stimulated	
preferentially,	although	not	exclusively	(184).		
	 	
	
	
	
	
	
Figure	4.1:	Implanted	vagal	nerve	stimulator	
	
More	recently	however,	an	external	transcutaneous	VNS	(t-VNS)	system,	consisting	
of	an	earplug-like	electrode	to	 interface	with	 the	concha	of	 the	outer	ear,	and	a	handheld	
battery-powered	 electrical	 stimulator,	 has	 become	 commercially	 available	 (NEMOS	 device	
www.cerbomed.com)	(figure	4.4).	This	device	stimulates	the	cymba	conchae	of	the	ear	 for	
the	treatment	of	epilepsy,	and	it	has	been	shown	to	be	safe	and	well	tolerated	with	a	high	
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degree	 is	user	 friendliness	 (185).	 It	has	also	been	used	 in	a	preliminary	study	 investigating	
the	effect	of	tVNS	on	pain	perception	(186).		
Auricular	branch	of	the	vagus	nerve	
The	 cymba	 conchae	 of	 the	 ear	 is	 used	 due	 to	 the	 innervation	 of	 this	 area	 by	 the	
auricular	 branch	 of	 the	 vagus	 nerve.	 The	 cymba	 conchae	 of	 the	 ear	 is	 almost	 exclusively	
supplied	 by	 the	 auricular	 branch	of	 the	 vagus	 nerve	 (187)	 (figure	 4.2	 and	 figure	 4.3).	 This	
therefore	 is	 an	 easily	 accessible	 area	 to	 place	 a	 tVNS	 electrode	 in	 order	 to	 stimulate	 the	
vagus	nerve.	Functional	magnetic	resonance	 imaging	(fMRI)	studies	have	confirmed	similar	
patterns	of	 cerebral	activation	with	both	 tVNS	of	 the	cymba	conchae	and	 implanted	vagal	
nerve	stimulators	(188).	
	
Figure	4.2:	Surface	anatomy	of	the	ear	
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Figure	4.3:		Distribution	of	the	nerve	supply	of	the	ear.	
 
 
	
	
	
	
	
	
	
Figure	4.4:	NEMOS	tVNS	device	(www.cerbomed.com).	
 
Study	design	
In	view	of	 the	need	 for	effective	 therapies	 for	 refractory	NERD,	and	 in	view	of	 the	
increasing	 evidence	 for	 the	 analgesic	 effects	 of	 increasing	 parasympathetic	 tone,	 in	 this	
study	I	proposed	that	there	is	value	in	investigating	the	effect	of	tVNS	on	oesophageal	pain	
hypersensitivity	 in	 healthy	 volunteers.	 The	 rationale	 for	 investigating	 tVNS	 in	 healthy	
	
	
	 148	
volunteers	 was	 threefold.	 Firstly,	 studying	 the	 effect	 of	 tVNS	 on	 a	 validated	 healthy	
volunteer	model	of	oesophageal	pain	hypersensitivity	would	allow	us	to	compare	the	effect	
of	 tVNS	 with	 other	 healthy	 volunteer	 studies	 investigating	 the	 effect	 of	 increasing	
parasympathetic	 tone	 using	 slow	 deep	 breathing	 for	 example	 (12).	 Secondly,	 a	 cohort	 of	
healthy	volunteers	is	likely	to	be	more	homogeneous	compared	to	a	cohort	of	patients	with	
NERD,	due	to	the	well	recognised	heterogeneity	of	this	group	of	patients.	Thirdly,	a	cohort	of	
healthy	volunteers	would	afford	a	baseline	and	proof	of	concept	 for	patient	studies	 in	 the	
future.		
This	study	was	designed	as	a	prospective	randomised	single	blind	placebo	controlled	
crossover	 trial.	 The	 active	 intervention	 involved	 vagal	 nerve	 stimulation	 using	 the	 above	
tVNS	device	with	the	electrode	stimulating	the	cymba	conchae	of	the	left	ear	(figure	4.4).		
	
	
	 149	
	
Figure	4.5:	Study	design	flowchart.	
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The	sham	intervention	involved	stimulation	using	the	tVNS	device	with	the	electrode	
stimulating	the	lobule	of	the	ear.	A	sham	control	was	chosen	as	a	suitable	control	for	tVNS	in	
order	 to	 standardize	 the	 subject	 experience,	 ensuring	 both	 groups	 were	 comparable.	
Subjects	 were	 randomised	 to	 either	 start	 with	 the	 active	 intervention	 or	 the	 sham	
intervention.	The	study	was	single	blinded	so	that	the	subjects	were	unaware	of	which	was	
the	active	treatment.	A	minimum	2	week	washout	period	was	added	to	minimise	a	possible	
order	effect.		
Inclusion	and	exclusion	criteria	
Inclusion	criteria:	
• Healthy	 subjects,	 aged	 18-65,	 from	 staff	 and	 local	 population	 of	 Queen	 Mary,	
University	of	London.		
• Inclusion	was	 determined	 on	 the	 basis	 of	 availability,	 with	 no	 prior	 selection	 bias	
included.		
Exclusion	criteria:	
• Participants	unable	to	provide	informed	consent.	
• Participants	 with	 any	 systemic	 disease	 or	 medications	 that	 may	 influence	 the	
autonomic	nervous	system	(e.g.	beta-agonists	or	Parkinson’s	disease).	
• Participants	with	a	history	of	cardiovascular	conduction	problems.		
• Participants	who	were	pregnant.	
• Participants	who	had	tinnitus.	
• Those	with	reflux	disease	
• Those	on	medication,	whether	prescribed	or	(over	the	counter)	OTC,	including	acid	
reduction	medication.	
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Objectives	and	endpoints	
To	 determine	 whether	 electrical	 stimulation	 of	 the	 auricular	 branch	 of	 the	 vagus	
nerve	 influences	 the	development	of	hypersensitivity	 in	a	validated	model	of	acid	 induced	
esophageal	pain.	
	
Objectives		
Primary	 objective	 -	 to	 compare	 change	 from	 baseline	 electrical	 pain	 tolerance	 threshold	
measured	 in	 the	proximal	oesophagus	between	 the	 tVNS	group	and	 the	 sham	stimulation	
group	in	response	to	acid	infusion	in	the	distal	oesophagus.		
Secondary	 objective	 -	 to	 evaluate	 the	 effect	 of	 t-VNS	 and	 sham	 stimulation	 on	 change	 in	
parasympathetic	tone	from	baseline	to	during	the	acid	infusion.	
	
Endpoints	
Primary	 endpoint	 –	 change	 from	 baseline	 of	 electrical	 pain	 tolerance	 threshold	 after	 acid	
infusion.	
Secondary	 endpoint	 -	 the	 effect	 of	 t-VNS	 and	 sham	 stimulation	 on	 parasympathetic	 tone	
during	acid	infusion.		
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Sample	size	rationale	and	statistical	analysis	
Based	 on	 previous	 experience	 in	 our	 department	 using	 the	 oesophageal	 pain	
hypersensitivity	model	to	study	the	effects	of	both	pregabalin	and	deep	slow	breathing	on	
oesophageal	pain	hypersensitivity	(189)	(12),	our	data	suggested	that,	in	order	to	achieve	a	
similar	difference	(i.e.	prevention	of	acid	induced	pain	hypersensitivity)	of	40%	between	the	
two	groups	at	5%	significant	level	and	80%	power,	the	minimum	sample	size	was	calculated	
as	 15.	 Continuous	 variables	were	 presented	 as	mean	 and	 standard	 deviation,	 or	medians	
and	 inter-quartile	 ranges,	 dependent	 on	 data	 distribution.	 Categorical	 variables	 were	
summarised	by	the	mean	and	standard	deviation.	
The	primary	endpoint	of	change	from	baseline	of	electrical	pain	tolerance	threshold	
after	acid	infusion	between	tVNS	and	sham	stimulation	was	analysed	using	linear	regression	
analyses.	 Comparison	 between	 tVNS	 and	 sham	 stimulation	 was	 done	 using	 a	 Wilcoxon	
matched-pairs	test.	The	secondary	endpoint	was	analysed	similarly.		
Analyses	were	performed	using	proprietary	software	(GraphPad	Prism	version	7.00	
for	 MAC,	 GraphPad	 Software,	 La	 Jolla	 California	 USA,	 www.graphpad.com).	 P<0.05	 was	
adopted	as	the	level	of	statistical	significance.	
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Methods	
Healthy	 subjects,	 aged	 18-65,	 from	 staff	 and	 local	 population	 of	 Queen	 Mary,	
University	of	London	were	recruited	to	the	study	via	a	recruitment	poster	placed	in	staff	and	
student	areas	of	the	University.		
Potential	 subjects	were	 supplied	with	an	approved	 information	 sheet,	 and	queries	
were	answered	prior	to	their	first	visit.	The	study	comprised	of	2	visits,	spaced	a	minimum	of	
2	weeks	apart.	The	study	received	ethical	approval	(Re:	QMERC2014/56)	by	the	Queen	Mary	
University	Research	Ethics	Committee	(REC).	
Visit	1	
- Written	informed	consent	obtained.	
- A	medical	history	was	taken	and	inclusion/exclusion	criteria	were	reviewed.		
- If	the	subject	was	deemed	eligible,	they	were	asked	to	complete	3	questionnaires,	to	
assess	personality	type	(BFI),	to	assess	anxiety	and	depression	levels	(HADS)	and	to	
assess	anxiety	state	and	trait	(STAI	state/trait).		
- The	subject	then	underwent	an	abbreviated	HRM	study	to	identify	the	upper	border	
of	the	LOS.		
- At	baseline,	and	continuously	thereafter,	measurement	of	PNS	tone	was	made	using	
the	non-invasive	Neuroscope	system.	
- Intra-oesophageal	 intubation	 using	 a	 specialised	 infusion/electrical	 stimulation	
catheter	was	performed.	
- Baseline	electrical	pain	threshold	was	assessed.	
- The	subject	then	underwent	a	30	minute	distal	oesophageal	 infusion	of	0.15M	HCL	
whilst	undergoing	tVNS	or	sham	stimulation	of	the	cymba	conchae	of	the	left	ear.	
- Electrical	pain	tolerance	threshold	was	measured	at	30	minutes,	60	minutes	and	90	
minutes	following	the	start	of	the	oesophageal	acid	infusion.	
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Visit	2	
- Following	a	period	of	no	less	than	two	weeks,	in	order	to	reduce	any	potential	carry	
over	 effect,	 participants	 were	 crossed	 over	 and	 re-studied	 to	 receive	 the	
intervention	 they	 did	 not	 receive	 in	 visit	 1.	 They	 competed	 a	 STAI	 state	
questionnaire	prior	to	invasive	procedures	at	the	start	of	visit	2.	
	
Study	questionnaires	
Three	 questionnaires	 were	 used	 in	 the	 study	 –	 the	 big	 five	 inventory	 (assessing	
personality	 type),	 the	 hospital	 anxiety	 and	 depression	 scale	 and	 the	 state/trait	 anxiety	
assessment	questionnaire.	The	personality	type	questionnaire	was	included	as	there	is	some	
evidence	to	suggest	that	some	personality	types	may	have	lower	baseline	parasympathetic	
tone,	with	 consequent	higher	pain	 tolerance	 thresholds	 (171).	The	anxiety	and	depression	
questionnaires	were	 added	 to	 assess	 if	 anxiety	 and	 depression	 levels	 had	 any	 bearing	 on	
either	basal	cardiac	vagal	tone	or	pain	tolerance	threshold.		
Big	Five	Inventory	
The	Big	 Five	 Inventory	 is	 a	 self-report	 inventory	 designed	 to	measure	 the	Big	 Five	
dimensions.	 It	 is	 a	multidimensional	personality	 inventory	 (44	 items	 total),	 and	consists	of	
short	phrases	with	a	 relatively	accessible	vocabulary.	The	validated	Big	Five	 Inventory	was	
used	to	measure	the	personality	traits	of	neuroticism	and	extroversion	in	particular	(190).	
Hospital	anxiety	and	depression	scale	
The	 HADS	 is	 a	 short	 self-administered	 questionnaire	 that	 takes	 approximately	 5	
minutes	 to	 complete.	 It	 is	 designed	 to	 screen	medical	 patients	 for	 anxiety	 and	depression	
and	 is	well	validated	 (162).	There	are	seven	 items	on	the	questionnaire	relating	 to	anxiety	
and	seven	relating	to	depression.	The	subject	is	asked	to	indicate	how	closely	they	relate	to	
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each,	 and	 a	 score	 of	 0–3	 is	 generated	 for	 each	 answer.	 An	 overall	 score	 (out	 of	 21)	 was	
generated	for	both	anxiety	and	depression	(163).	
State-Trait	Anxiety	Assessments	
This	 is	 a	 widely	 used	 self-report	 questionnaire	 to	 assess	 anxiety,	 which	 has	 good	
reliability	 and	 has	 been	 validated	 extensively	 (160).	 As	 one	 may	 expect,	 the	 state	
questionnaire	 asks	 how	 the	 subject	 feels	 at	 the	 present	 moment,	 whereas	 the	 trait	
questionnaire	enquires	about	 longer	 term	 feelings	of	anxiety.	The	 subject	was	 required	 to	
select	how	closely	they	identified	with	20	different	emotions	at	that	point	in	time	on	a	scale	
of	1	 (“not	at	all”)	 to	4	 (“very	much	so”).	The	Trait	Anxiety	Questionnaire	examines	 longer-
term	 traits	 that	 tend	 towards	 anxiety.	 The	 subject	was	 required	 to	 select	 how	 frequently	
they	 associated	 with	 20	 different	 traits	 on	 a	 scale	 of	 1	 (“almost	 never”)	 to	 4	 (“almost	
always”).
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Study	procedures	
Autonomic	Nervous	System	Monitoring	
Autonomic	 monitoring	 was	 carried	 out	 using	 a	 Neuroscope.	 	 The	 Neuroscope	
measures	 real	 time,	 beat-to-beat,	 cardiac	 vagal	 tone	 (parasympathetic	 efferent),	 cardiac	
sensitivity	 to	 the	 baroreflex	 (parasympathetic	 afferent)	 and	 blood	 pressure	 (sympathetic	
efferent)	(171).		
1. The	electrocardiograph	was	recorded	by	placing	3	small	electrode	stickers	over	the	
left	and	right	shoulder	and	left	side	of	the	abdomen.	
2. Blood	pressure	was	measured	non-invasively	 using	 a	 small	 sensor	 attached	 to	 the	
left	index	finger	using	a	Velcro	strap.	
Subjects	underwent	baseline	autonomic	monitoring	and	measurements	were	taken	
continuously	thereafter.	
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Acid	infusion	test	
During	this	test,	0.15	M	hydrochloric	acid	was	infused	into	the	distal	oesophagus	of	
the	subject	(10cm	above	the	LOS)	at	a	rate	of	8ml/minute	for	a	period	of	30	minutes	using	a	
syringe	 pump	 device	 (12).	 The	 catheter	 used	 was	 a	 combined	 electrical	 stimulation	 and	
perfusion	catheter	(Unisensor,	Gaeltec,	Isle	of	Skye,	UK).	
	
	
	
	
	
	
	
Figure	4.6:	Distal	oesophageal	acid	infusion	and	electrical	stimulation.		
tVNS	and	sham	stimulation	
The	tVNS	device	was	fitted	 in	the	active	position	with	the	stimulating	electrode	on	
the	cymba	conchae	of	the	left	ear,	or	in	the	sham	position	with	the	electrode	on	the	lobule	
of	the	ear	(figure	4.7).	The	stimulator	was	switched	on	and	set	to	produce	a	pulse	width	of	
250	μs	at	25	Hz	with	a	30	second	“on”,	30	second	“off”	cycle.	The	 intensity	of	the	stimulus	
was	increased	from	0.1mA,	in	0.1mA	increments,	until	the	participant	reported	a	“tingling”	
sensation	 that	was	 below	 the	 intensity	 that	 produced	 a	 noxious	 “pricking”	 sensation.	 The	
stimulation	was	then	continued	for	the	duration	of	the	acid	perfusion	test.	I	was	careful	to	
attach	the	stimulating	electrode	in	a	similar	manner,	such	that	the	subject	was	not	able	to	
15cm 
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pH	in	proximal		oesophagus	
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bipolar	electrical	
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tell	the	active	position	from	the	sham	position.		The	subject	was	not	able	to	see	the	position	
of	the	stimulating	electrode	either.		
	
	
	
	
	
	
	
	
	
	
Figure	4.7:	Electrode	placement	in	the	active	and	sham	positions	
	
Pain	threshold	measurements	
All	subjects	had	proximal	oesophageal	pain	threshold	measured	at	baseline	and	then	
at	30,	60	and	90	minutes	after	the	acid	perfusion	test.	This	was	done	using	a	catheter	with	a	
distal	infusion	port	and	a	pair	of	silver-silver	chloride	bipolar	ring	electrodes,	although	in	this	
experiment,	only	the	proximal	electrode	was	used.	The	proximal	electrode	was	sited	15	cm	
above	the	acid	infusion	port	and	pain	threshold	was	determined	by	increasing	the	electrical	
stimulation	intensity	in	steps	of	2	mA,	until	the	subject	first	reported	a	sensation	of	pain.	The	
mean	of	three	separate	measurements	was	recorded	as	the	pain	threshold.	The	duration	of	
the	electrical	stimulus	pulse	was	200μs	and	the	frequency	of	stimulation	was	0.5	Hz.	
	
Sham	stimulation Electrical	vagal	nerve	
stimulation 
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Figure	4.8:	Distal	stimulating	electrode	pair	and	infusion	port.		
	
	
	
	
	
	
	
	
Figure	4.9:	Combined	electrical	stimulation	and	perfusion	catheter	(Unisensor,	Gaeltec,	Isle	of	
Skye,	UK).	
	
	
	
	
	
	
	
	
Figure	4.10:	Lab	set	up	for	distal	oesophageal	electrical	stimulation	and	acid	infusion.				
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Results		
The	 recruitment	 target	was	met	with	 15	 healthy	 subjects	 included	 in	 the	 study,	 6	
female,	with	a	median	age	of	26	years	 (range	21-48).	Medical	histories	did	not	 reveal	any	
features	to	exclude	any	of	the	subjects,	and	in	particular,	migraine,	epilepsy	and	GORD	were	
excluded.	 .	 Median	 BMI	 was	 24.60	 Kg/M2	 (range	 19.92-36.63).	 Subjects	 were	 Caucasian	
except	for	2	individuals	who	were	of	Japanese	and	South	East	Asian	ethnicity	respectively.	
Table	4.1:	Demographics	data	of	subjects	(C=Caucasian,	SEA=South	East	Asian,	
JAP=Japanese).		
Questionnaire	analysis	
HADS	questionnaire	
Mean	HADS	anxiety	score	was	4.33	±	2.97	and	mean	HADS	depression	score	was	2	±	
2.99.	 The	 maximum	 score	 for	 each	 parameter	 is	 21,	 and	 a	 score	 up	 to	 a	 value	 of	 7	 is	
considered	normal	based	on	validation	studies.	Similarly,	scores	from	8	to	10	are	considered	
as	borderline	and	scores	over	11	are	categorized	as	abnormal.	One	subject	scored	8	and	one	
subject	scored	12	in	the	anxiety	category,	whilst	only	one	subject	scored	8	in	the	depression	
category.	
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STAI	Trait	questionnaire	
This	questionnaire	assesses	underlying	anxiety	traits.	It	was	completed	at	baseline	
and	the	mean	score	was	31.4	±	8.67.	The	scores	range	from	a	minimum	possible	score	of	20	
to	a	maximum	possible	score	of	80.	Some	of	the	questions	are	anxiety	absence	scores,	and	
this	is	collated	into	a	scoring	algorithm	to	reach	a	final	score.	Cut	off	scores	are	variable	
between	difference	populations,	but	the	lower	the	score,	the	lower	the	anxiety	levels.	
Therefore	a	mean	score	of	31.4	±	8.67	denotes	low	levels	of	trait	anxiety	in	this	cohort.	The	
minimum	STAI	Trait	score	recorded	in	this	cohort	was	20	and	the	maximum	score	was	51.		
STAI	State	anxiety	questionnaire	
There	was	no	difference	in	the	mean	state	anxiety	score	at	the	start	of	the	visit	with	
the	 tVNS	 intervention	 (31.4	 ±	 8.67),	 and	 at	 the	 start	 of	 visit	 with	 the	 sham	 intervention	
(36.07	±	12.89)	(p	=	0.1836).	 
BFI	
BFI	was	 assessed	at	 the	 start	of	 visit	 1,	 before	any	procedures,	 irrespective	of	 the	
nature	of	the	treatment	subsequently	received	in	the	visit.		When	considering	the	BFI	at	this	
time	 point,	 there	 was	 no	 correlation	 between	 personality	 type	 and	 baseline	 CVT	 for	 all	
subjects	 as	 a	 single	 group.	Most	 subjects	 had	dominant	 agreeableness	 scores	 (6/15),	with	
fewer	subjects	having	dominant	scores	for	conscientiousness	(2/15),	extraversion	(5/15)	and	
neuroticism	 (2/15).	 Two	 subjects	 were	 co-dominant	 for	 agreeableness	 and	 openness.	
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Oesophageal	pain	hypersensitivity	results	
There	was	no	significant	drop	in	oesophageal	pain	tolerance	threshold	(mA)	after	a	
30	minute	 acid	 infusion	 in	 the	 tVNS	 group	 at	 T30,	 T60	 and	 T90	 (p	 =	 0.6785,	 0.9020	 and	
0.7510 respectively).	 	 Therefore,	mean	pain	 tolerance	 threshold	 at	 baseline	was	 37.53mA	
(±16.63),	at	30	minutes	was	36.09mA	(±14.87),	at	60	minutes	was	36.2mA	(±14.97)	and	at	90	
minutes	 was	 36.61mA	 (±14.75).	 That	 is	 to	 say	 that	 oesophageal	 pain	 hyperalgesia	 was	
prevented	in	the	tVNS	group,	and	baseline	pain	tolerance	threshold	was	sustained	after	acid	
infusion	for	a	period	of	90	minutes	after	the	start	of	the	acid	infusion.		
In	 the	 sham	stimulation	group,	after	a	30	minute	oesophageal	acid	 infusion,	 there	
was	a	significant	drop	in	pain	tolerance	threshold	at	all	three	time	points,	T30,	T60	and	T90	
(0.0002,	 0.0002	 and	 0.0008	 respectively).	 Therefore,	 mean	 pain	 tolerance	 threshold	 at	
baseline	was	 33.56mA	 (±11.36),	 at	 30	minutes	was	 25.22mA	 (±6.888),	 at	 60	minutes	was	
25.13mA	(±8.941)	and	at	90	minutes	was	28.71mA	(±9.206).	That	is	to	say	that	oesophageal	
pain	 hyperalgesia	 was	 caused	 by	 the	 30	 minute	 acid	 infusion	 as	 expected,	 and	 sham	
stimulation	had	no	effect	on	this	(figure	4.11).		
	
	
	
	
	
Figure	4.11:	Oesophageal	pain	tolerance	threshold	(mA)	for	the	tVNS	group	and	the	sham	
stimulation	group.	The	magnitude	of	change	in	pain	tolerance	threshold	was	similar	to	that	
seen	by	Botha	et	al	(176).
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When	change	in	mean	pain	threshold	as	a	whole	from	baseline	was	compared,	tVNS	
produced	 a	 significantly	 smaller	 reduction	 in	 pain	 tolerance	 threshold	 compared	 to	 sham	
stimulation	(p	=	0.0155)	(figure	4.12).	
	
	
	
	
	
	
	
	
	
	
Figure	4.12:	Change	in	oesophageal	pain	tolerance	threshold	(mA)	for	the	tVNS	group	and	
the	sham	stimulation	group.		
	
	
	
	
	
	
	
	
	
Figure	4.13:	Mean	CVT	pain	tolerance	threshold	at	T0,	T30,	T60	and	T90	for	the	tVNS		group	
and	the	sham	stimulation	group,	showing	an	increase	in	CVT	with	time	in	the	tVNS	group	
compared	to	the	sham	stimulation	group.
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Figure	4.14:	Absolute	change	in	CVT	(and	thus	parasympathetic	tone)	from	baseline	to	T90,	
was	significantly	positive	in	the	tVNS	group	compared	to	the	sham	stimulation	group.		
	
There	was	no	significant	difference	between	baselines	CVT	between	either	group	(p	
=	0.8702).	There	was	a	significant	increase	from	baseline	in	CVT	in	the	tVNS	group	compared	
to	the	sham	stimulation	group	at	T90	(p	=	0.0034).	
	 	
tV
NS
Sh
am
 
-4
-2
0
2
4
6
8
10
Ch
an
ge
	in
	C
VT
	
	
	 165	
Discussion		
There	is	increasing	evidence	for	the	use	of	vagal	nerve	stimulation,	and	in	particular,	
tVNS	as	a	therapy	for	pain	with	studies	in	fibromyalgia	and	migraine	as	described	previously.	
The	mechanism	 of	 action	 is	 likely	 to	 involve	modulation	 of	 parasympathetic	 tone,	 as	 the	
vagus	 nerve	 is	 a	 major	 component	 of	 the	 parasympathetic	 nervous	 system.	 Increasing	
parasympathetic	tone	has	been	shown	to	produce	an	analgesic	effect	(175)	and	therefore	a	
means	of	vagal	nerve	stimulation	is	an	ideal	target	for	the	treatment	of	pain	conditions.	
In	 this	 study,	 I	 have	 clearly	 shown	 that	 stimulation	 of	 the	 auricular	 branch	 of	 the	
vagus	nerve	by	a	non-invasive	transcutaneous	stimulator	produced	a	significant	 increase	in	
parasympathetic	tone	compared	to	sham	stimulation.	This	increase	in	parasympathetic	tone	
was	sustained	at	90	minutes	post	acid	infusion,	which	is	similar	to	results	achieved	with	slow	
deep	 breathing	 in	 a	 study	 using	 the	 same	 model	 by	 Botha	 et	 al	 (12).	 There	 was	 also	 a	
sustained	prevention	of	 reduction	of	pain	 tolerance	 threshold	 in	 response	 to	oesophageal	
acid	 infusion	 compared	 to	 sham	stimulation,	which	again,	 is	 similar	 to	 results	 achieved	by	
slow	 deep	 breathing	 as	mentioned	 above.	 The	mechanism	 of	 this	 sustained	 effect	 is	 less	
clear.	 In	 the	 short	 term	 (upto	 90	 minutes),	 it	 is	 possible	 that	 in	 addition	 to	 increased	
parasympathetic	 tone,	 changes	 in	 perception,	 motivation	 and	 emotion	 may	 play	 a	 part,	
affecting	interoceptive	awareness	and	interoceptive	accuracy.			
As	these	findings	have	now	been	shown	using	two	differing	modalities	of	increasing	
PNS	 tone,	 the	 role	 of	 increased	 parasympathetic	 tone	 in	 the	 prevention	 of	 acid	 induced	
oesophageal	hyperalgesia	 is	further	confirmed.	Based	on	this	study,	 it	 is	also	clear	that	the	
oesophageal	hypersensitivity	model	I	used	continues	to	perform	robustly.	
A	limitation	of	this	study	was	the	absence	of	an	arm	to	investigate	the	effects	of	the	
vagolytic	 drug	 atropine,	 which	 might	 have	 abolished	 the	 effect	 of	 tVNS,	 preventing	 the	
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reduction	of	pain	 tolerance	 threshold	as	was	 seen	 in	 the	deep	breathing	study	mentioned	
above.		
The	 effect	 of	 tVNS	 in	 this	 healthy	 volunteer	 study	 paves	 the	 way	 for	 studies	
investigating	the	role	of	tVNS	in	patients	with	oesophageal	pain,	in	particular,	patients	with	
NERD.	 This	 group	 of	 patients	 is	 ideally	 suited	 due	 to	 the	 role	 that	 increased	 distal	
oesophageal	 acid	 exposure	 plays	 in	 their	 symptomatology.	 Therefore,	 investigation	 of	
baseline	 and	 interval	 pain	 threshold	 levels	 with	 tVNS	 compared	 to	 sham	 stimulation	 is	 a	
possible	means	 of	 translating	 the	 results	 seen	 in	 this	 study	 into	 the	 realm	 of	 therapeutic	
intervention,	potentially	adding	another	avenue	of	treatment	for	patients	with	NERD.		
There	is	evidence	to	show	that	the	therapeutic	effects	of	vagal	nerve	stimulation	at	
least	 in	the	context	of	depression	and	epilepsy	is	 long	lasting	(191).	The	prevention	of	acid	
induced	 oesophageal	 hyperalgesia	 for	 a	 period	 of	 60	 minutes	 after	 the	 end	 of	 the	 acid	
infusion	 seen	 in	 this	 study	 provides	 evidence	 for	 longer	 lasting	 analgesic	 effects	 in	
oesophageal	 pain	 hypersensitivity.	 Dose	 finding	work	 on	 the	 effect	 of	 tVNS	 stimulation	 in	
oesophageal	 pain	 as	well	 as	more	 longer	 term	 studies,	 initially	 in	healthy	 volunteers,	may	
help	clarify	the	extent	of	this	effect	in	the	context	of	oesophageal	pain.	
Baseline	PNS	tone	is	interesting	in	itself,	considering	the	multitude	of	ways	in	which	
the	ANS	contributes	to	the	process	of	 interoception	(defined	as	 ‘the	physiological	sense	of	
the	condition	of	the	body’).	Awareness	of	the	physiological	state	of	the	body	is	thought	to	be	
underpinned	 by	 a	 neural	 network	 involving	 afferent	 pathways	 that	 perceive	 the	
physiological	state	of	the	body	and	which	project	to	the	autonomic	and	homeostatic	centres	
of	the	spinal	cord	and	brain.	The	anterior	insular	cortex	receives	this	information	and	forms	
a	 representation	 of	 the	 state	 of	 the	 body.	 	 This	 information	 is	 influenced	 by	 the	 anterior	
cingulate	 cortex	 (involved	 in	 motivation,	 emotion,	 memory	 and	 learning),	 and	 in	
combination,	 a	 process	 of	 interoceptive	 awareness	 occurs.	 Reduction	 in	 interoceptive	
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awareness	as	well	as	 ineroceptive	accuracy	has	been	associated	with	 increased	perception	
of	pain	in	chronic	pain	conditions	and	pain	perception	(192)	(118).	Thus,	components	of	this	
interoceptive	network	such	as	autonomic	afferents	may	be	harnessed	as	a	means	of	treating	
pain.			
An	 interesting	 extension	 of	 this	 work	 would	 be	 to	 extend	 the	 assessment	 of	 PNS	
tone	in	the	context	of	ANS	modulating	therapies,	over	the	longer	term.	Adding	assessment	
of	baseline	parasympathetic	tone	to	such	work	may	help	elucidate	 if	any	 longer	term	anti-
nociceptive	 effect	 of	 ANS	 modulating	 therapies	 is	 in	 part	 at	 least,	 due	 to	 an	 increase	 in	
baseline	parasympathetic	tone.		
The	 body	 of	 work	 in	 this	 chapter	 adds	 to	 previous	 work	 demonstrating	 the	 anti-
nociceptive	effect	of	the	PNS,	thus	paving	the	way	forward	in	the	search	for	new	treatment	
measures	 for	 pain	 and	 disease.	 Further	 work	 on	 the	 role	 of	 the	 ANS	 in	 pain	 perception,	
inflammation,	 affect	 and	 health	 continues	 to	 be	 spurred	 on	 by	 advances	 in	 the	
neurophysiological	basis	of	interoception	(173).	
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Conclusions	
The	 development	 of	 oesophageal	 hyperalgesia	 is	 prevented	 by	 transcutaneous	
electrical	stimulation	of	the	auricular	branch	of	the	vagus	nerve.	This	study	provides	further	
evidence	of	the	anti-nociceptive	role	of	the	parasympathetic	nervous	system.	Further	work	
is	warranted	 in	 patients	 groups	 such	 as	 those	with	NERD	 and	 other	 gastro	 intestinal	 pain	
disorders.	
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Chapter	5		
A	 randomized	 single	 blinded	 parallel	 study	 to	 investigate	 the	
effect	 of	 physiological	 modulation	 of	 the	 ANS	 using	 deep	 slow	
breathing	 on	 oesophageal	 pain	 hypersensitivity	 in	 patients	with	
NERD	
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Introduction	
The	previous	chapters	in	this	thesis	described	the	therapeutic	gap	in	the	treatments	
available	 for	 patients	 with	 refractory	 symptoms	 of	 GORD	 in	 the	 absence	 of	 macroscopic	
oesophageal	injury	(NERD).	They	also	described	the	sizeable	demographic	that	falls	into	this	
group	of	patients	as	well	as	the	significant	financial	burden	of	refractory	NERD.				
Modulation	 of	 the	 autonomic	 nervous	 system	 was	 discussed	 as	 a	 therapeutic	
measure	for	the	treatment	of	pain	in	the	previous	chapter	(118)	(119).	Work	in	our	group	by	
Botha	et	al	(176)	showed	that	ANS	modulation	by	slow	deep	breathing	had	an	effect	on	pain	
thresholds	 in	healthy	 volunteers,	 and	 in	 the	previous	 chapter,	 I	 showed	 that	 tVNS	did	 the	
same.	This	study	takes	this	work	a	step	further,	by	assessing	the	effects	of	ANS	modulation	
in	patients	with	NERD	and	oesophageal	reflux	hypersensitivity.		
I	 investigated	 the	 effect	 of	 deep	 slow	 breathing	 compared	 to	 sham	 breathing	 on	
oesophageal	 pain	hypersensitivity	 in	 a	 group	of	 patients	with	NERD.	A	modified	Bernstein	
test	was	used	as	 the	 stimulus	model	 in	 this	 study.	This	model	has	been	used	 in	 the	NERD	
patient	 population	 previously	 (152,	 153),	 and	 therefore	 it	 was	 felt	 this	 would	 allow	 for	 a	
better	 comparison	 with	 similar	 studies.	 I	 used	 ANS	 monitoring	 to	 assess	 if	 slow	 deep	
breathing	 was	 able	 to	 increase	 parasympathetic	 tone	 in	 this	 population	 of	 patients	 with	
NERD.		
I	also	investigated	the	effect	of	slow	deep	breathing	as	a	self-administered	potential	
therapeutic	measure	over	a	4-week	period.		
Slow	deep	breathing	and	parasympathetic	tone	
The	 slow	 deep	 breathing	 protocol	 used	was	 developed	 as	 a	method	 of	 increasing	
parasympathetic	 tone	 by	 exaggerating	 the	 normal	 sinus	 arrhythmia	 controlled	 by	 the	
parasympathetic	nervous	system.		This	reflex	is	termed	the	Hering	Breuer	Reflex.		
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The	Hering–Breuer	 reflex,	 named	after	 the	German	physiologists	 Josef	Breuer	 and	
Ewald	Hering	working	 in	the	1860s,	 is	a	reflex	that	 is	activated	to	prevent	over	 inflation	of	
the	 lungs	 (193).	 Pulmonary	 stretch	 receptors,	 located	 in	 the	 smooth	muscle	 of	 the	 lungs,	
trigger	 action	 potentials	 if	 there	 is	 excessive	 stretching	 on	 the	 airways	 during	 inspiration.	
Increased	 sensory	 activity	 of	 the	 pulmonary-stretch	 lung	 afferents	 (via	 the	 vagus	 nerve)	
results	 in	 inhibition	 of	 the	 central	 inspiratory	 drive	 and	 thus	 inhibition	 of	 inspiration	 and	
initiation	of	expiration	(194).	These	pulmonary	afferents	also	send	projections	to	the	cardiac	
vagal	motor	neurones	 in	 the	nucleus	 ambiguus	as	well	 as	 the	dorsal	motor	 vagal	 nucleus,	
located	in	the	brainstem.	Cardiac	vagal	motor	neurones,	which	provide	motor	fibres	to	the	
heart	via	the	vagus	nerve,	are	responsible	for	tonic	inhibitory	control	of	heart	rate.	Thus,	an	
increase	in	pulmonary	stretch	receptor	activity	leads	to	activation	of	the	cardiac	vagal	motor	
neurons,	 reduced	 inhibitory	 control	 and	 an	 elevation	 in	 heart	 rate.	 This	 is	 a	 normal	
occurrence	in	healthy	individuals,	and	is	referred	to	as	respiratory	sinus	arrhythmia.	
In	 an	experimental	 setting	 in	healthy	 volunteers,	 this	 reflex	 can	be	modified	using	
deep	 slow	 breathing	 to	 physiologically	 elevate	 vagal	 tone.	 Therefore,	 during	 deep	 slow	
breathing,	 there	 is	an	 increase	 in	 cardiac	vagal	 tone	with	a	 concomitant	decrease	 in	heart	
rate,	 an	 effect	 that	 is	 abolished	 with	 concomitant	 administration	 of	 the	 vagolytic	 drug,	
atropine	(176).	
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Study	design	
This	 study	was	designed	as	a	 randomised,	 sham	controlled,	 single	blinded,	parallel	
study.	A	sham	control	was	chosen	as	a	suitable	control	for	slow	deep	breathing	in	order	to	
standardize	 the	 patient	 experience	 ensuring	 both	 groups	 of	 patients	 are	 comparable.	
Patients	 were	 randomised	 to	 either	 have	 the	 sham	 therapy	 or	 slow	 deep	 breathing.	 The	
study	was	single	blinded	so	that	 the	patients	were	unaware	of	which	the	active	treatment	
was.	 There	 was	 no	 facility	 to	 blind	 the	 investigator	 due	 to	 a	 lack	 of	 personnel,	 although	
ideally	this	would	have	been	preferable.	A	parallel	design	was	chosen	due	to	the	fact	that,	as	
seen	in	the	3rd	chapter	of	this	thesis,	there	is	a	suggestion	that	there	may	be	an	order	effect	
if	 the	modified	Bernstein	test	 is	repeated	over	more	than	one	study	period.	Thus,	patients	
were	randomised	to	one	of	two	groups,	one	receiving	the	active	breathing	protocol	and	one	
receiving	the	sham	breathing	protocol.		
In	 contrast	 to	 the	 study	 in	 chapter	 3	 where	 the	MBT	was	 also	 used,	 the	 primary	
endpoint	 was	 chosen	 as	 lag	 time	 instead	 of	 APSS.	 As	 APSS	 is	 a	 function	 of	 lag	 time	 and	
sensory	 intensity	 rating,	 both	 of	 which	 are	 subjective	 stimulus	 responses,	 it	 was	 felt	 that	
using	a	 single	 subjective	 stimulus	 response	as	an	endpoint	would	be	preferable	 to	using	a	
combination	of	two	subjective	stimulus	responses	as	an	endpoint.		
At	 the	end	of	 the	 study	period,	 all	 the	patients	were	 instructed	on	how	 to	do	 the	
active	breathing	protocol	twice	a	day	for	10	minutes	over	the	next	4	weeks.	They	were	then	
asked	to	complete	a	symptom	based	and	state	based	questionnaire	after	the	4-week	period.	
This	was	in	order	to	assess	any	possible	benefit	of	self-administered	deep	slow	breathing	for	
all	patients.	The	participants	were	randomly	allocated,	using	randomisation	software,	such	
that	equal	numbers	started	 in	each	of	 the	two	groups.	 It	was	planned	to	screen	a	suitable	
number	of	patients	 in	order	to	randomise	68	subjects.	Patients	were	recruited	from	the	GI	
physiology	Unit	and	the	Endoscopy	Unit	at	the	Royal	London	Hospital.	
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Sample	Size	Calculation		
The	 sample	 size	 calculation	 was	 based	 on	 the	 primary	 endpoint,	 mean	 lag	 time.	
Previous	research	(155)	found	a	mean	lag	time	of	136	seconds,	with	a	standard	deviation	of	
39	 seconds.	A	 difference	 in	 lag	 time	between	 groups	 of	 20%	 (equivalent	 to	 27.2	 seconds)	
was	regarded	as	being	of	clinical	importance.	Using	a	5%	significance	level	and	80%	power,	it	
was	calculated	that	34	subjects	per	group	(a	total	of	68	subjects),	was	required	to	detect	a	
reduction	of	20%	in	the	primary	outcome.		
	
	
Figure	5.1:	Schematic	diagram	of	study	design.	
assessed	for	eligibility	
excluded		 enrolled		
baseline	RESQ7	and	randomised	to	slow	deep	breathing	during	acid	infusion	
return	4	weeks	later	after	doing	deep	breathing	twice	a	day	for	4	weeks	to	repeat	RESQ7	
baseline	RESQ7	and	randomised	to	sham	breathing	during	acid	infusion		
return		4	weeks	later	after	doing	sham	breathing	twice	a	day	for	4	weeks	to	repeat	RESQ7	
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Objectives	
Primary	objective	
To	 evaluate	 the	 effect	 of	 slow	 deep	 breathing	 and	 sham	 breathing	 on	 oesophageal	 pain	
hypersensitivity	on	experimental	acid	infusion	in	patients	with	NERD.	
	
Secondary	objectives	
• A	pilot	follow-up	study	to	evaluate	the	effect	of	slow	deep	breathing	as	a	self-
administered	therapeutic	measure	for	oesophageal	symptoms	in	patients	with	
NERD.	
• Evaluate	the	effect	of	slow	deep	breathing	and	sham	breathing	following	
oesophageal	acid	perfusion	on	APSS	(acid	perfusion	sensitivity	score).		
• Determine	ANS	changes	before	and	after	slow	deep	breathing/sham	breathing.	
	
Endpoints	
Primary	endpoint	
• Difference	in	lag	time	to	first	sensation	of	discomfort	following	oesophageal	acid	
perfusion	between	the	slow	deep	breathing	group	and	the	sham	breathing	group.	
	
Secondary	endpoints	
• Change	in	reflux	symptom	questionnaire,	before	and	after	4	weeks,	between	the	
slow	deep	breathing	and	sham	breathing	groups.		
• Difference	in	APSS	(acid	perfusion	sensitivity	score)	following	oesophageal	acid	
perfusion	between	the	slow	deep	breathing	group	and	the	sham	breathing	group.	
• 	Comparison	of	ANS	changes	before	and	after	slow	deep	breathing	versus	sham	
breathing	in	visit	1.	
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Methods	
Duration	of	patient	participation	and	visit	details	
Patients	were	enrolled	for	a	period	of	4	weeks,	and	attended	the	Wingate	Institute	
for	 2	 visits.	 The	 first	 visit	 consisted	 of	 informed	 consent	 and	 checking	 for	 eligibility,	 after	
which	the	patients	were	randomised	to	start	with	either	the	slow	deep	breathing	protocol	or	
the	sham	breathing	protocol	in	a	single	blinded	fashion.	That	is,	the	patient	was	unaware	of	
whether	 they	 were	 receiving	 the	 active	 breathing	 or	 the	 sham	 breathing	 exercise.	 Once	
randomized,	 they	completed	a	baseline	RESQ	7	questionnaire	after	which	 they	underwent	
an	 acid	 perfusion	 test	whilst	 performing	 the	 relevant	 breathing	 exercise.	 The	 patient	was	
then	trained	to	self-administer	the	breathing	exercise	used	at	visit	1,	to	be	used	twice	a	day	
for	10	minutes	over	the	next	4	weeks.	
Visit	2	occurred	4	weeks	later	when	they	attended	the	Wingate	Institute	in	order	to	
complete	 another	 RESQ	 7	 questionnaire,	 demonstrate	 their	 breathing	 exercise	 technique,	
and	to	debrief.	
Visit	1	
• Written	informed	consent	
• Demographics,	medical	history	and	medication	history	
• Questionnaire	(RESQ-7)	
• Physical	examination,	vital	signs	and	ECG	
• Inclusion	/	exclusion	criteria	review	
• Randomisation	
• Baseline	autonomic	nervous	system	(ANS)	recording	10	minutes,	and	continuously	
thereafter.	
• Intubation	with	oesophageal	catheter	with	10	minutes	to	accommodate.	
• Start	breathing	protocol	5	minutes	before	start	of	Modified	Bernstein	test.	
• Modified	Bernstein	test	(2	minutes	saline	followed	by	10	minutes	0.1M	HCL).	
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Visit	2	
• Complete	RESQ	7	questionnaire.	
• Demonstrate	breathing	exercise	technique	to	ensure	good	practice.	
• Debrief	session	to	review	compliance,	ease	of	use	and	any	issues	encountered.		
	
Eligibility	criteria	
Inclusion	criteria	
• Male	and	female	patients	over	the	age	of	18	years.	
• Women	in	the	follicular	phase	of	the	menstrual	cycle	(visits	will	be	arranged	so	that	in	
menstruating	women,	the	study	will	be	started	in	the	follicular	phase	of	the	
menstrual	cycle	to	standardise	for	possible	confounding	effects	of	the	menstrual	
cycle	on	symptom	perception).				
• Able	to	give	informed	consent	
• Able	to	speak	and	understand	English	without	the	need	for	an	interpreter	
• Negative	OGD	
• Positive	reflux	study	(a	reflux	study	confirming	GORD	or	RH)	
• An	established	diagnosis	of	NERD		
	
Exclusion	criteria	
• Current	or	previous	GI	or	medical	illnesses	that	may	affect	ANS	/	GI	function	
• Current	or	previous	significant	CNS	illness	
• Current	medications	affecting	the	CNS,	GI	or	ANS	systems	
• Scoring	less	than	very	mild	at	the	modified	Bernstein	test		
• Pregnancy	and	lactation	
• Cardiac	dysrhythmias	
	
Patients	were	 asked	 to	 refrain	 from	 smoking	 for	 12	 hours	 and	 drinking	 alcohol	 as	well	 as	
using	recreational	drugs	for	48	hours	prior	to	study	visit.	
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Deep	breathing	protocol	
The	 deep	 breathing	 protocol	 used	 in	 this	 study	 consisted	 of	 a	 cycle	 of	 deep	
breathing	 at	 full	 inspiratory	 capacity	 for	 4	 seconds	 followed	 by	 forced	 expiration	 in	 6	
seconds	(forced	vital	capacity),	at	a	frequency	of	6	breaths	per	minute	for	every	5th	minute	
for	 5	 minutes	 prior	 to	 and	 for	 the	 duration	 of	 a	 modified	 Bernstein	 test	 (described	 in	
previous	 chapters),	 which	 involves	 infusion	 of	 acid	 into	 the	 lower	 oesophagus	 and	 is	
validated	for	assessment	of	acid	 induced	oesophageal	hypersensitivity	 in	GORD	patients.	A	
standard	video	providing	a	demonstration	of	slow	deep	breathing	and	sham	breathing	was	
used	 in	 order	 to	 ensure	 standardisation	 and	 consistency	 in	 the	 advice	 given	 to	 patients	
about	 the	 slow	 deep	 breathing	 versus	 sham	breathing	 protocol,	which	was	 of	 paramount	
importance.	The	surroundings	were	kept	neutral	and	relaxing	with	minimal	distractions.		
Sham	breathing	protocol		
The	sham	breathing	protocol	was	developed	using	breathing	as	a	basis,	but	with	no	
particular	 instruction	 regarding	 depth	 or	 tempo	 of	 breathing.	 Patients	 were	 instructed	 to	
count	10	breaths	and	tick	a	box	every	time	they	counted	ten	breaths.	The	counting	distracts	
the	patient	reducing	the	effect	of	focussing	of	breathing	on	their	autonomic	nervous	system	
(12).	The	surroundings	were	kept	neutral	and	relaxing	with	minimal	distractions.		
	
	
	 178	
Study	procedures	
Autonomic	Nervous	System	Monitoring	
Autonomic	testing	was	carried	out	using	a	Neuroscope.		The	Neuroscope	measures	
real	 time	beat-to-beat	 cardiac	 vagal	 tone	 (parasympathetic	 efferent),	 cardiac	 sensitivity	 to	
the	baroreflex	(parasympathetic	afferent)	and	blood	pressure	(sympathetic	efferent).	
Modified	Bernstein	Test	
During	this	test,	0.9%	saline	was	initially	infused	into	the	oesophagus	(10	cm	above	
the	 lower	 oesophageal	 sphincter)	 at	 a	 rate	 of	 10	 mL/min	 for	 2	 minutes.	 Subsequently,	
without	the	subject’s	knowledge,	0.1	M	hydrochloric	acid	was	infused	for	10	minutes	at	the	
same	rate.		
Stimulus-response	 functions	 to	 acid	 were	 quantified	 by	 lag	 time	 to	 symptom	
perception,	 Sensory	 intensity	 rating	 (at	 the	 end	 of	 the	 acid	 perfusion);	 and	 APSS	 (acid	
perfusion	sensitivity	score).		
Lag	time	was	defined	as	the	time	(in	seconds)	to	initial	first	symptom	perception.	Lag	
time	 values	 for	 healthy	 controls	 have	 been	 previously	 assessed	 by	 Fass	 et	 al	 (152).	 An	
assessment	of	 the	 intensity	of	symptoms	associated	with	acid	perfusion	was	made	using	a	
verbal	 descriptor	 scale	 (154).	 The	 scale	 consists	 of	 a	 20-cm	 vertical	 bar	 flanked	 by	
descriptors	 of	 increasing	 intensity	 (no	 sensation,	 very	 weak,	 faint,	 weak,	 very	 mild,	 mild,	
moderate,	 barely	 strong,	 slightly	 intense,	 strong,	 intense,	 very	 intense,	 and	 extremely	
intense).	 Placement	 of	 words	 along	 the	 scale	 was	 determined	 from	 their	 relative	 log	
intensity	 rating	 in	 a	 normative	 study	 (156).	 The	 validity	 of	 these	 scales	 for	 assessing	 the	
perceived	intensity	of	visceral	sensation	has	been	confirmed	(157).	
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Deep	breathing	protocol	and	sham	breathing	protocol	administration	
During	both	breathing	protocols,	the	patient	watched	and	following	a	standardised	
instructional	 video	 in	 a	 quiet	 and	 calm	 environment	 for	 the	 duration	 of	 the	 Modified	
Bernstein	test.		
Questionnaires	
• RESQ	–	7		
This	 is	 a	well-validated	questionnaire	 used	 in	 patients	with	GORD	who	experience	
only	a	partial	 response	to	PPI	 therapy.	 It	 is	brief	and	easy	 to	complete	and	 is	 intended	 for	
use	 in	 routine	 clinical	 care.	 It	 consists	 of	 13	 items	 incorporating	 oesophageal	 and	 extra	
oesophageal	 symptoms	 of	 GORD,	 and	 requires	 the	 patient	 to	 document	 frequency	 and	
intensity	 of	 symptoms	 over	 the	 previous	 7	 days.	 It	 is	 frequently	 used	 in	 clinical	 trials	
assessing	 new	 therapies	 for	 the	 treatment	 of	 GORD	 and	 it	 would	 therefore	 be	 a	 suitable	
questionnaire	to	study	the	effect	of	treatment	on	symptoms	of	GORD	(159).	It	was	also	the	
questionnaire	used	to	assess	the	value	of	self-administered	slow	deep	breathing	at	the	end	
of	the	study.	
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Data	analysis	and	statistical	considerations	
Outcome	measures		
As	mentioned	above,	stimulus–response	outcome	measures	to	acid	perfusion	were	
quantified	using	three	standard	validated	parameters:		
•				 Lag	time:	Defined	as	the	time	to	initial	symptom	perception	following	acid	perfusion.		
•				 Sensory	 intensity	 rating:	An	assessment	of	 the	 intensity	of	 symptoms	at	 the	end	of	
the	 acid	 perfusion	made	using	 a	 previously	 validated	 verbal	 descriptor	 scale	 at	 the	
end	of	the	acid	perfusion		
•				 APSS:	 calculated	 from	 lag	 time	 (T)	expressed	 in	 seconds	 (sec)	and	 sensory	 intensity	
rating	(I)	expressed	in	centimetres	(cm).			
	
Although	 lag	 time	 was	 used	 as	 the	 primary	 endpoint,	 studies	 using	 the	Modified	
Bernstein	test	often	use	the	APSS,	and	so	for	the	sake	of	comparison,	I	calculated	this	as	well	
(47).	The	APSS	was	calculated	by	multiplying	the	lag	time	to	symptom	perception	(expressed	
in	seconds)	and	the	symptom	intensity	rating	(expressed	in	cm	on	a	validated	scale),	divided	
by	100	for	convenience	to	yield	a	score	in	cm	seconds.		
APSS	=	(I)	x	(T)/100	(cm	x	sec/100).	
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Statistical	Analyses	
Continuous	variables	are	presented	as	mean	and	standard	deviation,	or	medians	and	
inter-quartile	 ranges,	 dependent	 on	 data	 distribution.	 Categorical	 variables	 were	
summarized	by	the	mean	and	standard	deviation.	
The	primary	endpoint,	lag	time	(in	seconds)	to	first	sensation	of	discomfort	following	
oesophageal	 acid	 infusion	 was	 analyzed	 using	 the	 Mann-Whitney	 test	 because	 of	 the	
assumed	non-parametric	nature	of	the	data.	Lag	time	data	was	analysed	for	normality	using	
the	 Shapiro	 Wilk	 normality	 test	 and	 only	 the	 slow	 deep	 breathing	 group	 passed	 the	
normality	test.		RESQ7	scores	were	analysed	using	the	methods	as	described	for	the	primary	
outcome.	
Analyses	were	performed	using	proprietary	software	(GraphPad	Prism	version	7.00	
for	 MAC,	 GraphPad	 Software,	 La	 Jolla	 California	 USA,	 www.graphpad.com).	 P<0.05	 was	
adopted	as	the	level	of	statistical	significance.	
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Results	
116	patients	who	were	eligible	to	participate	were	approached.	They	were	provided	
with	an	 information	sheet.	35	patients	agreed	to	participate	 in	the	study	and	attended	for	
visit	1.	Of	these	35,	5	met	exclusion	criteria	and	did	not	continue	with	visit	1.	Therefore	30	
patients	 were	 randomised	 and	 completed	 visit	 1	 of	 the	 study.	 There	 were	 no	 drop-outs	
between	randomisation	and	completion	of	visit	1.	24	of	the	30	patients	completed	visit	2	of	
the	study,	although	all	30	were	given	the	opportunity	to	participate.		
The	 demographics	 of	 patients	 approached	 who	 declined	 to	 participate	 were	 not	
collected.	In	general	however,	the	reason	for	declining	was	informally	noted,	with	reluctance	
to	 undergo	 further	 non-essential	 invasive	 tests	 (after	 having	 completed	 their	 clinically	
indicated	HRM	and	24	our	pH	studies)	being	the	predominantly	sited	reason.		
There	were	 equal	 numbers	 in	 both	 arms	of	 the	 study,	 and	both	 groups	were	well	
matched	for	age	and	sex.	As	a	whole,	median	age	of	the	30	participants	was	55	(44	–	60).	11	
were	female.	23	were	of	white	ethnicity,	with	4	of	south	Asian	ethnicity,	2	of	black	ethnicity	
and	one	other.	Median	BMI	was	28.21	Kg/m2	(25.15	–	32.22).	
All	participants	had	a	diagnosis	of	NERD,	with	a	confirmed	negative	gastroscopy	and	
24	hour	pH	or	MII	pH	study.	25	were	on	a	regular	dose	of	a	PPI,	with	the	other	5	using	an	
alginate	(Gaviscon	®)	as	required.	1	participant	was	on	low	dose	amitriptyline	and	one	was	
on	treatment	dose	amitriptyline	(for	a	diagnosis	of	depression),	2	were	on	an	SSRI	(one	for	a	
diagnosis	of	depression)	whilst	one	was	on	an	SNRI	(for	a	diagnosis	of	depression).	
Lag	time	analysis	
Analysis	of	lag	time	formed	the	primary	endpoint	of	the	study.	Mean	lag	time	for	the	
slow	deep	breathing	group	was	203.9	seconds	(±140.9)	and	median	lag	time	was	168	(102-
240).	For	the	sham	breathing	group,	mean	lag	time	was	231.8	seconds	(±	166.2)	and	median	
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lag	 time	was	185	seconds	 (143-319).	There	was	no	significant	difference	between	 the	 two	
groups	when	comparing	 lag	 times	 (p	=	0.6022).	 The	difference	 in	APSS	was	not	 significant	
either	(p	=	0.8702).	
Lag	 time	 values	 for	 the	 slow	 deep	 breathing	 group	 were	 more	 evenly	 scattered,	
compared	 to	 the	 sham	 breathing	 group,	 where	 there	 was	 a	 notable	 outlier.	 Although	
removal	of	this	outlier	from	the	data	set	altered	the	mean	and	median	lag	time	values	in	the	
sham	breathing	group,	when	comparing	both	groups,	there	was	still	no	significant	difference	
between	both	groups	(p	=	0.8218).	 
	
	
Figure	5.2:	Distribution	of	lag	time	for	the	slow	deep	breathing	group.			
	
Figure	5.3:	Distribution	of	lag	time	for	the	sham	breathing	group.			
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Figure	 5.4:	 There	 was	 no	 significant	 difference	 between	 the	 two	 groups	 when	 comparing	
median	lag	times	(p	=	0.6022).	
	
Cardiac	vagal	tone	analysis	
Comparing	 ANS	 changes	 before	 and	 after	 the	 two	 breathing	 protocols	 was	 a	
secondary	endpoint	of	the	study.	Mean	baseline	CVT	was	4.333	(±2.514)	for	the	slow	deep	
breathing	group	and	5.659	(±2.555)	for	the	sham	breathing	group.	There	was	no	significant	
difference	between	the	2	treatment	groups	(p	=	0.1488).			
Pre	Bernstein	mean	CVT	during	the	deep	breathing	protocol	was	5.751	(±3.576),	and	
during	the	sham	breathing	protocol	was	5.944	(±2.933).	During	the	Bernstein	test,	mean	CVT	
during	 the	 deep	 breathing	 protocol	 was	 6.063	 (±3.714),	 and	 during	 the	 sham	 breathing	
protocol	was	5.809	(±3.037).			
The	mean	change	of	CVT	from	baseline	to	pre	Bernstein	breathing	protocol	was	1.42	
for	the	deep	breathing	group	and	0.28	for	the	sham	breathing	group.	The	mean	change	of	
CVT	 from	 baseline	 to	 the	 Bernstein	 plus	 breathing	 protocol	 was	 1.7	 for	 the	 slow	 deep	
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breathing	group	and	0.15	 for	 the	 sham	breathing	group.	These	changes	were	of	 the	 same	
magnitude	as	the	study	by	Botha	et	al	(176).	
There	was	 a	 significant	 rise	 from	 baseline	 CVT	when	 participants	 performed	 slow	
deep	 breathing	 (p	 =	 0.0052).	 The	 rise	 from	 baseline	 remained	 significant	 when	 the	
participants	performed	slow	deep	breathing	during	the	Modified	Bernstein	test	as	well	(p	=	
0052).		
In	 the	 sham	 breathing	 group	 however,	 this	 was	 not	 apparent.	 There	 was	 no	
significant	rise	 in	CVT	from	baseline	when	the	participants	performed	sham	breathing	 (p	=	
0.5245).	 CVT	 did	 not	 rise	 from	 baseline	when	 the	 participants	 performed	 sham	 breathing	
during	the	Modified	Bernstein	test	either	(p	=	0.7197).	
	
	
	
	
	
	
Figure	5.5:	There	was	a	significant	rise	from	mean	baseline	CVT	in	the	deep	slow	breathing	
group	 with	 deep	 slow	 breathing	 alone	 (p	 =	 0.0052)	 as	 well	 as	 with	 deep	 slow	 breathing	
during	a	Modified	Bernstein	test	(p	=	0052).	This	was	not	shown	in	the	sham	breathing	group	
(p	=	0.5245	and	p	=	0.7197)	respectively.	
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Questionnaire	analysis		
Questionnaire	analysis	was	done	prior	to	any	procedures	and	served	a	baseline	for	
both	 groups.	Mean	baseline	RESQ7	 score	was	 62.73	 (±28.55)	 for	 the	 slow	deep	breathing	
group	and	51.57	(±28.63)	for	the	sham	breathing	group.	There	was	no	significant	difference	
between	mean	baseline	RESQ7	for	the	2	groups	(p	=	0.3823).	
After	 4	 weeks	 of	 twice	 daily	 breathing	 exercises,	mean	 RESQ7	 score	 for	 the	 slow	
deep	breathing	 group	was	 53.23	 (±32.67)	 and	mean	RESQ7	 for	 the	 sham	breathing	 group	
was	43.27	(±26.85).	There	was	no	significant	difference	from	baseline	to	follow	up	scores	in	
either	group		(figure	5.4).	
	
	
	
	
	
	
	
Figure	5.6:	There	was	no	significant	difference	between	the	baseline	vs	follow	up	scores	for	
either	the	slow	deep	breathing	group	(p	=	0.2354)	or	the	sham	breathing	group	(p	=	0.8867).	
	
Comparison	of	RESQ7	scores	was	made	between	visit	1	and	visit	2	for	each	group.	Thus,	the	
change	from	baseline	scores	for	each	subject	was	expressed	as	a	delta	value	for	both	groups.	
I	then	compared	mean	delta	values	between	the	slow	deep	breathing	group	and	the	sham	
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breathing	 group.	 There	 was	 no	 significant	 difference	 between	 the	 delta	 RESQ7	 scores	
between	the	slow	deep	breathing	group	and	the	sham	breathing	group.	That	 is	to	say,	the	
mean	 change	 from	 baseline	 RESQ7	 score	 between	 the	 2	 groups	 was	 not	 significant	 (p	 =	
0.6150)	(figure	5.5).	
	
	
	
	
	
	
	
	
Figure	 5.7:	 Mean	 change	 from	 baseline	 RESQ7	 score	 to	 follow	 up	 RESQ7	 score	 was	 not	
significant	between	the	2	groups	(p	=	0.6150).	
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Summary	
In	 this	 study	 I	 have	 shown	 that	 a	 slow	 deep	 breathing	 protocol	 produced	 a	
significant	rise	in	parasympathetic	tone	from	baseline	when	compared	to	a	sham	breathing	
protocol.		
I	was	 not	 able	 to	 show	a	 significant	 difference	 in	 lag	 time,	 defined	 as	 the	 time	 to	
initial	 symptom	 perception	 following	 acid	 perfusion,	 when	 I	 compared	 the	 slow	 deep	
breathing	protocol	group	to	the	sham	breathing	protocol	group.	APSS	was	not	significantly	
different	either.	
Both	groups	were	equally	matched	with	regards	to	symptom	scores.	These	scores	at	
baseline	did	not	significantly	change	after	4	weeks	of	self-administered	slow	deep	breathing.		
Discussion	
The	study	in	this	chapter	set	out	to	investigate	if	a	deep	slow	breathing	protocol	was	
able	 to	 raise	parasympathetic	 tone,	 and	 thus	 reduce	oesophageal	 pain	hypersensitivity,	 in	
comparison	to	sham	breathing.		
The	power	calculation	used	in	this	study	was	aimed	at	detecting	a	difference	in	lag	
time	 of	 20%	 between	 the	 2	 groups.	 Using	 a	 5%	 significance	 level	 and	 80%	 power,	 it	 was	
calculated	 that	 I	 required	 34	 patients	 in	 each	 group	 to	 detect	 a	 reduction	 of	 20%	 in	 the	
primary	 outcome.	 The	 sample	 size	was	 not	 achieved	 due	 to	 difficulties	 in	 recruitment.	 As	
mentioned	 above,	 116	 eligible	 patients	 were	 approached,	 with	 a	 yield	 of	 30	 patients	
completing	 visit	 1.	 If	 I	 revised	down	my	 aim,	 to	 detect	 an	 even	 smaller	 difference	of	 10%	
between	the	2	groups,	 I	would	have	met	our	sample	size.	 I	still	would	not	have	achieved	a	
positive	 result,	 as	 the	 difference	 in	 lag	 time	 between	 the	 2	 groups	 was	 not	 significantly	
different.	
	
	
	 189	
The	 low	uptake	 from	multiple	 recruitment	 strategies	 is	not	a	new	phenomenon	 in	
the	 field	of	GORD	research.	As	described	 in	chapter	3,	 in	 the	ONO	8539	study,	 there	were	
also	 significant	 recruitment	 difficulties	 encountered.	 It	 is	 possible	 that	 although	 refractory	
GORD	 symptoms	 are	 problematic	 for	 a	 significant	 proportion	 of	 patients,	 current	
experimental	 models	 are	 relatively	 invasive	 and	 perhaps	 less	 appealing	 from	 a	 patient’s	
perspective.		
As	 mentioned	 above,	 I	 was	 able	 to	 show	 that	 a	 slow	 deep	 breathing	 protocol	
produced	a	significant	rise	in	parasympathetic	tone	from	baseline	when	compared	to	a	sham	
breathing	protocol.	 This	 rise	was	 similar	 to	 the	 study	 in	 healthy	 volunteers	 by	Botha	et	 al	
(176).	Here	we	may	also	ponder	the	potential	mode	of	action	of	pain	reduction	by	means	of	
deep	 slow	 breathing	 as	 an	 effect	 of	 increasing	 interoceptive	 accuracy	 by	 raising	
parasympathetic	 tone.	As	mentioned	previously,	 an	 increase	 in	 interoceptive	accuracy	has	
been	shown	to	be	associated	with	reduced	pain	and	symptom	severity,	so	this	is	a	plausible	
idea.	
It	is	unclear	why	a	significant	rise	in	parasympathetic	tone,	which	in	previous	studies	
has	been	shown	to	increase	oesophageal	pain	threshold,	did	not	lead	to	a	change	in	lag	time	
to	initial	symptom	perception	following	acid	perfusion.	The	cohort	of	patients	studied	were	
phenotyped	as	carefully	as	possible,	considering	previous	pitfalls	described	in	the	literature	
(70,	105).	Another	possibility	is	the	fact	that	I	used	a	primary	endpoint	that	is	perhaps	more	
susceptible	to	subjectivity	than	an	alternative	endpoint	such	as	pain	threshold	to	electrical	
stimulation,	 which	 is	 more	 definitive	 and	 likely	 to	 give	 a	 more	 objective	 endpoint	 (103).	
Efforts	 to	 hone	 an	 experimental	model	 for	 NERD	 patients	 with	more	 objective	 endpoints	
would	 be	 helpful	 in	 the	 search	 for	 newer	 therapies	 in	 the	 field	 of	 oesophageal	 pain	
hypersensitivity.	
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A	further	reason	for	a	 lack	of	an	increase	in	 lag	time	might	have	been	because	the	
dose	of	the	slow	deep	breathing	protocol	in	my	study	may	have	been	inadequate.	Botha	et	
al	(176)	used	a	35	minute	slow	deep	breathing	protocol	(30	minutes	of	which	were	during	a	
distal	oesophageal	acid	infusion),	whilst	I	used	17	minutes,	5	of	which	were	prior	to	the	start	
of	the	modified	Bernstein	test.	Further	work	with	dose	finding	experiments	may	help	in	this	
instance.	 It	 is	 possible	 that	 I	 did	 not	 see	 a	 difference	 in	 lag	 time	 because	 both	 breathing	
protocols	behaved	as	a	distraction	technique.	Distraction	and	attention	have	been	shown	to	
reduce	pain	perception	(195)	(196).	In	the	model	that	was	used	in	this	study,	there	was	no	
baseline	 for	 the	 response	 to	 acid	 infusion,	 hence	 the	 inability	 to	 assess	 if	 there	 was	 a	
difference	in	one	or	both	of	the	protocols	from	baseline.	I	consider	this	to	be	a	limitation	of	
this	study.	
Based	 on	 the	 above,	 an	 updated	 model	 of	 oesophageal	 pain	 hypersensitivity	 is	
needed	 for	 experimental	 work	 in	 patients	 with	 NERD.	 The	 30	 minute	 oesophageal	 pain	
hypersensitivity	model	described	in	chapter	4	as	well	as	in	work	by	Botha	et	al	and	Sarkar	et	
al	has	been	used	 in	studies	 involving	patients	with	NERD	(197)	but	based	on	experience	 in	
our	 group,	 is	 likely	 to	 be	 less	 tolerated	 in	 patients	with	 NERD	 due	 to	 possible	 underlying	
peripheral	 as	 well	 as	 central	 sensitization.	 In	 addition	 to	 this,	 as	 mentioned	 previously,	
recruitment	 difficulties	 are	 likely	 to	 be	 increased	 with	 more	 prolonged	 invasive	 testing.	 I	
propose	 therefore	 that	 a	 similar	 testing	 protocol	 using	 pain	 threshold	 tolerance	 as	 an	
endpoint	but	with	a	shorter	period	of	acid	perfusion	(shorter	than	35	minutes)	is	likely	to	be	
better	tolerated.			
The	secondary	endpoint	of	this	study	was	to	assess	change	in	reflux	symptom	scores	
between	before	and	after	4	weeks	of	using	slow	deep	breathing	or	sham	breathing	as	a	self-
administered	therapeutic	measure	for	oesophageal	pain	in	patients	with	NERD.	This	was	not	
shown	 in	my	 study.	 Although	 I	 did	 collect	 self	 reported	 compliance	 data	 suggesting	 good	
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compliance	overall,	 this	 is	 likely	 to	be	open	 to	 error,	which	was	 a	 limitation	of	 this	 study.	
Furthermore,	 I	did	not	reach	my	 intended	sample	size	and	 it	 is	 therefore	possible	 that	 the	
study	was	underpowered	to	assess	any	change	in	symptoms.	Finally,	a	dose	finding	study	of	
frequency	 and	 duration	 of	 slow	 deep	 breathing	 is	 required	 to	 determine	 the	 optimal	
parameters	for	this	intervention.		
	 In	conclusion,	slow	deep	breathing	has	been	shown	in	this	study	to	increase	
parasympathetic	 tone	 compared	 to	 sham	breathing.	 Further	work	 is	 required	 to	 elucidate	
the	 lack	 of	 reduction	 in	 time	 to	 perception	 of	 symptoms,	 including	 improving	my	 current	
model	of	assessing	changes	in	oesophageal	pain	hypersensitivity	in	response	to	therapeutic	
measures.	
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Chapter	6	
Discussion	
GORD	is	a	leading	cause	of	gastrointestinal	morbidity	world	wide,	with	a	significant	
financial	 burden	 (37).	With	 rising	 rates	 of	 obesity,	 the	 incidence	 of	 GORD	 is	 predicted	 to	
increase	further	still	(198).		Although	lifestyle	modifications	(199)	and	PPI	therapy	form	the	
mainstay	of	treatment	in	GORD,	we	have	little	else	to	fall	back	on	when	they	are	ineffective.	
Alginates,	 H2RAs	 as	well	 as	 isomeric	 PPIs,	 as	well	 as	 combinations	 of	 these	 drugs	 are	 the	
current	 add	 on	 therapies	 available	 for	 refractory	 GORD	 whilst	 surgical	 and	 endoscopic	
therapies	serve	as	means	of	primarily	augmenting	the	GOJ	to	improve	extent	of	reflux	(200).	
In	addition	to	this,	considerable	efforts	have	been	made	to	improve	diagnostic	algorithms	in	
GORD,	in	order	to	ensure	we	optimize	current	available	therapies	(201).	
	
Oesophageal	 RH	 addressed	 in	 previous	 chapters	 of	 this	 thesis	 is	 thought	 to	 arise	
from	 physiological	 distal	 oesophageal	 acid	 exposure	 as	 well	 as	 non-acid	 exposure.	 The	
mechanism	 of	 oesophageal	 pain	 here	 is	 thought	 to	 involve	 peripheral	 sensitization	 from	
exposure	 of	 nociceptors	 to	 acid	 and	 non-acid	 reflux	 possibly	 facilitated	 via	 dilated	 inter	
cellular	 spaces	 in	 addition	 to	 central	 sensitization	 of	 spinal	 dorsal	 horn	 neurons	 (94).	 The	
placement	of	RH	 in	 the	 category	of	 a	 functional	 type	disorder	 in	ROME	 IV	 is	 therefore	 an	
attempt	at	facilitating	strategies	for	studies	into	new	therapies	for	RH	(2).		
	
Although	 newly	 re-defined,	 RH	 is	 not	 a	 new	 pathology.	 Despite	 this,	 the	
epidemiology	of	RH	is	not	well	defined	and	nor	is	the	phenotype.	In	this	thesis,	I	have	added	
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to	 the	 understanding	 of	 the	 phenotype	 of	 the	 patient	with	 RH.	 I	 have	 confirmed	 that	 RH	
shares	phenotypical	attributes	with	both	NERD	and	FH/	FCP.	Crucially	though,	in	chapter	2,	I	
demonstrated	 that	 our	 cohort	 of	 patients	with	RH	 lie	more	 towards	 the	NERD	end	of	 the	
spectrum	than	the	functional	end	of	the	spectrum.	Considering	this	 is	the	largest	cohort	of	
patients	 with	 RH	 studied	 at	 present,	 these	 findings	may	 have	 a	 bearing	 on	 the	 future	 of	
where	this	condition	sits	best	from	a	mechanistic	point	of	view.		
	
Recent	work	by	Frazzoni	et	al	have	shown	impaired	mucosal	clearance	and	reduced	
mean	 baseline	 nocturnal	 impedance	 (MBNI)	 of	 the	 oesophagus	 in	 patients	 with	 RH	
compared	 to	 FH	 (133),	 a	 finding	 seen	 in	 other	 studies	 as	 well	 (202).	 Woodland	 et	 al	
demonstrated	 that	 the	distribution	of	 afferent	nerves	 in	 the	oesophageal	mucosa	 is	more	
superficial	in	NERD	compared	to	FH	(203),	reinforcing	the	idea	that	symptoms	in	NERD	may	
be	 due	 to	 exposure	 of	 afferent	 nerve	 endings	 to	 noxious	 stimuli	 via	 impaired	 mucosal	
integrity	in	the	form	of	dilated	intercellular	spaces,	a	surrogate	marker	of	which	is	reduced	
mean	baseline	 impedance	 (204).	 In	 view	of	 reduced	MBNI	 levels	 seen	 in	RH,	 this	 suggests	
that	 the	 observations	 of	Woodland	 et	 al	 are	 likely	 to	 be	 present	 in	 RH	 as	 well.	 It	 would	
therefore	be	enlightening	to	assess	MBNI	in	our	cohort	of	patients	with	RH	as	well.	This	will	
also	add	weight	to	the	search	for	topical	mucosal	protectants	as	a	therapeutic	measure	as	
shown	by	Woodland	et	al	(205).	
	
In	 terms	 of	 other	 treatment	 options,	 in	 chapter	 3,	 I	 assessed	 an	 EP1	 receptor	
antagonist.	 This	 was	 an	 exploratory	 study,	 and	 unfortunately	 the	 sample	 size	 was	 not	
achieved.	The	sample	size	calculation	was	based	on	pre	clinical	studies,	and	due	to	the	lack	
of	data	on	the	effect	of	ONO-8539	on	oesophageal	pain,	formal	power	calculations	were	not	
possible.	It	is	not	possible	to	know	whether	I	might	have	seen	an	increase	in	lag	time	or	APSS	
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even	 if	 I	 achieved	 the	 sample	 size	 of	 30.	 There	 is	 also	 the	 issue	 I	 discussed	 in	 chapter	 5,	
regarding	 the	 possibly	 subjective	 nature	 of	 lag	 time	 as	 a	 stimulus	 response	 measure.	 To	
counter	 this,	 electrical	 pain	 threshold	 was	 also	 measured	 in	 this	 study	 but	 a	 significant	
difference	 was	 not	 seen	 between	 ONO-8539	 and	 placebo.	 Further,	 well-designed	
exploratory	 studies	may	help	 in	 this	 respect.	 The	 fact	 that	 antagonism	of	 other	 promising	
receptor	targets	such	as	the	TRPV1	have	not	been	shown	to	reduce	oesophageal	pain	(100)	
despite	valiant	efforts	should	not,	however,	deter	the	search	for	new	targets.	In	contrast,	in	
healthy	 subjects,	 oesophageal	 pain	 hypersensitivity	 to	 electrical	 stimulation	 following	 acid	
infusion	 has	 been	 an	 effective	 model	 to	 demonstrate	 efficacy	 of	 pharmacological	
(pregabalin)	and	non-pharmacological	(slow	deep	breathing)	therapies.	Therefore,	in	future	
studies,	sensitivity	to	electrical	stimulation,	or	reduction	in	symptoms	may	be	more	effective	
end	points	in	well-powered	studies.		
	
My	 studies	 have	 highlighted	 a	 possible	 limitation	 of	 this	 modified	 Bernstein	 test	
(MBT)	model,	because	of	the	order	effect	seen	when	multiple	MBTs	were	carried	out.	This	
was	apparent	despite	a	4	week	period	between	each	MBT.	It	is	possible	that	the	order	effect	
seen	was	more	due	to	reduced	anxiety	levels	when	faced	with	subsequent	MBTs	but	 I	was	
not	able	to	show	this	in	my	analysis	of	change	in	anxiety	scores.	The	attention	received	from,	
and	 inevitable	 rapport	 developed	with	 the	 study	 team,	 during	 a	 10	 visit	 clinical	 trial,	may	
have	had	an	effect	as	well,	which	was	not	controlled	for.		
	
	Learning	effects	are	not	uncommon	 in	 cross	over	experimental	 studies,	 and	more	
complex	 invasive	measures	 are	 prone	 to	 the	occurrence	of	 an	order	 effect	 due	 to	 this.	 In	
animal	models	this	is	well	recognized	with	the	use	of	multiple	test	batteries,	and	caution	is	
exercised	 to	 reduce	 the	bias	 this	brings	 to	experimental	work	 (206).	The	situation	appears	
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more	 complex	 in	 humans,	 and	 experimental	models	 have	 shown	 that	 the	 brain	 is	 able	 to	
rapidly	 adapt	 and	 learn,	 with	 this	 manifesting	 as	 a	 carry	 over	 effect	 from	 a	 preceding	
stimulus	or	event	(207).		
	
To	counter	this	effect,	I	designed	the	study	in	chapter	5	as	a	parallel	study,	so	that	a	
carry	 over	 bias	 was	 not	 possible	 between	 the	 slow	 deep	 breathing	 group	 and	 the	 sham	
breathing	group.	The	study	was	also	of	a	shorter	duration,	in	an	attempt	to	reduce	potential	
effects	 from	 prolonged	 contact	 with	 a	 study	 team.	 A	 parallel	 study	 such	 as	 this	 has	 the	
disadvantage	 of	 requiring	 a	 larger	 sample	 size	 to	 demonstrate	 any	meaningful	 difference	
between	 treatment	 arms.	 I	 was	 not	 able	 to	 achieve	 my	 sample	 size	 however,	 which	
highlights	again,	the	problem	of	recruitment	in	this	patient	population.		
	
I	 have	discussed	 the	 fact	 that	 the	APSS	may	have	 limited	use	 in	 the	 evaluation	of	
patients	when	investigating	therapies	for	oesophageal	pain.	There	is	a	paucity	of	use	of	the	
APSS	in	patient	studies	of	therapies	for	oesophageal	pain,	and	the	subjective	nature	of	the	
components	of	the	APSS	is	less	preferable	in	the	context	of	such	studies.	A	single	subjective	
measure	such	as	lag	time	may	have	been	appropriate,	but	as	discussed	in	chapter	5,	the	use	
of	lag	time	as	an	endpoint	is	also	likely	to	be	problematic,	due	to	the	subjective	nature	of	the	
request	being	posed	to	the	study	subject.	A	perception	of	“slightest	discomfort”	is	less	easy	
to	define	than	a	perception	of	pain	tolerance,	supporting	the	idea	of	a	need	to	update	this	
model	for	oesophageal	pain	in	patients	with	NERD.		
	
In	 chapter	 4,	 I	 investigated	 the	 effect	 in	 healthy	 volunteers,	 of	 tVNS	 versus	 sham	
stimulation	 of	 the	 auricular	 branch	 of	 the	 left	 vagus	 nerve	 using	 an	 oesophageal	 pain	
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hypersensitivity	model.	As	described	 in	chapter	4,	this	model	had	been	used	extensively	 in	
healthy	volunteer	studies	with	good	reliability	and	reproducibility.	Based	on	the	work	in	this	
thesis,	it	appears	that	the	above	reliability	and	reproducibility	of	this	model	is	probably	due	
to	the	use	of	more	objective	stimulus	response	measures.	An	order	effect	was	not	seen	 in	
this	 study,	 nor	 has	 it	 been	 observed	 in	 previous	 studies	 using	 this	model.	 Therefore,	 the	
learning	 effect	 did	 not	 seem	 to	play	 a	 part	 here,	 even	 in	 the	 context	 of	 a	 shorter	 2	week	
washout	 period.	 This	 lends	 weight	 to	 the	 attention	 and	 rapport	 aspect	 of	 the	 study	 in	
chapter	 3	 as	 a	 stronger	 contender	 for	 the	 cause	 of	 the	 order	 effect.	 It	 should	 be	 noted	
however,	 that	even	 if	 this	was	 the	case,	although	 there	may	have	been	a	 smaller	 learning	
effect	between	 the	 first	 and	 second	MBTs	which	 I	did	not	detect,	 the	effect	of	2	previous	
MBTs	on	a	 third	and	 fourth	MBT,	4	and	8	weeks	 later	 is	 likely	 to	present	a	much	stronger	
learning	stimulus.		
	
A	 rise	 in	 parasympathetic	 tone	 was	 observed	 in	 the	 treatment	 groups	 of	 both	
studies	where	ANS	monitoring	was	used.	In	chapter	4,	I	was	also	able	to	demonstrate	a	rise	
in	stimulus	response,	whilst	in	chapter	5,	I	was	not	(in	terms	of	pain	tolerance	and	lag	time	
respectively).	The	lack	of	a	stimulus	response	in	chapter	5,	as	discussed	above	may	be	due	to	
limitation	 of	 the	 model	 used.	 Either	 way,	 the	 work	 in	 this	 thesis	 demonstrated	 a	 rise	 in	
parasympathetic	tone	in	the	treatment	group	as	a	consistent	finding.	This	reinforces	the	idea	
that	 the	 treatment	 modalities	 used	 (tVNS	 and	 deep	 slow	 breathing)	 were	 both	 able	 to	
significantly	increase	parasympathetic	tone	compared	to	sham.	A	proposed	mechanism	for	a	
possible	 reduction	 of	 pain	 in	 this	 instance	 was	 discussed	 in	 the	 context	 of	 improved	
interoceptive	 accuracy	 by	 increasing	 parasympathetic	 tone	 (modulating	 the	 autonomic	
afferent	input).		
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In	 conclusion,	 based	on	 the	 above	discussion,	 I	 suggest	 that	we	need	 for	 a	 newer	
model	 of	 oesophageal	 pain	 hypersensitivity	 in	 NERD	 patients,	 in	 order	 to	 evaluate	 novel	
therapies	 for	 oesophageal	 pain	 as	well	 as	 to	 further	 elucidate	 the	mechanistic	 aspects	 of	
how	 these	novel	 therapies	may	help.	Based	on	 the	work	 in	 chapter	4	and	5,	 the	need	 for	
ANS	 testing,	 even	 in	 treatment	 strategies	 to	 increase	 parasympathetic	 tone	 as	 an	 anti-
nociceptive	 measure,	 appears	 less	 crucial	 as	 there	 is	 now	 significant	 evidence	 that	 these	
measures	are	indeed	able	to	increase	parasympathetic	tone.	During	the	development	stage	
of	 a	 new	 model,	 confirming	 consistent	 ANS	 changes	 was	 however	 needed	 for	 validation	
purposes.	
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Further	work	
	 A	 new	 model	 of	 oesophageal	 pain	 hypersensitivity	 in	 NERD	 patients	 as	
discussed	above	is	likely	to	involve	the	following	–		
• a	shorter	duration	of	distal	oesophageal	acid	infusion	(that	is,	30	minutes	or	less),		
• a	more	objective	stimulus	response	(pain	tolerance	threshold),		
• a	4	week	washout	period	(in	view	of	the	fact	that	an	order	effect	was	not	seen	in	the	
healthy	volunteer	model),	
• a	cross	over	study	(in	view	of	recruitment	difficulties	in	this	study	population),	
• ANS	monitoring	at	baseline	and	extended	time	points	to	measure	the	durability	of	
the	stimulus	response.		
• Addition	of	0.9%	saline	as	a	null	stimulus	may	be	an	idea	to	assess	as	well.		
	
In	addition	to	this,	 in	view	of	current	MNBI	 findings,	 I	could	consider	assessing	
the	 longer	 term	 benefit	 of	 treatment	 strategies,	 including	 those	 designed	 to	 increase	
parasympathetic	 tone,	 using	 MNBI	 as	 a	 marker	 of	 response,	 considering	 the	 clear	
differences	 have	 been	 reported	 between	 RH	 and	 FH	 as	 well	 as	 before	 and	 after	 PPI	
therapy	 (133,	 204).	 The	 fact	 that	 diagnostic	 algorithms	 especially	 in	 refractory	 GORD	
include	MII-pH	monitoring,	this	has	the	added	advantage	of	a	ready	made	baseline	value	
if	 the	 therapeutic	 intervention	 studies	 are	 timed	 appropriately,	 to	 reduce	 research	
related	additional	invasive	procedures.		
	
	 Alternatives	 to	ANS	monitoring	using	 the	Neuroscope	device	will	 also	help	
move	 forward	 future	 work	 on	 the	 investigation	 of	 ANS	 modulation	 as	 a	 therapy	 for	
oesophageal	pain.	This	 is	because	the	neuroscope	technique	 is	expensive	and	not	very	
portable.	 Newer,	 cheaper	 and	 more	 portable	 ambulatory	 methods	 are	 now	 available	
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that	 may	 facilitate	 future	 studies	 especially	 where	 long-term	 ANS	 measurements	 are	
required.			
	
	 Additionally,	 to	 complement	 my	 findings	 in	 chapter	 2,	 confirmation	 of	
afferent	 nerve	 distribution	 in	 RH	 compared	 to	 NERD	 and	 FH	 may	 help	 increase	 our	
understanding	of	the	mechanism	of	pain	hypersensitivity	in	RH.	
	
In	 summary,	 in	 this	 thesis,	 this	 body	 of	 work	 improves	 upon	 current	 knowledge	 of	 the	
phenotypic	characteristics	of	RH,	adding	further	weight	to	the	definition	of	RH	as	a	distinct	
condition.	 I	 have	 demonstrated	 that	 tVNS	 and	 deep	 slow	 breathing	 increase	
parasympathetic	 tone	 in	 healthy	 volunteers	 and	 patients	 with	 NERD.	 I	 was	 able	 to	
demonstrate	the	anti	nociceptive	effect	of	raising	parasympathetic	tone	a	healthy	volunteer	
model	of	oesophageal	pain	hypersensitivity,	 but	not	 in	patients	with	NERD	using	 the	MBT	
model.	 The	 performance	 of	 the	 MBT	 model	 used	 in	 the	 two	 patient	 studies	 was	 not	 as	
reliable	 as	 the	 healthy	 volunteer	 model,	 and	 I	 have	 proposed	 a	 new	 oesophageal	 pain	
hypersensitivity	model	for	patients	with	NERD.			
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